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General introduction and outline of this thesis 
13 
Pulmonary hypertension 
Pulmonary hypertension (PH) is a chronic pathophysiological disorder of the 
pulmonary vasculature and is defined as a chronic pulmonary artery pressure 
(PAP) ≥ 25mmHg at rest (26). Pulmonary hypertension is a collective name for 
different types of PH. The world health organization (WHO) distinguishes 5 
different subgroups of PH, based on etiology: type 1, pulmonary arterial 
hypertension; type 2, pulmonary hypertension due to left heart disease; type 3, 
pulmonary hypertension due to lung diseases and/or hypoxia; type 4, chronic 
thromboembolic pulmonary hypertension and other pulmonary artery 
obstructions; and type 5, pulmonary hypertension with unclear and/or 
multifactorial mechanisms (14) (Figure 1).  
 
Figure 1. Pulmonary Hypertension definition and subtypes. 
Indicated is the definition, and the subtypes, of pulmonary hypertension as an elevated 
mean arterial pressure ≥ 25 mmHg measured by right heart catheterization. Image 
provided by, and used with permission of Jorge Muniz (www.medcomic.com). 
Symptoms of PH are very non-specific and include shortness of breath, 
fatigue, syncope, chest pain, palpitations, angina, weakness, dry cough and a 
reduced exercise capacity. All these symptoms contribute to a decreased quality 
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of life for the pulmonary hypertension patients (66). Due to the unspecific nature 
of the symptoms, PH is often diagnosed late in the process, or in some cases even 
remains undiagnosed. The true incidence and prevalence of PH in the general 
population are unknown and since it is even suggested that a group of patients is 
undiagnosed, all reported numbers are probably an underestimation (49). 
 Currently, treatment modalities for PH are still very limited and, even when 
treated, the disease often progresses to right heart failure and death. Heart 
failure means that the heart is not capable of pumping enough blood to the body 
to meet the oxygen demand of the body.  
General cardiovascular physiology 
In patients with PH, the work load of the right ventricle is increased, and the 
pump capacity of the right ventricle ultimately falls short. In order to understand 
the problems that may arise in PH, this section will first describe the healthy 
cardiopulmonary system. 
Cells require oxygen and nutrients to be able to function and essentially 
keep the human body alive. In tissue, oxygen and nutrients are metabolized and, 
in this process, carbon dioxide (CO2) is produced. Oxygen is taken up by the lungs, 
where CO2 is released. The medium to transport these substances through the 
body is blood. Blood is transported though the body using blood vessels, called 
the circulatory system (Figure 2).This circulatory system is divided into two 
circulations, the pulmonary circulation and the systemic circulation. The 
movement (flow) of blood through these circulations is actively driven by the 
heart. The heart functions as a pump which contracts about 60 times each minute 
and ejects about 5 liters of blood per minute at rest. Heart rate can increase to 
200 times each minute, circulating 20 liters of blood per minute during exercise 
(34, 35). The heart consists of two collecting compartments, called the atria, and 
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two ejecting compartments, called the ventricles. In short, deoxygenated blood 
from the body is collected in the right atrium, then goes in to the right ventricle, 
which subsequently pumps it in to the pulmonary circulation. Blood is oxygenated 
in the lungs where after it is collected in the left atrium. The left atrium pumps the 
oxygen rich blood to the left ventricle which subsequently pumps it to the various 
organs in the body via the aorta. The pressure in the aorta is what is commonly 
called “the blood pressure” as measured by the general practitioner. This mean 
systemic blood pressure is approximately 90mmHg in health. In the organs oxygen 
is absorbed and deoxygenated blood returns to the right atrium where the cycle 
starts again (69). 
Pulmonary circulation 
The pulmonary circulation is the part of the cardiovascular system which 
is affected in pulmonary hypertension. In the pulmonary circulation, the right 
ventricle pumps deoxygenated blood into the pulmonary artery (PA), from which 
it flows into the pulmonary vasculature for oxygenation and removal of carbon 
dioxide. The oxygen is supplied by the airways (bronchi) which subdivide into 
bronchioles and ultimately branches into the smallest air sacs (alveoli) which are 
in contact with the pulmonary capillaries for the diffusion of oxygen and carbon 
dioxide. 
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Figure 2. Schematic representation of the cardiovascular system.
Oxygen rich blood is depicted in red and oxygen deprived blood is depicted in blue. The 
arrows indicate the direction of flow.
Following oxygenation,  blood is transported to the left side of the heart via the 
pulmonary veins. To optimize gas exchange in the pulmonary circulation, the  
blood-gas barrier needs to be thin, which results in a low-pressure, high-flow 
circulation. The pulmonary blood flow is equal to the systemic cardiac output 
while the mean pulmonary artery pressure is approximately 15mmHg in health 
(>25mmHg in PH patients). Since the pressure drop over the pulmonary 
vasculature from the PA to the left atrium (LA) is very low (approximately 7 
mmHg) to enable blood to flow through the lungs, the pulmonary vascular 
resistance (PVR) is also very low (approximately one tenth of the systemic 
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resistance) in healthy individuals (69). In PH patients, this PVR is substantially 
increased due to constriction, remodeling and rarefaction of the pulmonary blood 
vessels, resulting in a higher pressure to maintain blood flow through the 
pulmonary vascular bed. 
CTEPH 
The World Health Organization differentiates 5 groups of PH based on their 
etiology. Chronic thromboembolic pulmonary hypertension (CTEPH), categorized 
as group 4 PH, is pulmonary hypertension caused by thrombo-emboli in the 
pulmonary vasculature. These thrombo-emboli can be, for instance, originating 
from a deep vein thrombosis, from which the emboli are released and travel 
through the body. The first small vascular bed these emboli travel through is the 
pulmonary vascular bed, in which these emboli get stuck. This is called acute 
pulmonary embolism and can be treated by anticoagulation and thrombolysis (30, 
31). However, in a subgroup of these patients, not all the emboli will resolve. 
When these emboli remain in the pulmonary vasculature, most likely in 
combination with other risk factors, CTEPH can develop. Some of the risk factors 
that are linked and hypothesized to play a role in the development of CTEPH are 
genetics, ineffective endogenous fibrinolysis, hypercoagulability, deficient 
angiogenesis, inflammation and platelet endothelial cell adhesion molecule-1 
deficiency (37, 59). In these patients the pressure and resistance in the pulmonary 
vasculature will rise and eventually result in chronic PH. CTEPH develops in about 
3-4% of patients after acute pulmonary embolism and up to 10% of patients with 
recurrent pulmonary embolism (11, 65, 70). The definition of CTEPH is therefore 
defined as a persistent PAP above 25mmHg at rest for at least 3 months, despite 
therapeutic anticoagulation (14, 26, 27, 33), although pulmonary artery pressures 
≥ 19mmHg at rest following embolism are already associated with increased 
mortality at long term (63). The prevalence of CTEPH is still largely unknown. The 
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reported annual incidence of acute pulmonary embolism ranges from 750 to 2700 
per million adults (30, 50, 68) of which 3-4% of the survivors develop CTEPH (11, 
65). According to these numbers, the expected incidence of CTEPH would be 22.5 
to 108 per million adults, while the reported numbers of diagnosed patients with 
CTEPH are substantially smaller. Three countries assessed the CTEPH incidence 
through nationwide registries. In the United Kingdom the CTEPH incidence was 
1.75 per million (6), in Spain it was 0.9 per million adults (12) and in Germany it 
was 5.7 per million adults (32). Between approximately 300 and 400 patients were 
newly diagnosed with CTEPH per year in France and Germany (32, 58), while the 
disease is still incompletely understood and therapeutic interventions are still 
limited, showing the importance of research into this disease. 
The symptoms of CTEPH are the same as of other forms of PH, such as 
shortness of breath, fatigue, syncope, chest pain, palpitations and reduced 
exercise capacity, which (together with physician unawareness) contribute to the 
late diagnosis in a large number of patients. This delayed diagnosis in turn impacts 
the prognosis negatively (29). Unfortunately, to this day, treatment options for 
CTEPH patients are also not optimal. The main treatment options for CTEPH are 
surgical interventions to remove proximal obstructions such as pulmonary 
endarterectomy or balloon angioplasty (10, 16, 23) although these can only be 
performed in eligible patients. Therapeutic agents to modulate the pulmonary 
vascular tone are limited to date. Riociguat, which is a soluble guanylyl cyclase 
stimulator, that activates the nitric oxide (NO) pathway without endogenous NO, 
thus acting as a vasodilator, inhibiting pulmonary smooth muscle cell growth and 
antagonizes platelet inhibition (i.e. preventing clot formation) is the only 
approved therapeutic agent in CTEPH (2, 10, 21, 46). Nevertheless, treatment 
modalities for CTEPH are very limited and, even when treated, the disease often 
progresses to right heart failure and even death. 
General introduction and outline of this thesis 
19 
Changes in the control of vascular tone and remodeling of the pulmonary 
vasculature 
The pathogenesis of CTEPH encompasses a combination of endothelial 
dysfunction, pulmonary vascular structural remodeling, thrombophilia, 
inflammation, vasoconstriction and impaired vasodilation (39). In the healthy 
pulmonary vasculature, endothelin and nitric oxide are key players in regulating 
pulmonary vascular resistance. In PH, pulmonary vascular resistance increases due 
to endothelial dysfunction resulting in a shift towards vasoconstriction and 
remodeling.  
The vessel diameter is set by the contractile state (tone) of the smooth 
muscle cells in the vascular wall. Smooth muscle cells are lined underneath the 
endothelial cells of which the inner lining of the arterial wall is composed. 
Vascular tone is determined by many competing constricting (vasoconstrictor) and 
relaxing (vasodilator) influences acting on the muscular layer of the blood vessel. 
These influences can be divided into metabolic, mechanic, neurohumoral, 
endocrine, paracrine and endothelial influences. The endothelium plays a very 
important role in the regulation and excretion of vasodilators such as the key 
factor nitric oxide (NO), and vasoconstrictors, such as the key factor endothelin-1 
(ET-1), which are the key regulators of vascular tone in the pulmonary circulation 
(55).  
Nitric oxide is a vasoactive agent synthesized from L-arginine by 
endothelial NO synthase (eNOS) in the endothelium. NO diffuses from the 
endothelial cell to the adjacent vascular smooth muscle cell where it binds to, and 
thereby activates, soluble guanylyl cyclase (sGC). This enzyme increases the 
conversion rate of guanosine triphosphate (GTP) to cyclic guanosine 
monophosphate (cGMP). cGMP in turn leads to relaxation of the vascular smooth 
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muscle cells via reduction of Ca2+release from the sarcoplasmic reticulum and 
activation of K+ channels (55). Via this pathway, NO acts as a potent vasodilator 
(Figure 3), inhibits pulmonary smooth muscle cell growth and inhibits clot 
formations.
Figure 3. Vascular anatomy with the NO and ET-1 pathways.
Healthy human artery with endothelium and smooth muscle cell layers depicted on the 
left. The interplay of nitric oxide (NO) and endothelin-1 (ET-1) in the regulation of vascular 
tone in the right. L-arg, L-arginine; eNOS, endothelial nitric oxide synthase; sGC, soluble
guanylyl cyclase; GTP, guanosine triphosphate; cGMP, cyclic guanosine monophosphate; 
ppET-1, preproendothelin-1; Big-ET-1, Big endothelin-1; ECE-1, endothelin converting 
enzyme-1; ETA, endothelin receptor A; ETB, endothelin receptor B; IP3, inositol 
triphosphate.
Endothelin-1 is a peptide which is synthesized from big ET (produced from 
preproendothelin by furin-like enzymes) by the endothelin converting enzyme 
(ECE)-1, which is found on the endothelial cell membrane (38). Upon release, ET-1 
binds to its receptors on either the endothelium (ETB receptor) or the vascular 
smooth muscle cell (ETA or ETB receptor). NO is one of the substances that is able 
to inhibit this ET-1 release which shows the delicate balance between these 
regulatory substances. Activation of the ETB receptor on the endothelium leads to 
vasodilation by releasing prostacyclin and NO. In healthy conditions, ET-1 
predominantly binds to the ETA or ETB receptor on the vascular wall, leading to 
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increases of inositol triphosphate (IP3) concentrations which in turn release Ca2+ 
from the sarcoplasmic reticulum. This Ca2+ release subsequently leads to 
contraction of the vascular smooth muscle cells (55). Via this pathway, ET-1 acts 
as a potent vasoconstrictor (Figure 3). 
The obstructions in the pulmonary vascular bed in CTEPH cause a direct 
increase in pulmonary vascular resistance, and a redistribution of flow through 
the unobstructed parts of the pulmonary vasculature, which result in an increase 
in PAP. Both the increase in pressure and the local increase in flow are thought to 
contribute to remodeling of the unobstructed pulmonary vascular bed (15, 43). 
This remodeling encompasses structural remodeling of both the pulmonary small 
arteries (diameter >50μm) as well as the microvasculature (diameter <50μm). The 
structural remodeling presents predominantly with an increase in pulmonary 
vascular wall thickness which encroaches on the vascular lumen thereby 
increasing the resistance. In addition, the prolonged endothelial dysfunction, 
either as a cause or a consequence of the increased PAP, results in a shift towards 
vasoconstriction, even further increasing the vascular resistance, leading to a 
vicious cycle. 
It is well known that both dysfunction of the endothelin and the nitric 
oxide pathway play important roles in the dysregulation of pulmonary vascular 
tone as well as microvascular remodeling in pulmonary arterial hypertension 
(PAH)(13, 60). However, how alterations in these pathways affect pathogenesis of 
microvascular structural and functional remodeling in CTEPH remains 
incompletely understood. Plasma markers of oxidative stress and the endogenous 
endothelial NO synthase (eNOS) inhibitor asymmetric dimethyl arginine (ADMA) 
are increased in patients with CTEPH (71). Moreover, circulating ET-1 levels are 
elevated in patients with CTEPH and correlate with clinical severity of the disease 
as well as with hemodynamic outcome after pulmonary endarterectomy (51). 
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However, there is some controversy as to whether therapeutic agents that 
interfere with the NO and the ET-1 systems, such as phosphodiesterase 5 (PDE5)-
inhibitors and ET-receptor antagonists, that are the cornerstones of PAH therapy, 
are equally effective in CTEPH (10, 21, 46). The only approved therapy for CTEPH 
is the sGC stimulator Riociguat (10, 21, 46), suggesting that the NO-pathway is 
compromised in CTEPH.  
Remodeling of the heart 
The high pressure and resistance in the pulmonary vasculature impose an 
increased afterload on the right ventricle. As contractile reserve of the RV is 
limited (22), initially, subacute RV dilation and dysfunction present (59). With 
sustained PH, the increased pressure subsequently produces an augmentation of 
wall thickness by increasing the muscle mass resulting in right ventricular 
hypertrophy (59), in order to normalize RV wall stress. Although RV remodeling is 
initially beneficial and aims to normalize wall stress, the RV is not capable of 
sustaining a long-term progressive pressure overload. The dilation increases wall 
stress which requires a higher oxygen demand and thus decreases the perfusion 
of the RV leading to a vicious circle of compromised contractility of the 
cardiomyocytes and dilation which eventually leads to the development of RV 
failure. 
V/Q mismatch in CTEPH 
Obstructions in the pulmonary vasculature as observed in CTEPH patients impair 
ventilation (V) and perfusion (Q) matching. In the embolized lungs, there are areas 
that are overventilated and underperfused and areas that are underventilated 
and overperfused. This heterogeneity can be explained by the fact that some 
areas are not perfused due to the obstructions and some areas are overperfused 
due to redirection of the blood flow. Ventilation-perfusion inequality hampers 
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(i.e. reduces) the arterial oxygen uptake and carbon dioxide clearance, and leads 
to compensatory hyperventilation in an attempt to increase the carbon dioxide 
clearance but inadvertently leads to increased dead space ventilation of the lungs. 
Moreover, this hyperventilation of the lungs is insufficient to increase oxygen 
uptake (40). This decreased oxygenation of blood and increased lung ventilation 
contribute to the shortness of breath experienced by patients.  
Exercise intolerance in CTEPH 
Exercise intolerance is one of the symptoms of CTEPH and evaluation of RV 
function during stress testing has been shown to be of prognostic value in patients 
(24, 25, 52). RV dysfunction is exacerbated during exercise, when cardiac demand 
increases and the RV is required to pump more blood against an even more 
elevated afterload. Therefore, RV functional measurements during stress enable 
the evaluation of the capacity of the RV to cope with an elevated afterload and 
can facilitate early detection of RV dysfunction (56). Although the main cause of 
exercise intolerance in CTEPH is cardiac, the V/Q mismatch is thought to also play 
a role in the exercise intolerance observed in patients with CTEPH (4, 5, 52). To 
date, however studies describing animal models of CTEPH have not evaluated the 
pathophysiology during exercise.  
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CTEPH Animal models 
Dating back to 1984, many investigators have attempted to establish a large 
animal model to study the pathophysiology of CTEPH using different embolization 
frequencies and embolization materials including air, autologous blood clots, 
sephadex beads and glue (Table 1). Although the PAP increases acutely upon 
embolization in these models, most studies were unsuccessful in establishing a 
sustained level of elevated PAP during prolonged follow-up (7, 9, 18, 35, 42, 61, 
64, 73, 74). Those studies that did report CTEPH during prolonged follow-up (8, 
36, 45, 64, 73) have in common that they used repeated (between 4 and 40 times) 
embolization procedures, thereby obstructing a significant fraction of the 
pulmonary vasculature. In these studies, PAP also decreased in between 
embolization procedures, but gradual increase in PAP occurred over time. 
However, most studies did not determine whether this gradual increase in PAP 
was solely due to the progressive embolization of pulmonary vessels or that distal 
pulmonary microvasculopathy also developed. Recent findings by Boulate et al. 
suggest that distal vasculopathy was present in their model of left pulmonary 
artery ligation in combination with glue-embolizations (74). However, in the latter 
study, as in most of the aforementioned studies, hemodynamic measurements 
were performed under anesthesia, which may have influenced cardiac function 
and pulmonary hemodynamics (7, 36, 74). Moreover, and in most cases due to 
the use of anesthetic agents, pulmonary hemodynamics were not assessed during 
exercise. This shows the need for a large CTEPH animal model without all the 
previous limitations.   
General introduction and outline of this thesis 
27 
Outline of this thesis 
The general aim of this thesis is to characterize and study the complex 
mechanisms involved in the development and progression of CTEPH. For this 
purpose, we developed and utilized a novel large animal model for CTEPH and 
studied the effects of cardiopulmonary exercise testing. In addition, we 
investigated the role of pulmonary endothelial (dys)function in the development 
and progression of CTEPH and characterize (molecular) pathways involved in 
cardiac remodeling with the emphasis on hypertrophy, contractility, 
inflammation, oxidative stress, apoptosis and angiogenesis 
Part I Development and Validation   
In order to study hemodynamic changes in a large animal model in the 
awake state, we developed a model of chronic instrumentation of swine as 
described in Chapter 2. The chronic instrumentation of swine allows for serial 
examination of hemodynamic parameters as well as blood samples in the awake 
state, and facilitates the infusion of embolizing material. In addition, treadmill 
exercise is possible with these catheterized animals, allowing cardiopulmonary 
exercise testing in health and disease in the experimental setting.  
 To investigate the development and pathophysiology of CTEPH, we aimed 
to develop a novel CTEPH large animal model to overcome the shortcomings, as 
described above, of previous animal models. We therefore developed a 
chronically instrumented, double-hit CTEPH swine model, by using the 
instrumentation method of Chapter 2 and a combination of inducing endothelial 
dysfunction and emboli. We investigated the development of the disease and 
utilized cardiopulmonary exercise testing to allow for earlier detection of the 
disease in Chapter 3 of this thesis. In Chapter 4, we present a state of the art 
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imaging modality, 4D flow MRI. The goal of this study was to validate this imaging 
modality against the established 2D MRI and the in vivo flow measurement, 
enabled by the catheterization described in Chapter 2. In addition, we 
investigated potential differences in pulmonary and aorta flow profiles in the 
CTEPH swine, as developed in Chapter 3, compared to healthy swine. 
Part II Characterization 
Since the pathophysiology of CTEPH is incompletely understood, we 
studied changes in both pulmonary microvascular (Chapter 5) and cardiac 
(Chapter 6) remodeling. We aimed to elucidate some of the mechanisms involved 
in this remodeling to better understand the pathophysiology of the disease. The 
pressing importance to elucidate this pathophysiology are all the patients for 
which no clear therapy is present to date. We believe that endothelial dysfunction 
plays a key role in the progression of the disease, and therefore focus on 
investigating pulmonary vascular remodeling and the role of the NO and 
endothelin pathways. Other factors involved in the development and progression 
of disease such as pulmonary and cardiac inflammation and angiogenesis were 
investigated as well. In addition, the influence of exercise on the pulmonary 
ventilation/perfusion and cardiac function was investigated for both contributions 
to exercise limitations and role for disease detection in patients.  
A summary of the study protocol and the chapters in which we investigate what 
parts are depicted in Figure 4. 
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Abstract 
This protocol describes the surgical procedure to chronically instrument swine and 
the procedure to exercise swine on a motor-driven treadmill. Early 
cardiopulmonary dysfunction is difficult to diagnose, particularly in animal 
models, as cardiopulmonary function is often measured invasively, requiring 
anesthesia. As many anesthetic agents are cardiodepressive, subtle changes in 
cardiovascular function may be masked. In contrast, chronic instrumentation 
allows for measurement of cardiopulmonary function in the awake state, so that 
measurements can be obtained under quiet resting conditions, without the 
effects of anesthesia and acute surgical trauma. Furthermore, when animals are 
properly trained, measurements can also be obtained during graded treadmill 
exercise.  
Flow probes are placed around the aorta or pulmonary artery for measurement of 
cardiac output and around the left anterior descending coronary artery for 
measurement of coronary blood flow. Fluid-filled catheters are implanted in the 
aorta, pulmonary artery, left atrium, left ventricle and right ventricle for pressure 
measurement and blood sampling. In addition, a 20 G catheter is positioned in the 
anterior interventricular vein to allow coronary venous blood sampling.  
After a week of recovery, swine are placed on a motor-driven treadmill, the 
catheters are connected to pressure and flow meters, and swine are subjected to 
a five-stage progressive exercise protocol, with each stage lasting 3 min. 
Hemodynamic signals are continuously recorded and blood samples are taken 
during the last 30 sec of each exercise stage.  
The major advantage of studying chronically instrumented animals is that it allows 
serial assessment of cardiopulmonary function, not only at rest but also during 
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physical stress such as exercise. Moreover, cardiopulmonary function can be 
assessed repeatedly during disease development and during chronic treatment, 
thereby increasing statistical power and hence limiting the number of animals 
required for a study. 
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Introduction 
Adequate cardiopulmonary function is essential to supply the body with oxygen 
and nutrients, particularly during conditions of increased metabolic demand such 
as during exercise (9). The cardiopulmonary response to exercise is characterized 
by a number of adaptations in cardiac function, i.e., an increase in heart rate, 
contractility and stroke volume, and microvascular function, i.e., vasodilation in 
the vascular beds supplying exercising muscles as well as in the pulmonary 
vasculature, and vasoconstriction in the vascular beds supplying the 
gastrointestinal system as well as inactive muscles (9). Impaired exercise capacity 
is an early hallmark of cardiopulmonary dysfunction, and cardiopulmonary 
exercise testing is used as an effective method to delineate between cardiac 
dysfunction, vascular dysfunction and/ or pulmonary dysfunction in patients with 
impaired exercise capacity (2). Early cardiopulmonary dysfunction is difficult to 
diagnose, particularly in animal models, as cardiopulmonary function is often 
measured invasively, requiring anesthesia, with many anesthetic agents 
possessing cardiodepressive properties (20). Chronic instrumentation allows for 
measurement of cardiopulmonary function in the awake state, and when the 
animals are fully adjusted to the laboratory conditions measurements can be 
obtained under quiet resting conditions without the effects of anesthesia and 
acute surgical trauma. Furthermore, when the animals are appropriately trained, 
measurements can also be obtained during graded treadmill exercise (4, 18). 
More specifically, left and right ventricular function can be assessed and related 
to myocardial perfusion, while regulation of vasomotor tone in the coronary, 
systemic and pulmonary microcirculation can be determined. The use of fluid-
filled catheters allows measurement of pressure as well as taking blood samples 
without imposing additional stress on the animals. Another advantage of studying 
chronically instrumented animals is that cardiopulmonary exercise testing can be 
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repeated allowing the use of an animal as its own control, either during disease 
development or during chronic treatment, thereby increasing statistical power 
and hence limiting the number of animals required for a study. Cardiopulmonary 
anatomy of swine closely resembles that of humans and it is possible to induce 
various forms of cardiopulmonary disease, such as diabetes (19), myocardial 
infarction (23), pulmonary hypertension (11, 15) and pacing-induced heart failure 
(16, 21). Moreover, the size of swine allows chronic instrumentation, and 
repeated blood sampling of sufficient quantity to analyze not only blood gases, 
but also to perform neurohumoral measurements and/or to search for 
biomarkers of disease. This protocol describes the surgery used to chronically 
instrument swine as well as the protocol for exercising the swine on a motor-
driven treadmill. 
Protocol 
Procedures involving animal subjects have been approved by the Animal Care 
Committee at Erasmus Medical Center Rotterdam (NL). Swine with weights 
between 6 and 80 kg have been successfully instrumented using this protocol.  
1. Adaptation of the Animals to Human Handling  
1. After arrival in the facility, house the animals solitarily but enable them 
to interact with each other.  
2. Accustomize swine to human handling and transportation from the 
animal facility to the experimental laboratory, by handling the animal at 
least once a day for one week.  
Cardiovascular exercise testing in chronically instrumented swine 
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3. Train the animals appropriately for exercise experiments on a motor-
driven treadmill by exercising them on the treadmill for a minimum of 
three times before surgery.  
4. Animals should be fasted O/N before surgery to prevent nausea, 
vomiting and thereby potential aspiration of stomach fluids.  
2. Preparation for Surgery  
1. Sedation  
1. Prepare medication for sedation in a 10 ml syringe. Premedication 
consists of tiletamine/zolazepam (5 mg/kg), xylazine, (2.25 mg/kg) and 
atropine (1 mg).  
2. Inject the medication intramuscularly in the trapezius muscle with a 19 
G 1.5'' needle to sedate the pig.  
3. Wait for approximately 10 min and check for muscle relaxation and 
unconsciousness to confirm appropriate and stable level of sedation.  
4. Place a 20 G peripheral safety catheter in an ear vein for subsequent 
intravenous administration of anesthesia and/or fluids.  
2. Intubation and Ventilation  
1. Place the animal on a table and/or trolley in supine position.  
2. Open the mouth of the animal with an oral spreader.  
3. In case of insufficient relaxation of the jaws or presence of swallowing 
reflexes, which hinder intubation, administer thiopental (10 mg/ kg) 
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intravenously via the ear vein catheter. Alternatively, the pig could be 
masked with isoflurane to induce sedation.  
4. Use a conventional laryngoscope with a light and a Miller blade to allow 
the laryngoscopist to directly view the larynx. If there is laryngospasm, 
apply 2% lidocaine to the cords and larynx to reduce the spasm and allow 
intubation.  
5. Insert an intubating stylet into the endotracheal tube to make the tube 
conform better to the upper airway anatomy and pass the tube through 
the mouth and between the vocal cords into the trachea.  
6. Inflate the balloon cuff with a 10 ml syringe to help secure it in place, to 
prevent leakage of respiratory gases, and to protect the airways from 
possible aspiration of stomach fluid.  
7. Connect the tube to a breathing filter (heat and moisture exchanger) 
and to the mechanical ventilator.  
8. Place the animal on its right side on the surgical table.  
9. To achieve pO2 levels of 100-120 mmHg, ventilate the animal with a 
mixture of oxygen and nitrogen (1:2 v/v), using the following ventilator 
settings: Pressure control mode: positive end-expiratory pressure (PEEP) 4 
cmH2O; peak inspiratory pressure 16 - 18 cmH2O; breathing frequency 
depending on the size of the animal (for a 20 kg animal, decrease 
frequency with increasing body weight) this should result in a tidal volume 
of ~10 ml/kg, monitor ventilation with capnography.  
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10. Monitor temperature using a rectal thermometer and maintain 
temperature between 37 - 39 ºC using a heat lamp or heat mat. 
Moreover, monitor heart rate with electrocardiography.  
3. Anesthesia  
1. Induce and maintain anesthesia preferably by adding 2.0% of isoflurane 
(v/v) to the ventilation gas-mixture or alternatively by intravenous 
administration of fentanyl (10 μg/kg/h) via the ear vein catheter.  
2. Check adequate depth of anesthesia by testing pain reflexes with a hind 
leg toe pinch before starting surgery. When necessary, add additional 
anesthesia or wait for a few minutes. Check pain reflexes regularly 
throughout the surgery.  
4. Fluids and Antibiotics  
1. Administer the first dose of amoxicillin (25 mg/kg) intravenously via the 
ear vein catheter. 2. Connect a transfusion system to the ear vein catheter 
to enable slow infusion of glucose 10% (500 ml) during surgery.  
5. Sterilization of Surgical Site  
1. Shave and clean the skin of the animal over an area of approximately 25 cm 
width from the vertebral column all the way to the left axilla.  
2. Scrub the moisturized skin with povidone-iodine scrub (75 mg/ml) for 
approximately 5 min. 
3. Remove the povidone-iodine soap from the skin with wet sterile gauzes, before 
sterilizing the skin with povidone-iodine lotion (100 mg/ ml).  
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4. Cover the animal with sterile surgical drapes to reduce bacterial transfer and 
subsequent contamination of the surgical site.  
3. Surgery  
1. Opening the Thorax (Thoracotomy)  
1. Make an incision in the skin, starting 1 cm caudal to the left inferior 
angle of the scapula down to the left axilla (Figure 1). Use diathermy to 
cauterize blood vessels in the skin to prevent excessive bleeding.  
2. Cut through the serratus muscle and pectoralis major muscle, using the 
cutting modality of the diathermy. Also use diathermy to cauterize blood 
vessels in the muscle layer to prevent excessive bleeding.  
3. Use blunt dissection to carefully divide the intercostal muscle of the 
fourth left intercostal space with a mosquito clamp. Now the costal 
surface of the left lung covered with visceral and parietal pleura should be 
exposed.  
4. To enter the pleural cavity, carefully pierce both layers of the pleura 
and tear them open.  
5. Use a thoracic retractor to separate the edges of the wound and the 
ribs and to forcefully drive tissues apart to obtain good exposure of the 
pleural cavity.  
6. Push away the left lung in the caudal direction and keep it in place with 
a wet gauze. Now the heart and great vessels should be clearly exposed.  
Cardiovascular exercise testing in chronically instrumented swine 
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2. Placement of Catheters and Flow Probes (Figure 1)  
1. Use blunt dissection to remove ~2 cm2 of the surrounding connective tissue of 
the descending thoracic aorta.  
2. Perform a purse-string suture, consisting of three stitches, in the aortic 
wall with a non-absorbable USP3-0 braided silk suture (Ø0.2 mm).  
3. Penetrate the aortic vessel wall with a stainless steel 16 G needle in the 
middle of the purse-string suture.  
4. Insert the tip of the fluid-filled catheter (until the ring) into the aorta, 
pull the purse-string suture firmly together and tie the two strings of the 
suture.  
5. To keep the catheter in place, wind the suture 3 times around the 
catheter above the ring and again tie the two strings of the suture. 
Further secure the catheter with a new stitch approximately 1 cm cranial 
from the insertion place.  
6. Connect the fluid-filled catheter to the calibrated pressure transducer, 
which is connected to the computer, to monitor the mean arterial 
pressure during the surgery. Obtain an arterial blood gas to verify or 
adjust for correct ventilation settings.  
7. Open the pericardium with a crossed cut. Be aware to keep the phrenic 
nerve that runs over the pericardium intact.  
8. Identify the pulmonary artery and pull it slightly in the caudal direction 
with a Farabeuf retractor. Now the ascending aorta and aortic arch should 
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be exposed. Monitor mean arterial pressure while retracting the 
pulmonary artery.  
9. Make a small cut (~1 cm) in the connective tissue between the 
ascending aorta and the pulmonary artery using Metzenbaum scissors, to 
be able to dissect either the ascending aorta or the pulmonary artery with 
a large curved mosquito clamp to place the flow probe.  
10. Place the rubber band of the flow probe around the vessel. To make 
this easier, place a suture through one end of the rubber band, place this 
suture around the vessel and pull it until the rubber band surrounds the 
vessel.  
11. Fix the flow probe measurement device on the rubber band. Connect 
the flow probe to the computer and check the cardiac output signal on 
the computer to confirm a correct placement of the flow probe.  
12. Place fluid-filled catheters in the pulmonary artery, right ventricle, left 
ventricle and left atrium at the same manner as described for the aortic 
fluid-filled catheter (3.2.2 - 3.2.5). Note that it is not necessary to remove 
connective tissue before performing a purse-string suture in these 
structures.  
13. Expose and dissect the proximal part of the left anterior descending 
coronary artery by first lifting the tissue with a forceps and making a small 
(2 - 3 mm) cut with Metzenbaum scissors, followed by carefully teasing 
the tissue away from the artery with a cotton swab. Ensure complete 
dissection of the coronary artery by passing a small straight angled 
mosquito clamp underneath.  
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14. Make a stitch parallel to the anterior interventricular coronary vein 
with a suture, which is connected to the coronary venous catheter.  
15. Puncture the coronary vein with the 20 G needle of the coronary 
venous catheter and insert the cannula of the catheter intravenously.  
16. Remove the needle and secure the catheter with the already 
performed stitch (3.2.14). Further secure the catheter with a new stitch 
approximately 1cm from the place of initial puncture.  
17. Place the coronary flow probe around the previously dissected left 
anterior descending coronary artery. When the artery is constricted and is 
hardly visible, use lidocaine 10% spray to relax the vessel to get a better 
exposure of the vessel. Check the signal of the coronary flow on the 
computer to confirm a correct placement of the flow probe (Figure 2).  
3. Tunneling  
1. Tunnel the flow probes individually through the third left intercostal 
space beneath the muscle and above the rib by using a large curved 
mosquito clamp.  
2. Tunnel the fluid-filled catheters through either the third or the fifth left 
intercostal space by piercing the intercostal muscle. Clamp off the fluid-
filled catheters and remove the three-way stopcock to minimize the 
piercing area and prevent leakage of the fluid-filled catheters during the 
tunneling.  
3. Fix the flow probes and the fluid-filled catheters with non-absorbable 
USP2-0 braided silk (Ø0.3 mm) by means of a purse string suture on the 
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intercostal muscle. This suture also serves to prevent air leakage after re-
instating negative intrathoracic pressure.  
4. Make three incisions in the skin approximately 2 cm sinister and parallel 
to the vertebral column, approximately 3 cm in length 3 cm apart of each 
other.  
5. Pierce a trochar beneath the left latissimus dorsi muscle from rostral 
incision site to the incisions on the back. Tunnel the flow probes and fluid 
catheters to the back within this trochar.  
6. Place the stopcocks on the fluid-filled catheters and remove the clamp. 
Withdraw blood to remove clots and air bubbles and fill the fluid-filled 
catheters with 1,000 IU/ml heparin. Coronary venous catheters should be 
filled with 5,000 IU/ml heparin.  
4. Closing the Thorax 
1. Make an incision with a length of approximately 1.5 cm, 8 cm caudal 
and parallel to the first incision.  
2. Lead the drain from the pleural cavity through the sixth intercostal 
muscles subcutaneously to this incision with a large curved mosquito 
clamp. Connect the drain to the suction device to remove any remaining 
fluid and reinstate negative pressure in the pleural cavity during the 
closing of the thorax.  
3. Relieve and inflate the lung with an end-inspiratory hold. Ensure 
adequate filling of the lung by visual monitoring.  
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4. Close the thorax by pulling the ribs of the fourth intercostal space 
together at two separate sites with non-absorbable USP6 braided 
polyester (Ø0.8 mm).  
5. Close the serratus muscle and pectoralis major muscle with a running 
stitch and the skin with a running subcuticular suture using nonabsorbable 
USP2-0 braided silk (Ø0.3 mm)  
6. Suture the incisions on the dorsal side with non-absorbable USP2-0 
braided polyester (Ø0.3 mm) between the catheters. First tie a knot 
directly onto the skin to close the incision, then fixate the catheters to the 
suture with a knot 1 cm from the skin. For the flow probes, use an 
absorbable USP2-0 braided polyglactin (Ø0.3 mm) suture to prevent 
cutting of the suture in the flow probe wire (Figure 1).  
7. Carefully remove the drain while applying pressure on the cranial side 
of the incision to maintain negative pressure in the pleural cavity. Close 
the incision with a purse string suture using non-absorbable USP2-0 
braided polyester (Ø0.3 mm) and seal the wound with petroleum jelly. 
5. Termination of anesthesia and recovery from surgery  
1. Stop anesthesia when all incision sites are closed.  
2. Provide analgesia by administering buprenorphine (0.015 mg/kg) i.m. in 
the gracilis muscle.  
3. Stop the ventilation when the animal is breathing independently and 
disconnect the tracheal tube from the ventilator. Check regularly if the 
animal is breathing sufficiently.  
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4. Place gauze pads between exteriorization sites of the catheters to 
absorb wound fluid.  
5. To protect the external segments of the catheters, give the animal an 
elastic vest and package the catheters between two pieces of artificial 
sheepskin.  
 
Figure 1. Overview of the Surgery.  
Top left panel: The sterile area of the animal, which should be shaved and sterilized lies 
between the bleu lines. The incision site is depicted as the red dotted line. Bottom left 
panel: Picture of catheters and flow probes: fluid-filled catheter (A), aorta/ pulmonary flow 
probe including rubber band (B), coronary venous catheter including 20 G needle (C) and 
the coronary flow probe (D). Top right panel: Schematic overview of placement of the 
catheters and flow probes. MAP, mean arterial pressure; Cor venous, coronary venous 
catheter; LAP, left atrial pressure; LVP left ventricular pressure; RVP, right ventricular 
pressure; PAP, pulmonary artery pressure; CO, cardiac output; CBF, coronary blood flow. 
Bottom right panel: Tunneled catheters exiting the back secured with a stitch and a knot at 
approximately 1 cm distance along the suture.  
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6. Deflate the balloon of the tracheal tube and extubate when the animal 
regains its swallowing reflex.  
7. Provide long-term analgesia by means of a Fentanyl slow-release patch 
(12 µg/hr for a 20 kg pig; adjust strength according to bodyweight). Place 
the patch on a thin part of the skin (such as the lower abdomen) to ensure 
adequate delivery of analgesia.  
8. House the animal separately for the entire post-operative period. 
Provide a heating lamp for the first week after surgery to keep the animal 
warm. 
9. Supply enough fluid i.v. if the animal is not drinking independently.  
10. Flush the fluid-filled catheters daily, by first withdrawing blood to 
remove clots, then refilling with saline and finally with heparinized saline 
(1,000 - 5,000 IU/ml) to prevent blood clot formation. Take care not to 
infuse any air bubbles while flushing the catheters.  
11. Administer amoxicillin (25 mg/kg) i.v. daily for 6 days after surgery to 
prevent post-surgical infections. 
4. Treadmill Experiment (Figure 2)  
1. Flush the fluid-filled catheters as described (3.5.10) and attach the 
flushed catheters to the pressure transducers. Measure the rectal 
temperature to be able to obtain temperature corrected blood gas values.  
2. Flush the pressure transducers with saline to prevent damping of the 
signals due to air bubbles. Attach the pressure transducers to the elastic 
vest on the dorsal side.  
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3. Connect the pressure transducers and flow probes to the amplifier. 
Start measuring in the computer program and calibrate the pressure 
transducers and flow probes with 0 mmHg being open to the air (and 
closed to animal) and 100 mmHg using a manometer.  
4. Switch the three-way stopcock in a way that the fluid catheters have an 
open connection with the pressure transducers. Note that the blood 
pressures can now be obtained. Check signals for shape and amplitude 
(Figure 2).  
5. If required, connect an extension line to either of the fluid catheters for 
sampling of mixed venous and arterial blood.  
6. Measure hemodynamics when the animal is lying as well as standing 
quietly on the treadmill. Average blood pressures are measured over a 
timeframe of 10 sec.  
7. Obtain arterial and mixed venous blood samples by first withdrawing 5 
ml of blood using a 10 ml syringe so that 1 ml of pure blood can be 
obtained using a heparinized 1 ml syringe. For the coronary venous blood 
samples, a 2 ml syringe is used instead of the 10 ml syringe and 
withdrawal of 1 ml is sufficient to obtain pure blood.  
8. Keep the sealed 1 ml syringes on ice before processing the blood 
samples with a blood gas analyzer to determine the metabolic and 
ventilatory condition of the animal.  
9. Subject the swine to a five-stage exercise protocol on the treadmill, 3 
min per speed, 1 - 5 km/hr (~85% of maximal heart rate). Obtain 
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hemodynamics and blood gases after 1.5 - 2 min per speed on each speed 
as in the resting position.  
 
Figure 2. Treadmill Experiment.  
Left panels: Instrumented swine on the treadmill. Fluid-filled catheters are connected to 
the pressure transducers, placed on the back of the swine. Top right panel: Overview of the 
total experimental set-up, including treadmill, amplifier and recording computer. Bottom 
right panel: Typical example of recorded hemodynamic data. From top to bottom; aortic 
pressure (AoP, blue) and left ventricular pressure (LVP, red); left atrial pressure (LAP,blue) 
and left ventricular pressure (red); pulmonary artery pressure (PAP, blue) and right 
ventricular pressure (RVP, red); aortic flow/cardiac output (AoF, blue); coronary blood flow 
(CBF, red). 
10. After the exercise protocol close the stopcocks and check if drift has 
occurred in the 0 mmHg calibration, make a note of this calibration. 
Remove the pressure transducers of the fluid-filled catheters and 
disconnect the flow probes.  
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11. Flush the fluid-filled catheters with saline and heparin (1,000 - 5,000 
IU/ml). Protect the catheters and flow probes by putting them beneath 
the elastic vest between two pieces of artificial sheepskin. The animal can 
now be returned to its cage. 
Representative results 
Exercise up to 5 km/hr resulted in a doubling of cardiac output from 4.3 ± 0.3 to 
8.5 ± 0.7 L/min which was principally accomplished by an increase in heart rate 
from 137 ± 7 to 256 ± 8 beats per min in combination with a small increase in 
stroke volume from 32 ± 2 to 36 ± 3 ml (Figure 3). The increase in stroke volume 
was facilitated by an increase in left ventricular contractility, as evidenced by an 
increase in the maximum of the first derivative of left ventricular pressure 
dP/dtmax together with an increased rate of relaxation of the left ventricle and an 
increase in left atrial pressure, being the filling pressure of the left ventricle 
(Figure 3). The increase in cardiac output together with an increase in hemoglobin 
concentration (from 8.5 ± 0.4 to 9.2 ± 0.4 g/dl) and an increase in body oxygen 
extraction from 45 ± 1 to 71 ± 1% allowed a tripling of body oxygen consumption 
(Figure 3). Systemic vasodilation occurred as evidenced by an increase in systemic 
vascular conductance and a decrease in systemic vascular resistance, which 
accommodated the increase in cardiac output almost completely, so that mean 
aortic pressure increased only slightly (Figure 3). Exercise also resulted in modest 
vasodilation in the pulmonary circulation, as evidenced by a 33 ± 8% increase in 
pulmonary vascular conductance. However, the 101 ± 8% increase in cardiac 
output, together with the increase in left atrial pressure (from 3 ± 1 to 10 ± 1 
mmHg), resulted in an increase in pulmonary artery pressure and thereby in an 
increase in right ventricular afterload (Figure 3). The increase in heart rate, 
together with the slight increase in arterial pressure resulted in an increase in left  
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Figure 3. Typical Hemodynamic Response to Exercise. 
Body oxygen consumption (BVO2) was used as an index for exercise intensity (x-axes of 
panel A-L). Shown are the responses of heart rate (HR, panel A), stroke volume (SV, panel 
B), maximum and minimum of the first derivative of left ventricular pressure (dP/dtmax, 
panel C and dP/dtmin, panel D resp) as indices of contractility and rate of relaxation, 
cardiac output (CO, panel E), mean arterial pressure (MAP, panel F), systemic vascular 
conductance (SVC, panel G), systemic vascular resistance (SVR, panel H), Pulmonary artery 
pressure (PAP, panel J), left atrial pressure (LAP, panel I), pulmonary vascular conductance 
(PVC, panel K). Total pulmonary resistance (TPR index for right ventricular afterload 
increased during exercise, Panel L). The increase in heart rate, together with the slight 
increase in arterial pressure resulted in an increase in left ventricular myocardial oxygen 
consumption (x-axes of panels M-P), which was principally met by an increase in coronary 
blood flow (CBF, panel M), as myocardial oxygen extraction (MEO2, panel N), coronary 
venous oxygen saturation (CVSO2, panel O) and coronary venous oxygen tension (cvPO2, 
panel P) were minimally affected. All data are presented as mean with standard error of 
the mean (SEM). 
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ventricular myocardial oxygen consumption, which was principally met by an 
increase in coronary blood flow which, in combination with the increase in 
hemoglobin concentration resulted in an increase in myocardial oxygen delivery 
(from 310 ± 37 to 738 ± 68 µmol/min). The increase in myocardial oxygen demand 
was commensurate with the increase in myocardial oxygen supply, as myocardial 
oxygen extraction (79.8 ± 1.9% at rest 81.6 ± 1.9% during maximal exercise) was 
essentially maintained constant, resulting in an unchanged coronary venous 
oxygen saturation and coronary venous oxygen tension (Figure 3). 
Discussion 
The present study describes the surgery for chronical instrumentation of swine as 
well as the protocol for exercising the instrumented swine on a motor-driven 
treadmill while measuring hemodynamics and taking blood samples for 
measurement of oxygen content in arterial, mixed venous and coronary venous 
blood.  
Critical Steps within the Protocol  
There are several critical steps within the protocol that start already during the 
intubation procedure. Thiopental (2.1.5) is a respiratory depressive agent, 
therefore requiring swift intubation upon administration. Also, it is important to 
carefully monitor ventilator settings during the procedure. Thus, when the 
thoracic cavity is opened (step 3.1.4), this results in a loss of the negative 
intrathoracic pressure. To compensate for this loss and to prevent alveolar 
collapse, ventilation requires positive end expiratory pressure (PEEP). Moreover, 
ventilator settings (peak inspiratory pressure) should be adjusted to maintain a 
tidal volume of ~10 ml/kg. Also note that when the left lung is pushed away 
Cardiovascular exercise testing in chronically instrumented swine 
63 
(3.1.6.) tidal volume is likely to be decreased because only part of the left lung is 
ventilated. Ventilator settings should be adjusted based on blood gasses.  
Another important note with respect to hemodynamic measurements 
with fluid filled catheters is that there is a hydrostatic pressure difference 
between the pressure transducer and the insertion site of the fluid-filled catheter 
into the cardiovascular system. The height difference between the level of the 
pressure transducer pressure on the elastic vest (4.2), and the insertion point of 
the catheter should be estimated during surgery and at sacrifice of the animal and 
corrected for by interpolation either pre- or post- processing of the data.  
Another important point to consider when using this technique is that 
blood loss, either during surgery or during repeated blood sampling should be 
minimized, despite the fact that swine are relatively large and consequently have 
a large blood volume (65 ml/kg). During surgery, blood loss during insertion of the 
catheters can be minimized by simply applying compression on the puncture 
wounds. According to animal experimentation guidelines, up to 10% of the 
circulating blood volume can be taken on a single occasion from normal, healthy 
animals with minimal adverse effects, but it will take an animal about 14 days to 
replenish this amount of blood (6). This means that the recovery from surgery is 
prolonged when a significant amount of blood is lost.  
During the repeated blood sampling during the exercise experiments, a 
maximum of 1.0% of an animal's circulating blood volume, or 0.6 ml/ kg can be 
removed every 24 hr 15. This also means that the amount of blood that is 
sampled during treadmill exercise, should be well-planned and that, after removal 
of the initial clots that are invariably present in the lumen of the catheter near the 
tip at the interface with the blood, the remaining blood withdrawn to flush the 
lines should be given back to the animals.  
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(3.1.6.) tidal volume is likely to be decreased because only part of the left lung is 
ventilated. Ventilator settings should be adjusted based on blood gasses.  
Another important note with respect to hemodynamic measurements 
with fluid filled catheters is that there is a hydrostatic pressure difference 
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sampled during treadmill exercise, should be well-planned and that, after removal 
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Modifications and Troubleshooting  
Implanted fluid-filled catheters should be flushed daily to prevent malfunctioning 
because of blood clot formation. Depending on the amount of blood clots in the 
fluid filled catheters, the amount of heparin in each line can be varied from 1,000 
IU/ml to 5,000 IU/ml. The amount of heparin should be kept to a minimum in the 
first week after surgery to prevent bleeding from surgical incision wounds due to 
the presence of the anticoagulant heparin.  
However, even when flushed daily, some fluid-filled catheters will get 
clogged. When this happens, try withdrawing blood with a smaller 2 ml syringe by 
applying minimal and/or pulsatile suction. It can take several minutes before the 
catheter will be unclogged. When this does not work, carefully flush a small 
amount of saline into the catheter and immediately try to withdraw blood. Be 
aware that infusion can result in a release of thrombus into the circulation and 
embolism of distal organs, depending on the site of the catheter. When careful 
flushing does not work, connect the clogged line to a pressure-transducer to 
check if there is still a hemodynamic signal. If there is no signal, the fluid filled line 
should be sealed by several knots and cut off.  
Interpretation and Limitations  
When all points as mentioned above are taken into account, the combination of 
hemodynamic measurements and blood samples allows for interpretation of the 
exercise response in terms of whole body and myocardial oxygen consumption, 
which are better measures for exercise intensity than treadmill speed alone (5, 17, 
22, 23).  
In order to meet the increased metabolic requirements of the body, 
exercise requires changes in cardiac function as well as changes in local perfusion. 
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Tissue perfusion is regulated by changes in diameter of the small arteries and 
arterioles of the vascular bed supplying the tissue. Myriad vasoactive factors, 
derived from neurohumoral systems, the endothelium and local metabolites 
interact to determine vascular tone and ensure adequate tissue perfusion (5, 9, 
12, 18). Changes in systemic and pulmonary vascular resistance or the inverse, 
vascular conductance, can be calculated from the blood pressure and flow signals 
and interpreted in terms of changes in vasomotor tone in the systemic and 
pulmonary vasculature. Intuitively, vascular resistance is often used to assess 
changes in vascular tone. However, in our research group, we advocate the use of 
conductance although conductance and resistance are mathematically related, 
with conductance being flow normalized for pressure, and resistance equaling 
pressure divided by flow. Although conductance and resistance are 
interchangeable if one investigates the effect of only a single stimulus (i.e., 
exercise) (3, 23), interpretation of the two parameters can differ when combining 
exercise with pharmacological interventions, to investigate the contributions of 
various vasoactive systems to regulation of vascular tone (4, 10, 18, 22, 23).  
During exercise, the systemic circulation transforms from a system at rest 
that is characterized by a low flow and a high resistance (i.e., low conductance) 
into a system with high flow and low resistance, (high conductance). As such, 
pharmacological vasodilation has different consequences for conductance and 
resistance during rest versus exercise. The decrease in resistance that is produced 
by a pharmacological vasodilator at rest is large while the increase in conductance 
is only small. In contrast, during exercise the same degree of vasodilation 
translates into a large increase in conductance, but only a small decrease in 
resistance. Thus, when conductance is used, a greater vasodilation seems to occur 
during exercise, while when looking at resistance vasodilation appears to be larger 
at rest. Interpretation of the data thus differs when using resistance or 
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conductance. Although the choice between resistance and conductance may 
seem rather arbitrary, in physics the variable that undergoes the primary change 
is designated as the numerator of the index for a response (3, 10, 23). Since 
during exercise aortic blood pressure remains fairly constant whereas cardiac 
output increases markedly, the most appropriate parameter to describe the 
systemic vascular response to exercise would appear to be systemic vascular 
conductance (cardiac output / aortic blood pressure), rather than resistance. 
Moreover, the systemic circulation consists of a multitude of vascular beds from a 
variety of organs that are principally perfused in a parallel manner. Since parallel 
resistors add up reciprocally, while parallel conductors add up in a linear manner, 
any change in conductance of a particular regional vascular bed translates into an 
identical (absolute) change of the total systemic vascular conductance. This 
consideration lends further support to the use of vascular conductance to 
describe the systemic vascular responses to exercise and pharmacological 
interventions.  
The choice for either resistance or conductance to describe the vascular 
responses to exercise in the pulmonary bed appears to be less obvious, because 
exercise produced increases in cardiac output as well as pulmonary artery 
pressure (3, 23). A choice for either resistance or conductance is also less critical, 
in view of the relatively minor exercise-induced changes in PVR and PVC as 
compared to the degree of vasodilation produced by, for example, ET-receptor 
blockade (23). As a result, the use of either resistance or conductance to 
characterize the vascular effects of a pharmacological vasodilator in the 
pulmonary circulation will yield similar conclusions.  
In the coronary circulation, interpretation of the data is even more 
complex as systemic administration of pharmacological antagonists of 
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endogenous vasoactive substances results not only in alterations in coronary 
resistance vessel tone, but often also produce pronounced changes in systemic 
hemodynamic variables (3, 14, 22, 23). These altered hemodynamics influence 
cardiac work, and thereby cause changes in coronary blood flow resulting from 
changes in metabolic requirements of the heart or from autoregulation, rather 
than as a direct effect of the intervention on coronary vascular tone. For example, 
blockade of an endogenous vasoconstrictor system decreases mean aortic 
pressure, as a consequence of systemic vasodilation, and elicits autoregulatory 
adjustments in coronary microvascular tone. Moreover, baroreceptor reflex 
activation acts to increase heart rate and myocardial contractility. Such changes in 
heart rate and/or blood pressure subsequently will result in alterations in 
myocardial metabolism, requiring an adjustment in myocardial oxygen supply and 
hence in coronary blood flow.  
To take into account the effects of such drug-induced alterations in 
myocardial oxygen consumption, investigators examine the relation between 
coronary venous oxygen levels and myocardial oxygen consumption (MVO2) (4, 
18), as this approach allows assessment of regulation of coronary resistance 
vessel tone independently of changes in myocardial oxygen demand. 
Administration of a vasodilator will increase myocardial oxygen delivery at a given 
level of MVO2. As this increase in oxygen delivery occurs without a change in 
oxygen consumption, myocardial oxygen extraction will decrease, thereby leading 
to increases in coronary venous oxygen content and hence in an upward shift of 
the relation between MVO2 and coronary venous oxygen levels. It is therefore 
imperative to measure both myocardial oxygen demand as well as myocardial 
oxygen supply in order to correctly study the regulation coronary resistance vessel 
tone (4, 18).  
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Notwithstanding its elegance and usefulness, some investigators have 
pointed out the limitations of this approach (8). Thus, plotting MVO2 versus 
coronary venous PO2 or coronary venous SO2 could be considered to be 
inappropriate because these variables are actually part of the equation to 
compute MVO2. Consequently, MVO2 is not a variable that is independent of 
coronary venous PO2 or SO2. Alternatively, investigators should consider using 
another index of myocardial work, the rate-pressure product (RPP), which is the 
product of heart rate and left ventricular systolic pressure. However, as RPP and 
MVO2 are almost linearly related, substituting RPP for MVO2 yields virtually 
identical results (22), and the relation between MVO2 and coronary venous 
oxygen levels is considered a sensitive way of studying alterations in coronary 
vasomotor tone.  
Significance with Respect to Existing Methods  
Another method commonly used to assess changes in regulation of vascular tone 
is the use of isolated coronary and pulmonary small arteries or arterioles in a 
pressure or wire myograph (13, 19, 22). The advantage of myograph studies is 
that vessels can be studied independent of surrounding tissue and without 
potentially confounding effect from circulating factors. These in vitro techniques 
are therefore complementary to the in vivo measurements. However, in vivo and 
in vitro techniques sometimes give opposing results. For example, the response to 
the potent vasoconstrictor endothelin was reduced in the intact coronary 
circulation after myocardial infarction, but was augmented in isolated coronary 
small arteries from swine with myocardial infarction as compared to healthy 
control swine (13). This difference between the in vivo and in vitro data was due 
to an increased suppression of the vasoconstrictor influence of endothelin by 
prostanoids in vivo (13).  
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Future Applications  
Given the proposed role of changes in coronary microvascular function in both left 
and right ventricular dysfunction, assessment of these changes in relevant models 
of cardiovascular disease is required. The use of chronically instrumented animals 
allows correlations of the severity of the disease with microvascular (dys)function. 
Moreover, both coronary and pulmonary microvascular function may appear 
normal under basal resting conditions, while microvascular dysfunction may be 
revealed under cardiovascular stress, such as during exercise.  
Several swine models of cardiopulmonary disease, such as diabetes (19), 
myocardial infarction (7), pulmonary hypertension (11, 15) and pacing induced 
heart failure (16) are available and could be combined with chronic 
instrumentation. A potential drawback is that, when commercially available swine 
breeds such as Yorkshire, Landrace, Large White etc, are used, adult swine are 
very large and may therefore be difficult to handle. Therefore, juvenile swine are 
often used. However, as juvenile swine grow rapidly, positioning and function of 
flow probes and pressure catheters and patency of fluid-filled catheters may 
become compromised, limiting the duration of serial measurements within 
individual animals to approximately 10 weeks. An alternative is the use of adult 
miniature swine, such as Yucatan or Gottingen swine, of which the adult weight is 
40 - 60 kg (1).  
In conclusion, the use of chronically instrumented animals allows serial 
assessment of cardiopulmonary function either during development of disease or 
evaluation of treatment, thereby increasing statistical power and limiting the 
number of animals required for a study.  
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Abstract 
Chronic thrombo-embolic pulmonary hypertension (CTEPH) develops in 4% of 
patients after pulmonary embolism and is accompanied by an impaired exercise 
tolerance, which is ascribed to the increased right ventricular (RV) afterload and a 
ventilation/perfusion (V/Q) mismatch in the lungs. This study investigated 
changes in arterial PO2 and hemodynamics in response to graded treadmill 
exercise during development and progression of CTEPH in a swine model.  
Swine were chronically instrumented and received multiple pulmonary embolisms 
by (i) microsphere infusion (Spheres) over five weeks, (ii) endothelial dysfunction 
by administration of eNOS inhibitor L-Nω-Nitroarginine methyl ester (LNAME) 
during seven weeks, (iii) combined pulmonary embolisms and endothelial 
dysfunction (LNAME+Spheres), or (iv) served as sham-operated controls (Sham). 
After nine weeks follow-up, embolization combined with endothelial dysfunction 
resulted in CTEPH as evidenced by a mean pulmonary artery pressure of 
39.5±5.1mmHg versus 19.1±1.5mmHg (Spheres, p<0.001), 22.7±2.0mmHg 
(LNAME, p<0.001) and 20.1±1.5mmHg (Sham, p<0.001), and a decrease in arterial 
PO2 that was exacerbated during exercise, indicating a V/Q-mismatch. RV 
dysfunction was present after five weeks of embolization, both at rest (trend 
towards increased RV end systolic lumen area, p=0.085 and decreased SVi 
p=0.042) and during exercise (decreased SVi vs Control p=0.040). With sustained 
PH, RV hypertrophy (Fulton index p=0.022) improved RV function at rest and 
during exercise, but this improvement was insufficient in the CTEPH swine to 
result in an exercise-induced increase in cardiac index. 
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In conclusion, embolization in combination with endothelial dysfunction results in 
CTEPH in swine. Exercise increased RV afterload, exacerbated the V/Q mismatch 
and unmasked RV dysfunction.  
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Introduction 
Pulmonary hypertension (PH) is a chronic pathophysiological disorder of the 
pulmonary vasculature and is defined as a chronic pulmonary artery pressure 
(PAP) ≥ 25mmHg at rest for a consecutive period of at least 6 weeks, although 
pulmonary artery pressures ≥ 19mmHg at rest are associated with increased 
mortality at long term (27). Treatment modalities for PH are very limited and, 
even when treated, the disease often progresses to right heart failure and death. 
The World Health Organization differentiates 5 groups of PH based on their 
etiology. Chronic thromboembolic PH (CTEPH), categorized as group 4, develops 
in about 4% of patients after acute pulmonary embolism and up to 10% of 
patients with recurrent pulmonary embolism (9, 59) and is defined as persistent 
PAP above 25mmHg for over 6 months (11). The obstructions in the pulmonary 
arteries increase pulmonary vascular resistance (PVR) and result in ventilation-
perfusion (V/Q) mismatch in the lungs. The main treatment options for CTEPH are 
interventions to remove proximal obstructions in eligible patients such as 
pulmonary endarterectomy or balloon angioplasty (57, 58, 65). Moreover, it is 
increasingly being recognized that distal pulmonary vasculopathy, which is left 
untreated when only removing the proximal obstruction(s) contributes 
significantly to the increase in pulmonary vascular resistance (32, 40, 53, 62). It is 
currently unknown when these distal vascular lesions develop, and whether 
endothelial dysfunction promotes such development. 
Dating back to 1984, many investigators have attempted to establish a 
solid large animal model to study the pathophysiology of CTEPH using different 
embolization frequencies and embolization materials including air, autologous 
blood cloths, sephadex beads and glue (Table 1). Although PAP increases acutely 
upon embolization in these models, most studies were unsuccessful in 
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establishing a sustained level of elevated PAP during prolonged follow-up (10, 12, 
15, 27, 34, 54, 57, 64, 65). Those studies that did report CTEPH during prolonged 
follow-up (11, 28, 57, 64) have in common that they used repeated (between 4 
and 40 times) embolization procedures, thereby obstructing a significant fraction 
of the pulmonary vasculature. In these studies, PAP also decreased in between 
embolization procedures, but gradual increase in PAP occurred over time. 
However, most studies did not determine whether this gradual increase in PAP 
was solely due to the progressive embolization of pulmonary vessels or that distal 
pulmonary microvasculopathy also developed. Recent findings by Boulate et al. 
suggest that distal vasculopathy was present in their model of left pulmonary 
artery ligation in combination with glue-embolizations (65). However, in the latter 
study, as in most of the aforementioned studies, hemodynamic measurements 
were performed under anesthesia, which may have influenced cardiac function 
and pulmonary hemodynamics (10, 28, 65). Moreover, and in most cases due to 
the use of anesthetic agents, pulmonary hemodynamics were not assessed during 
exercise.  
The increased PVR imposes an increased afterload on the right ventricle 
(RV). As contractile reserve of the RV is limited (10), PH results in subacute RV 
dilation and dysfunction (65). With sustained PH, the right ventricle undergoes 
structural remodeling and hypertrophy (65). Although RV remodeling is initially 
beneficial and helps the RV to cope with the increased afterload, it poses a risk 
factor for the later development of RV failure. Evaluation of RV function during 
stress has been shown to be of prognostic value in patients (10, 36, 64). RV 
dysfunction is exacerbated during exercise, when cardiac demand increases and 
the RV is required to pump more blood against an increased afterload. Therefore, 
RV functional measurements during stress enable the evaluation of the capacity 
of the RV to cope with an increased afterload and facilitate early detection of RV 
Exercise to predict cardiac and vascular remodeling in CTEPH 
81 
dysfunction (65). In addition to RV dysfunction, V/Q mismatch is thought to 
contribute to the exercise intolerance observed in patients with CTEPH (11, 57). 
To date, however studies describing animal models of CTEPH have not evaluated 
the occurrence of V/Q mismatch at rest and during exercise.  
In light of these considerations, we developed and characterized a 
clinically relevant swine model of PH type 4, using a double hit (endothelial 
dysfunction in conjunction with repeated embolizations) approach, in which we 
applied treadmill exercise as a physiological stressor to evaluate the function of 
the right ventricle in the development and progression of CTEPH. 
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Methods 
Studies were performed in accordance with the “Guiding Principles in the Care 
and Use of Laboratory Animals” as approved by the Council of the American 
Physiological Society, and with approval of the Animal Care Committee of the 
Erasmus Medical Center Rotterdam (3158, 109-13-09). Twenty-four Yorkshire x 
Landrace swine (2-3 months old, 21.5 ± 0.9kg at the time of surgery) of either sex 
entered the study. Eighteen animals completed the protocol as six animals were 
excluded due to complications; 2 due to infections, 2 due to catheter failure and 2 
animals due to acute cardiopulmonary failure after CTEPH induction. An overview 
of the experimental protocol is depicted in Figure 1. 
Surgery 
Surgical details have been extensively described previously (57). In short, swine 
were sedated with an intramuscular (i.m.) injection of tiletamine/zolazepam 
(5mg/kg, Virbac BV, Barneveld, The Netherlands), xylazine (2.25 mg/kg, AstFarma 
BV, Oudewater, The Netherlands) and atropine (1mg, Teva Nederland BV, 
Haarlem, The Netherlands), intubated and ventilated with a mixture of O2 and N2 
(1:2v/v) to which 2% (v/v) isoflurane was added to maintain anesthesia. Under 
sterile conditions, the chest was opened via a left thoracotomy in the fourth 
intercostal space and fluid-filled polyvinylchloride catheters (B Braun Medical Inc., 
Bethlehem, PA, USA) were placed in the right ventricle, pulmonary artery, aorta 
and left atrium for blood sampling and measurement of pressures. A flow probe 
(Transonic Systems Inc., Ithaca, NY, USA) was positioned around the ascending 
aorta for measurement of cardiac output. The catheters were tunneled to the 
back and animals were allowed to recover for one week, receiving analgesia 
(0.015mg/kg buprenorphine i.m. and a slow-release transdermal fentanyl patch 
12μg/h for 48 hours, Indivior, Slough, United Kingdom) on the day of the surgery 
Exercise to predict cardiac and vascular remodeling in CTEPH 
85 
and daily antibiotic prophylaxis (25mg/kg amoxicillin intravenous (i.v.), 
Centrafarm B.V. Etten-Leur, The Netherlands) for 7 days. 
Figure 1. Experimental protocol. 
Catheters were placed in the Aorta, Right Ventricle (RV), Pulmonary Artery (PA) and left 
atrium (LA) for blood sampling and measurement of pressures and a flow probe was 
positioned around the ascending aorta for measurement of cardiac output. The eNOS-
inhibitor LNAME was administered intravenously in both the LNAME and LNAME+Spheres 
groups until 2 weeks before sacrifice. Embolization procedures were performed in awake 
state in the Spheres and LNAME+Spheres group from week 2 until week 5. All animals 
performed the treadmill exercise protocol and RV function was echocardiographically 
determined weekly in awake state. At the end of the follow-up (week 9-10) all the animals 
were sacrificed and in-vitro experiments were performed. AoP, aorta pressure; CO, cardiac 
output; RVP, right ventricular pressure; PAP, pulmonary artery pressure; LAP, left atrial 
pressure. 
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CTEPH induction 
Four groups of animals were studied. In the first group (Spheres, N=3), multiple 
injections of fluorescent blue polyethylene microspheres (diameter 600-710μm 
(maximal microsphere size that did not cause clogging of the catheter); density 
1.134g/mL, UVPMS-BB-1.13, Cospheric LLC, Santa Barbara, CA, USA) were given. 
Microspheres (500mg, being equal to ∼2500 microspheres) were suspended in 
50mL autologous blood with 0.5mL 5000 I.U. heparin added and slowly infused 
into the right ventricle while monitoring PAP. Microsphere infusions were 
repeated until the PAP reached ~60mmHg, or when arterial PO2 (PO2art) dropped 
below ~40mmHg, measured 30 min after infusion in resting condition or a 
maximum of 3 gram (∼15000) microspheres were infused. In the subsequent four 
weeks, microsphere infusions were repeated. In the first animal, embolization 
procedures were performed multiple times per week, whereas in the subsequent 
two animals, embolization procedures were performed once per week. As no 
sustained PH was induced with this protocol, in the second group (N=6), multiple 
injections of microspheres were combined with a daily bolus infusion of the eNOS-
inhibitor L-Nω-Nitroarginine methyl ester (LNAME, Enzo Life Sciences International 
Inc, NY, USA) to mimic endothelial dysfunction often present in CTEPH patients. 
LNAME is converted to its active metabolite LNNA within 19 minutes, with the 
half-life of LNNA amounting to approximately 20 hours (22). On the first day, 
animals were given LNAME (10mg/kg i.v.) as a bolus infusion. On subsequent 
days, the dose of LNAME was increased by 10mg/kg per day up to 30mg/kg i.v., 
which was maintained until 2 weeks before the end of the study (35, 64). Four 
days after the first LNAME administration, hemodynamic measurements were 
performed as described above, then microspheres were infused into the right 
ventricle as described for group 1. In the subsequent four weeks, microsphere 
infusion was performed at weekly intervals if the PAP was <25mmHg and/or 
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PO2art>70mmHg, as described above. During the final four weeks of follow-up, no 
microsphere infusions were performed.  
The third group of sham animals did not receive LNAME or microspheres 
(Sham, N=4) and the fourth group was given chronic LNAME, but no microspheres 
were infused (LNAME, N=5). 
Exercise protocol 
Studies were performed 1-9 weeks after surgery. Catheters were connected to 
fluid-filled pressure transducers (Combitrans, B. Braun Medical, Oss, The 
Netherlands) positioned on the back of the animals and calibrated at mid-chest 
level. With swine standing quietly, resting hemodynamic measurements, 
consisting of cardiac output (CO), aorta pressure (MAP), pulmonary artery 
pressure (PAP), left atrial pressure (LAP) and right ventricular pressure (RVP), were 
obtained, and arterial and mixed venous blood samples were taken. 
Hemodynamic measurements and blood gas sampling were repeated during a 
graded exercise protocol, with swine running on a motor-driven treadmill (58, 64). 
During the embolization period, exercise was performed just prior to the weekly 
injection of microspheres and/or LNAME. Swine were subjected to a four-stage 
exercise protocol (1-4km/h). Hemodynamic variables were continuously recorded 
and blood samples were collected during the last 60sec of each 3min exercise 
stage, when hemodynamic steady-state was reached. Measurements of arterial 
and mixed venous PO2 (mmHg), pCO2 (mmHg), O2 saturation (%), hemoglobin 
concentration (g/dL) and lactate (mmol/L) were immediately performed with a 
blood gas analyzer (ABL 800, Radiometer Medical ApS, Brønshøj, Denmark) (35). 
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Echocardiography 
During the entire follow-up period, RV dimensions and tricuspid annular plane 
systolic excursion (TAPSE) were weekly assessed using echocardiography (ALOKA 
ProSound SSD-4000, Hitachi Aloka Medical, Ltd., Japan) in awake resting 
conditions. An apical four chamber view was obtained for the determination of RV 
end-diastolic cross-sectional lumen area (EDA) and end-systolic cross-sectional 
lumen area (ESA), whereas TAPSE was determined using M-mode in the four-
chamber view. 
Sacrifice 
After completing the experimental protocols, the animals were sedated and 
intubated as described before. With the animals ventilated under deep anesthesia 
(pentobarbital sodium (6-12mg kg/h)), a sternotomy was performed. The heart 
was arrested and immediately excised together with the lungs. To assess relative 
RV hypertrophy, the heart was sectioned into RV and left ventricle including 
septum (LV), weighed, and RV hypertrophy was assessed using the Fulton index 
(RV/LV). Myograph experiments were performed on isolated pulmonary small 
arteries (diameter ~300μm) (18, 58). Pulmonary small arteries were dissected and 
stored overnight in cold, oxygenated (95% O2/5% CO2) Krebs bicarbonate solution 
(in mM: 118 NaCl, 4.7 KCl, 2.5 CaCl2, 1.2 MgSO4, 1.2 KH2PO4, 25 NaHCO3, and 
glucose 8.3; pH 7.4). The next day, the dissected vessels were cut into segments of 
~2mm length, mounted in microvascular myograph baths (Danish 
MyoTechnology, Aarhus, Denmark) containing 6mL Krebs bicarbonate solution 
aerated with 95% O2-5% CO2, maintained at 37°C and the internal diameter was 
set to a tension equivalent of 0.9 times the estimated diameter at 20mmHg 
effective transmural pressure. Changes in contractile force were recorded with a 
Harvard isometric transducer. The vessels were subsequently exposed to 30mM 
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KCl twice. Endothelial function was measured by observing dilation to 10nM 
substance P after preconstriction with 100nM of the stable thromboxane-A2 
analog 9,11-dideoxy-11α,9α epoxymethanoprostaglandin F2α (U46619). 
Histology 
The accessory lobe of the right lung was first flushed with physiologic saline (0.9% 
NaCl) through the main bronchus to flush the airways from sputum and surfactant 
at constant physiological pressure of 25cmH2O. Subsequently, the lobe was fixed 
by tracheal installation of 3.5-4% buffered formaldehyde at constant physiological 
pressure of 25cmH2O for a minimum of 24 hours with the lobe submerged in 
fixative (32). Transverse sections were obtained from the tip, middle and base of 
the fixed accessory lobe for histology. All sections were processed and embedded 
in paraffin wax. Paraffin sections of 4.5µm were cut and stained with Resorcin 
Fuchsin von Gieson (RF). These sections were evaluated by light microscopy using 
the Hamamatsu NDP slide scanner (Hamamatsu Nanozoomer 2.0HT, Hamamatsu 
Photonics K.K., Hamamatsu City, Japan). Morphometric measurements of 
pulmonary arteries were performed using NanoZoomer Digital Pathology (NDP) 
viewer (Hamamatsu Photonics K.K., Japan). To ensure that pulmonary veins were 
excluded for analysis, vessels in close proximity to the septae were excluded from 
analysis. Only transversely cut vessels of predetermined diameters (<50µm) were 
analysed. Assuming circularity of the vessels, inner and outer radius were 
calculated as r = perimeter/2*π. Wall thickness was calculated as outer radius – 
inner radius. 
A section of the RV was processed and embedded in paraffin wax. Paraffin 
sections of 4.5µm were cut and stained with a Gomori staining. Only transversely 
cut cardiomyocytes were analyzed for cross sectional area (CSA) using NDP 
viewer.  
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Quantitative PCR 
For detection of IL-6, TNF-α, TGF-β1, Ang-1, Ang-2, TIE-2, VEGF-A, FLT-1 and KDR 
mRNA, lung tissue was snap frozen in liquid nitrogen after excision. Small pieces 
of tissue (<30mg) were homogenized by adding RLT lysisbuffer (Qiagen, Venlo, 
The Netherlands) and 2-mercaptoethanol (Sigma-Aldrich, Zwijndrecht, The 
Netherlands) using a homogenizer. After a proteinase K (Invitrogen, Breda, The 
Netherlands) treatment at 55°C for 10 min, total RNA was isolated using the 
RNeasy Fibrous Tissue Mini Kit (Qiagen, Venlo, The Netherlands). RNA was eluted 
in RNase-free water and the concentration was determined using a NanoDrop 
(NanoDrop1000, Thermo Fisher Scientific, Bleiswijk, The Netherlands). RNA 
integrity was confirmed with a Bioanalyzer (2100 Bioanalyzer, Agilent, Santa Clara, 
California, USA). cDNA was synthesized from 500ng of total RNA with SensiFAST 
cDNA Synthesis Kit (Bioline, London, UK). Quantitative PCR (qPCR) (CFX-96, Bio-
Rad, Hercules, California, USA) was performed with SensiFAST SYBR & Fluorescein 
Kit (Bioline, London, UK). Target gene mRNA levels were normalized against β-
actin, glyceraldehyde-3-phosphate dehydrogenase (GADPH), and Cyclophilin using 
the CFX manager software (Bio-Rad, Hercules, California, USA). Relative gene 
expression data were calculated using the ΔΔCt method. All primer sequences are 
presented in Table 2. 
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Table 2. Primer sequences used for the quantitative PCR. 
IL-6, interleukin 6; TNF-α, tumor necrosis factor α; TGF-β1, transforming growth factor β1; 
Ang-1, angiopoietin 1; Ang-2, angiopoietin 2; TIE-2, angiopoietin 1 receptor; VEGF-A, 
vascular endothelial growth factor A; FLT-1, vascular endothelial growth factor receptor 1; 
KDR, kinase insert domain receptor (vascular endothelial growth factor receptor 2).  
Data analysis and statistics 
Echocardiography data were analyzed using DICOM viewer (Rubo Medical Imaging 
BV, Aerdenhout, The Netherlands) and SigmaScan Pro (Systat Software Inc, San 
Jose, CA, USA). Three images of end-diastole, three images of end-systole and 
three TAPSE recordings per echo were selected in DICOM viewer. RV lumen area 
and TAPSE length were manually drawn per image, automatically calculated in 
SigmaScan and then averaged per animal per time point.  
Digital recording and offline analysis of hemodynamic data were 
performed with MatLab (MathWorks, Natick, MA, USA) and have been described 
in detail elsewhere (4, 40).To accommodate for growth, cardiac output was 
corrected for bodyweight, resulting in cardiac index (CI). Total pulmonary vascular 
resistance index (tPVRi) and systemic vascular resistance (SVRi) were calculated as 
PAP divided by CI and mean aortic pressure divided by CI, respectively. Body 
 Sequence 
Genes Forward Reverse 
IL-6 CTCCAGAAAGAGTATGAGAGC AGCAGGCCGGCATTTGTGGTG 
TNF-α TGCACTTCGAGGTTATCGGCC CCACTCTGCCATTGGAGCTG 
TGF-β1 GTGGAAAGCGGCAACCAAAT CACTGAGGCGAAAACCCTCT 
Ang-1 AATGGACTGGGAAGGAAACCG TCTGTTTTCCTGCTGTCCCAC 
Ang-2 AGGCAACGAGGCTTACTCAC TCGTTGTCTGCGTCCTTTGT 
TIE-2 GTCCCGAGGTCAAGAAGTGT AAGGGGTGCCACCTAAGCTA 
VEGF-A ACTGAGGAGTTCAACATCGCC CATTTACACGTCTGCGGATCTT 
FLT-1 AAGGAGGGCGTGAGGATGAGG GGCTTGCAGCAGGTCGCCTAG 
KDR TTCTCCGAGCTGGTGGAGCAC AGGTAGGCAGAGAGAGTCCGG 
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oxygen consumption index (BVO2i) was calculated as the product of CI and the 
difference between arterial and mixed venous oxygen content of the blood.  
Statistical analysis was performed using SPSS version 21.0 (IBM, Armonk, 
NY, USA). Differences between Spheres, LNAME+Spheres, LNAME and Sham over 
time at rest were analyzed with a two-way MANOVA with PAP, tPVRi, CI and 
stroke volume index (SVi) as dependent variables and time and group as fixed 
factors. As no differences were observed in hemodynamics, oxygenation, 
histology, inflammation and angiogenesis between Sham, LNAME and the Spheres 
groups, these groups were pooled into a single Control group (Control) for the 
subsequent analyses. Echocardiography data and Fulton index were analyzed by a 
one-way MANOVA with the RVESA, RVEDA, right ventricular fractional area 
change (RVFAC), TAPSE, CSA, RVW/LVW and RVW/BW as dependent variables and 
group as fixed factor. The difference in effect of exercise on the hemodynamic 
parameters between LNAME+Spheres and Control at the same time point were 
assessed by two-way repeated measures (RM)-ANOVA with exercise as within-
subject factor and group as between-subject factor. The difference in effect of 
exercise on hemodynamic parameters compared to baseline within the individual 
groups, a two-way RM-ANOVA with exercise as within-subject factor and time as 
between-subject factor. Statistical significance was accepted when p ≤ 0.05. Data 
are presented as mean ± SEM. 
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Results 
Induction and progression of CTEPH 
To induce CTEPH, microspheres (600-710μm) were infused slowly into the right 
ventricle. In the Spheres group, one animal received twenty-five embolizations 
with an average of 2700 microspheres per embolization procedure. The two other 
animals underwent five embolization procedures with an average of 9200 
microspheres per embolization procedure. Each microsphere has a cross-sectional 
area of 2.5-4.7 ⋅ 10-14m2, a volume 1.1-1.8 ⋅ 10-10m3 and a total surface area of 1.0-
1.9 ⋅ 10-13m2. With an average of 36000 spheres per animal. This results in a total 
cross-sectional area of 9.1-17.0 ⋅ 10-10m2, a total volume of 4.1-6.5 ⋅ 10-6m3 and a 
total surface area of 3.7-6.8 ⋅ 10-9m2. Although immediately following injection a 
substantial increase in PAP was observed, this increase waned over the course of 
the next few days, such that with weekly measurements, resting PAP and tPVRi 
did not increase significantly over time in these animals (PAP being 
21.0±1.8mmHg and tPVRi being 100±4mmHg⋅min/L/kg at baseline and 
19.1±1.5mmHg and 147±22mmHg⋅min/L/kg respectively at week 9).  
In the second group (LNAME+Spheres), an average of four embolization 
procedures (range between two and five), were required to induce chronic PH. 
The number of microspheres infused per embolization procedure did not change 
over time, being 9000±400. 
In these animals, resting PAP increased gradually over time (from 
21.8±1.1mmHg at baseline before LNAME to 32.2±3.1at week 5 and 
39.5±5.1mmHg at week 9) as a result of a progressive increase in pulmonary 
vascular resistance (Figure 2). The increase in tPVRi in the LNAME+Spheres 
animals was due to a combination of vascular obstruction by the injected spheres 
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in combination with remodeling and dysfunction of the pulmonary microvessels. 
The latter was reflected by an increased wall-thickness (Figure 4) and impaired 
vasorelaxation in response to Substance P in isolated pulmonary small arteries 
(86±3%, 82±3%, 90% and 62±8% in Sham, LNAME, Spheres and LNAME+Spheres 
respectively). Histologically, microspheres in the lungs were surrounded by fibrous 
tissue, however, qPCR analysis revealed no changes in the inflammatory markers 
IL-6, TNF-α and TGF-β1 (Figure 5). Moreover, expression of the angiogenic factors 
VEGF-A, Flt-1, KDR as well as Ang-1, Ang-2 and Tie-2 were also not different 
between groups (Figure 5). 
Although acute LNAME administration did result in a small increase in PAP 
and tPVRi within the first 30 minutes, both at baseline (BL) (17.3±0.9 to 
21.0±2.1mmHg and 101±14 to 137±17mmHg⋅min/L/kg) and after 5 weeks of 
LNAME administration (17.6±1.8 to 21.9±2.2 mmHg and 120±6 to 
150±18mmHg⋅min/L/kg), PAP and tPVRi normalized before the next injection. 
Thus, in the LNAME group, PAP did not significantly increase over time being 
18.0±1.4mmHg at week 1 and 22.7±2.0mmHg at week 9, which was not 
significantly different from PAP in the Sham group (17.5±1.2mmHg at BL and 
20.1±1.5mmHg at week 9) (Figure 2). As there were no sustained differences in 
hemodynamics, oxygenation, histology, inflammation and angiogenic markers 
between the Spheres, LNAME and Sham groups (Figure 2-5), these groups were 
pooled into one Control group (Control) for the remainder of the analyses. 
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Figure 2. Changes in pulmonary hemodynamics over time. 
Dotted bar indicates period of weekly embolizations with microspheres and white bar 
indicates administration time of LNAME. Please note that all baseline measurements were 
taken prior to administration of LNAME and/or Spheres. A) Mean pulmonary artery 
pressure (PAP); B) total pulmonary vascular resistance index (tPVRi); C) cardiac index (CI) 
and D) stroke volume index (SVi). Data are means ± SEM. Sham N=4; LNAME N=5; Spheres 
N=3; LNAME+Spheres N=6, N=5 from week 7 due to death of one animal caused by acute 
cardiopulmonary failure. * P < 0.05 vs baseline (prior to start of LNAME and/or Spheres; † 
P < 0.05 LNAME+Spheres vs Sham; ‡ P < 0.05 LNAME+Spheres vs LNAME; § P < 0.05 
LNAME+Spheres vs Spheres; Sham vs LNAME vs Spheres NS. 
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indicates administration time of LNAME. Please note that all baseline measurements were 
taken prior to administration of LNAME and/or Spheres. A) Mean pulmonary artery 
pressure (PAP); B) total pulmonary vascular resistance index (tPVRi); C) cardiac index (CI) 
and D) stroke volume index (SVi). Data are means ± SEM. Sham N=4; LNAME N=5; Spheres 
N=3; LNAME+Spheres N=6, N=5 from week 7 due to death of one animal caused by acute 
cardiopulmonary failure. * P < 0.05 vs baseline (prior to start of LNAME and/or Spheres; † 
P < 0.05 LNAME+Spheres vs Sham; ‡ P < 0.05 LNAME+Spheres vs LNAME; § P < 0.05 
LNAME+Spheres vs Spheres; Sham vs LNAME vs Spheres NS.
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Figure 3. Changes in pulmonary and cardiac hemodynamics with incremental levels of 
exercise at the end of follow-up of different control groups.
Presented is the effect of exercise on A) mean pulmonary artery pressure (PAP); B) total 
pulmonary vascular resistance index (tPVRi); C) cardiac index (CI) and D) arterial oxygen 
pressure (PO2art). Data are means ± SEM. Sham N=4; LNAME N=5; Spheres N=3. No 
significant differences were observed.
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Figure 3. Changes in pulmonary and cardiac hemodynamics with incremental levels of 
exercise at the end of follow-up of different control groups.
Presented is the effect of exercise on A) mean pulmonary artery pressure (PAP); B) total 
pulmonary vascular resistance index (tPVRi); C) cardiac index (CI) and D) arterial oxygen 
pressure (PO2art). Data are means ± SEM. Sham N=4; LNAME N=5; Spheres N=3. No 
significant differences were observed.
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Figure 4. Histological overview of lung tissue stained with Resorcin Fuchsin von Gieson.
Typical examples of bronchi with arteries of animals with A) Spheres; B) LNAME+Spheres; 
C) LNAME and D) sham at 20x magnification. Panels E-H are pulmonary microvessels 
adjacent to alveoli at 20x magnification in swine from different groups E) Spheres; F) 
LNAME+Spheres; G) LNAME and H) Sham. In the LNAME+Spheres lung tissue, microvessels 
presented with a thickened/muscularized wall (black arrows). Panel I shows an example of 
the occluded vessels due to the microspheres (blue arrows) surrounded by remodeled small 
unobstructed vessels in swine that received LNAME+Spheres. Panel J is a quantitative 
presentation of the microvascular remodeling. The wall of microvessels (diameter <50μm) 
of the LNAME+Spheres were thickened compared to all other groups.Data are means ± 
SEM.Sham N=4; Spheres N=3; LNAME N=5; LNAME+Spheres N=6. † P < 0.05 vs 
LNAME+Spheres.
Figure 5. Quantitative PCR.
Inflammatory (panel A-C) and angiogenic (panel D-I) gene expression in lung tissue of all 
experimental groups at the end time-point of A) Interleukin 6 (IL-6); B) tumor necrosis 
factor α (TNF-α); C) transforming growth factor β1 (TGF-β1); D) Angiopoietin 1 (Ang-1); E) 
Angiopoietin 2 (Ang-2); F) Angiopoietin 1 receptor (TIE-2); G) vascular endothelial growth 
factor A (VEGF-A); H) vascular endothelial growth factor receptor 1 (FLT-1) and I) vascular 
endothelial growth factor receptor 2 (KDR). Data are means ± SEM. Sham N=4; Spheres 
N=3; LNAME N=5; LNAME+Spheres N=6. No significant differences between groups were 
observed.
Exercise to predict cardiac and vascular remodeling in CTEPH 
99 
RV function and hypertrophy 
Echocardiography showed that RV diastolic and systolic lumen area increased 
over time, while TAPSE tended to increase and RVFAC remained constant in the 
Control group, reflecting growth of the RV over time (Figure 6). Repeated 
microsphere injections over 5 weeks in the LNAME+Spheres group resulted in a 
trend towards higher end-systolic (P=0.085) but not end-diastolic right ventricular 
lumen area (P=0.15), indicating mild RV contractile dysfunction. This was 
associated with a slight decrease in SVi as compared to BL, while RVFAC and 
TAPSE did not change. With sustained PH, SVi was reduced as compared to BL, but 
neither SVi, nor RV diastolic and systolic lumen area and RVFAC were significantly 
different from Control, although TAPSE showed a trend towards a reduction, 
indicating that resting RV function recovered. The Fulton index (RVW/LVW) and 
RVW/bodyweight (BW), measured at sacrifice after sustained PH, were 
significantly higher in LNAME+Spheres compared to Control swine, implying right 
ventricular hypertrophy due to chronic PH (Figure 6). 
Exercise response 
As CTEPH is accompanied by exercise intolerance due to both the increase in RV 
afterload and V/Q mismatch in the lungs, the response to exercise was examined 
in the initial phase after embolization (at 5 weeks, referred to as ‘after 
microspheres’ (AM) in the figures and at the end of follow-up (8-9 weeks after the 
first microsphere injection), referred to as ‘End’ in the figures, and compared to 
the pooled Control group at the corresponding time-points. Graded treadmill 
exercise resulted in an increase in PAP at all time-points in both LNAME+Spheres 
and Control animals (Figure 7). 
Kelly Stam Dissertatie V5.indd   98 12-8-2019   09:51:55
3Chapter 3.
98
Figure 4. Histological overview of lung tissue stained with Resorcin Fuchsin von Gieson.
Typical examples of bronchi with arteries of animals with A) Spheres; B) LNAME+Spheres; 
C) LNAME and D) sham at 20x magnification. Panels E-H are pulmonary microvessels 
adjacent to alveoli at 20x magnification in swine from different groups E) Spheres; F) 
LNAME+Spheres; G) LNAME and H) Sham. In the LNAME+Spheres lung tissue, microvessels 
presented with a thickened/muscularized wall (black arrows). Panel I shows an example of 
the occluded vessels due to the microspheres (blue arrows) surrounded by remodeled small 
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SEM.Sham N=4; Spheres N=3; LNAME N=5; LNAME+Spheres N=6. † P < 0.05 vs 
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 In the LNAME+Spheres animals, PAP was increased compared to its BL 
measurement as well as to the Control at the corresponding time-point in the 
initial phase after embolization (week 5), and the exercise-induced increase in PAP 
was exacerbated due to the significant elevation in tPVRi (Figure 7). This increase 
in tPVRi was also reflected in the significantly higher slope of the relation between 
CI and PAP (Figure 8). The exercise-induced increase in CI was attenuated in the 
LNAME+Spheres group, which was due to a significant decrease in SVi during 
exercise (Figure 7), as the exercise-induced increase in heart rate was not 
different between LNAME+Spheres and Control (Table 3). These observations 
indicate that the right ventricle could not cope with the increased afterload during 
exercise in the initial phase after embolizations.  
At the end of the follow-up period, PAP was still elevated compared to 
both BL and Control. Moreover, the exercise-induced increase in CI was 
attenuated while the exercise-induced increase in PAP was exacerbated at the 
end of the follow-up period in the Spheres+LNAME group compared to Control 
(Figure 7). This translated into a persistent elevation of the slope of the relation 
between CI and PAP compared with Control (Figure 8), reflecting the sustained 
increase in tPVRi (Figure 7). Interestingly, although SVi was still depressed at the 
End of follow-up, the exercise-induced decrease in SVi that was observed at AM, 
was no longer present at the End of follow-up. The significant RV hypertrophy and 
recovery of RV-function as assessed with echo, in conjunction with the blunted 
exercise-induced decrease of SVi as compared to the initial phase after 
embolization, could be interpreted to suggest that RV-hypertrophy served to 
restore RV function in the face of an increase in afterload. 
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Figure 6. Right ventricular remodeling. 
A) End-diastolic and end-systolic lumen area changes over time as measured with 
echocardiography compared to baseline (week 0, prior to injection of LNAME and Spheres). 
End-systolic RV lumen area tended to be increased in LNAME+Spheres compared to Control 
at the end of the embolization period (AM), but not at the time-point prior to sacrifice 
(End). B) RVFAC was decreased at all time-points in LNAME+Spheres compared to Control. 
C) TAPSE tended to be increased in LNAME+Spheres at the end time-point compared to 
Control. D) Right ventricular weight (RVW) over bodyweight (BW) was increased at 
sacrifice. E) Fulton index (RVW over left ventricular weight (LVW)) was increased in 
LNAME+Spheres vs Control. F) RV cardiomyocyte CSA tended to be increased in 
LNAME+Spheres compared to Control at sacrifice. AM, after microspheres; end, end of 
follow-up; RVFAC, right ventricular fractional area change; TAPSE, tricuspid annular plane 
systolic excursion; CSA, cross sectional area. Data are means ± SEM. A) Control AM N=6, 
End N=9; LNAME+Spheres AM N=5, End N=7. B-C) Control N=9; LNAME+Spheres N=5. D-F) 
Control N=9; LNAME+Spheres N=6. ‡ P < 0.1 End-Systole LNAME+Spheres vs Control; † P < 
0.05 LNAME+Spheres vs Control. 
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at the end of the embolization period (AM), but not at the time-point prior to sacrifice 
(End). B) RVFAC was decreased at all time-points in LNAME+Spheres compared to Control. 
C) TAPSE tended to be increased in LNAME+Spheres at the end time-point compared to 
Control. D) Right ventricular weight (RVW) over bodyweight (BW) was increased at 
sacrifice. E) Fulton index (RVW over left ventricular weight (LVW)) was increased in 
LNAME+Spheres vs Control. F) RV cardiomyocyte CSA tended to be increased in 
LNAME+Spheres compared to Control at sacrifice. AM, after microspheres; end, end of 
follow-up; RVFAC, right ventricular fractional area change; TAPSE, tricuspid annular plane 
systolic excursion; CSA, cross sectional area. Data are means ± SEM. A) Control AM N=6, 
End N=9; LNAME+Spheres AM N=5, End N=7. B-C) Control N=9; LNAME+Spheres N=5. D-F) 
Control N=9; LNAME+Spheres N=6. ‡ P < 0.1 End-Systole LNAME+Spheres vs Control; † P < 
0.05 LNAME+Spheres vs Control.
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Figure 7. Changes in pulmonary and cardiac hemodynamics during incremental levels of 
exercise at baseline (BL), after completion of embolization (AM) and at the end of 
follow-up (End).
Presented is the effect of exercise on: mean pulmonary artery pressure (PAP), panels A&B; 
total pulmonary vascular resistance index (tPVRi), panels C&D; cardiac index (CI), panels 
E&F; and stroke volume index (SVi) in panels G&H. Data are means ± SEM. Control N=12; 
LNAME+Spheres N=6. * P < 0.05 vs BL; † P < 0.05 vs corresponding Control; § P < 0.05 vs 
effect of exercise in Control.
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PO2art was lower in the LNAME+Spheres swine compared to Control after 
the embolization phase and at the end of follow-up. Moreover, PO2art decreased 
more during exercise in LNAME+Spheres compared to Control at both time-
points. After the embolization phase, body O2 extraction at rest was increased in 
the LNAME+Spheres group compared to both BL and Control group. The increased 
O2 extraction compensated for the decreases in CI and arterial oxygenation, so 
that body O2 consumption was unaltered. At the end of follow-up, the increase in 
body O2 extraction was insufficient to compensate for the decrease in PO2art and 
the O2 consumption was lower at rest (Figure 9). Although there was no 
difference in the exercise-induced increase in O2 extraction, the exercise-induced 
increase in O2 consumption was significantly attenuated both after the initial 
embolization phase (AM) and at the end of follow-up (End) in LNAME+Spheres 
compared to Control animals, reflecting the attenuated increase in CI. 
Figure 8. Pulmonary vascular reserve.
Presented is the relationship between pulmonary artery pressure (PAP) and cardiac index 
(CI) during incremental exercise at A) baseline (BL); B) after completion of embolization 
(AM) and C) at the end of follow-up (End). Data are means ± SEM. Control N=12; 
LNAME+Spheres N=6. § P < 0.05 Effect of exercise in LNAME+Spheres vs Control (slope).
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Figure 9. Systemic oxygenation and body oxygen consumption during incremental levels 
of exercise at baseline (BL), after microspheres (AM) and at the end of follow-up (End).
Presented is the effect of exercise on: Arterial oxygen pressure (PO2art), panels A&B; Body 
oxygen consumption index (BVO2i), panels C&D; and body oxygen extraction (BVO2ex), 
panels E&F. Data are means ± SEM. Control N=12; LNAME+Spheres N=6. * P < 0.05 vs BL; † 
P < 0.05 vs corresponding Control; § P < 0.05 vs effect of exercise in Control.
Exercise to predict cardiac and vascular remodeling in CTEPH 
105 
Discussion 
The main findings of this present study are that i) induction of CTEPH with a 
sustained increase in PAP and tPVRi over time required a combination of 
endothelial dysfunction (LNAME) and repeated embolization procedures, as either 
stimulus alone did not result in a sustained increase in PAP or tPVRi; ii) PAP and 
tPVRi were still increased up to 5 weeks after the last embolization and 2 weeks 
after the last LNAME injection, consistent with sustained pulmonary 
hypertension; iii) development of CTEPH is accompanied by a decrease in arterial 
oxygen tension during exercise both in the early phase following embolizations as 
well as at the end of follow-up; iv) impaired oxygenation of the arterial blood was 
compensated by a small increase in systemic oxygen extraction; v) repeated 
embolizations initially resulted in RV dysfunction at rest, as assessed with 
echocardiography, and by a decrease in SVi during exercise. However, at the end 
of follow-up, the presence of RV hypertrophy was associated with a maintained 
SVi during exercise. 
Induction of CTEPH requires both repeated embolizations and endothelial 
dysfunction 
As summarized in Table 1, over the past decades several research groups have 
attempted to develop a large animal model of CTEPH, using different embolization 
materials, particle sizes and embolization frequencies. Many of these attempts 
have failed to show a sustained (>2 weeks after the last embolization) increase in 
PAP (1, 17, 26, 33, 38, 41, 42, 48, 55, 60). The studies that did show a sustained 
increase in PAP (5, 16, 47, 49, 63), have in common that they embolized a large 
part of the pulmonary vasculature, with multiple embolization procedures. It has 
been suggested that 40-60% of the lung vasculature needs to be obstructed for 
CTEPH to develop (3, 13). Indeed, Mercier and co-workers performed ligation of 
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Figure 9. Systemic oxygenation and body oxygen consumption during incremental levels 
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the left pulmonary artery in combination with progressive embolization of the 
segmental arteries of the right lower lobe (5), leaving the right upper and possibly 
right middle lobe unaffected. 
Estimation of the relative magnitude of the obstructed part of the 
pulmonary vasculature requires comparison of the number of microspheres 
infused with the number of vascular branches of corresponding size present in the 
pulmonary vascular bed. The pulmonary vasculature can be morphometrically 
described with diameter defined Strahler orders, starting at the capillaries and 
ending at the main pulmonary artery (24). The pulmonary vascular tree of swine is 
less well described than that of humans, in which a total of 15 orders was 
observed (24). In swine, pulmonary vascular morphometry of pulmonary arteries 
larger than 160μm in diameter was analyzed using multidetector-row computed 
tomography, resulting in 10 branching orders (29). This number of branching 
orders corresponds well with the human study, in which vessels of the 5th order 
had an average diameter of 150μm. In the present study, CTEPH was induced with 
embolizations using microspheres of 600-710μm in diameter. This size of 
microspheres corresponds with order 3 (diameter 430μm, range 380-570μm) and 
order 4 (diameter 760μm, range 660-990μm), of which approximately 2100 and 
590 are present in the porcine pulmonary vasculature (29). It has to be taken into 
account that supernumerary vessels were not measured because of the 
computational model used. These supernumerary vessels are estimated to be 
present in a ratio of 1.6 (45) or 2.8 (6) to conventional arteries. Adding these 
vessels to the number of vessels results in an estimated total of 5460-7980 
arteries of order 3, and 1530-2240 arteries of order 4. Assuming that the 
pulmonary vascular tree of a 20kg pig is 3-fold smaller than that of a 70kg human, 
these numbers correspond well with the estimated 22000 (order 8, diameter 
510±40μm) and 6225 (order 9, diameter 770±70μm) pulmonary small arteries 
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present per lung in humans (24). To ensure full coverage of the pulmonary 
vasculature, microspheres were slowly injected into the RV, assuming that 
microspheres flow to perfused, non-embolized vessels. The presence of 
microspheres in all lung lobes was visually confirmed upon sacrifice, and no 
microspheres were observed in systemic organs. Histologically, microspheres in 
the lungs were surrounded by fibrous tissue, however, qPCR analyses revealed no 
changes in the expression of inflammatory markers IL-6, TNF-α and TGF-β1. 
Although some microspheres clustered, with an approximate total of 36000 
microspheres per animal, it is likely that 60% of these pulmonary small arteries 
were obstructed. Nevertheless, with microspheres alone, no sustained CTEPH 
developed. 
Since CTEPH patients present with dysfunctional endothelium as 
evidenced by alterations in coagulation, inflammation, angiogenesis and 
vasoregulation (2, 30, 43, 51, 52), endothelial dysfunction was used as a second 
hit to induce CTEPH. Nitric oxide is an important endothelium-derived anti-
coagulatory, anti-inflammatory, pro-angiogenic, vasodilator. Therefore, 
endothelial dysfunction was induced by inhibiting eNOS by chronic LNAME 
administration, which in combination with multiple microsphere infusions 
resulted in a sustained increase in PAP and tPVRi. This increase in PAP above 
25mmHg for a prolonged period of time after embolizations and in the awake 
state is evidence for successful induction of chronic PH (1, 17, 26, 33, 38, 41, 42, 
48, 49, 60, 63). Our findings are in accordance with a recent study in rats, that 
show that sustained CTEPH developed when combining embolizations with 
endothelial dysfunction produced by VEGF-inhibition (39). Importantly, in the 
present study CTEPH persisted when eNOS inhibition was discontinued, which 
together with the reduced endothelium-dependent vasodilator response to 
Substance P in isolated pulmonary small arteries, indicates that CTEPH in itself 
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was sufficient to maintain a state of endothelial dysfunction. It is well established 
that secondary to pulmonary embolisms, worsening of PH results from 
progressive microvascular remodeling of the non-obstructed pulmonary small 
arteries (23, 37). Indeed, we also observed microvascular remodeling as 
evidenced by an increased wall thickness of the non-obstructed pulmonary small 
arteries and exaggerated vasoconstriction to both KCl and the thromboxane 
analogue U46619. Contrary to results in lungs of patients with CTEPH, in which a 
reduction in VEGF-expression and an elevation of the anti-angiogenic factor 
angiopoietin-1 were observed (51), microvascular remodeling in our model was 
not accompanied by changes in expression of angiogenic factors as measured with 
qPCR in tissues obtained at sacrifice. The exact time-course of microvascular 
remodeling cannot be determined from our data, as the increase in resistance due 
to embolization cannot be distinguished from the increase in resistance due to 
microvascular remodeling during the embolization period. However, tPVRi 
continued to increase after cessation of the embolization procedures, which is 
consistent with remodeling of the distal vasculature, although an increase in 
microvascular tone secondary to endothelial dysfunction may also have 
contributed.  
Cardiopulmonary stress testing and RV function 
Exercise testing after pulmonary embolism is predictive of development of PH 
and/or patient outcome in established CTEPH (19-21, 46). Swine were exercised 
on a motor driven treadmill up to 4km/h prior to induction of CTEPH and on a 
weekly basis during and after the embolization period to investigate the influence 
of cardiopulmonary stress on hemodynamic variables and blood oxygenation. 
Swine reached heart rates of approximately 255bpm at the beginning of the study 
and 210bpm at the final exercise trial (Table 3), whereas maximal heart rates of 
Exercise to predict cardiac and vascular remodeling in CTEPH 
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272 bpm have been reported in literature in swine of similar size (61). 
Nevertheless, the significant lactate production during exercise at the beginning 
of the study as well as at the final exercise trial in the CTEPH swine suggests that 
near maximal levels were reached at those time points. 
In accordance with Claessen et al. 2015 (7, 8), we observed that the right 
ventricle was not able to cope with the increased afterload during exercise 
evidenced by a decreased SVi, particularly early after embolization. Furthermore, 
whereas RV EDA was unchanged but RV ESA tended to be increased, suggestive of 
systolic contractile dysfunction, although TAPSE was not different. The decreased 
SVi was not compensated by an increase in heart rate, and hence cardiac index 
was lower in swine with CTEPH. Despite the blunted exercise-induced increase in 
cardiac index, the increase in PAP and tPVRi were exacerbated during exercise. 
Moreover, the ventilation-perfusion mismatch was exacerbated during exercise, 
resulting in a further decrease in PO2art during exercise.  
At the end of follow-up, the time-point which resembles the time where 
most patients present in the hospital with symptoms, PAP and tPVRi were still 
elevated at rest and, similar to patients with CTEPH the increase in PAP was 
exacerbated during exercise (7, 8). However, as a result of the chronically elevated 
RV afterload, the RV underwent hypertrophy reflected by increases in RVW/BW, 
Fulton index and cardiomyocyte cross-sectional area. Although TAPSE showed a 
trend towards a decrease in LNAME+Spheres, RV hypertrophy blunted the systolic 
dysfunction of the heart as observed using echocardiography at rest, as well as 
the decrease in SVi during exercise. Nevertheless, CI was persistently decreased at 
rest and did not increase significantly during exercise. In addition, patients 
presenting with a V/Q mismatch in the lungs suffer a further decrease in 
ventilatory efficiency during exercise. Although this V/Q mismatch correlates to 
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RV function in other types of PH, there is no correlation in either CTEPH patients 
or in the LNAME+Spheres animals in the present study (data not shown) (14, 44, 
56). The reduction in O2 uptake was exacerbated during exercise as evidenced by 
a decrease in PO2art, which in combination with the decreased CI resulted in a 
reduced VO2max (25, 31, 46). Similarly, in our swine model, the V/Q mismatch 
increased in severity with incremental exercise intensity, as evidenced by a 
further decrease in arterial PO2. This V/Q mismatch remained present during the 
entire follow-up period. However, given the relatively mild reduction in PO2art, the 
capability of the body to increase O2 extraction, and the more severe reduction in 
SVi during exercise, it is likely that the main cause of the exercise limitations in 
CTEPH is cardiac insufficiency. These data in our porcine model are consistent 
with the observations by Claessen et al. (7, 8) that exercise intolerance in CTEPH 
patients is principally determined by a disproportional increase in RV afterload. 
Conclusions 
A combination of repeated embolization procedures and endothelial dysfunction 
was required to successfully develop a large animal model for chronic embolic 
pulmonary hypertension. To the best of our  knowledge the present study is the 
first to investigate the role of both cardiac dysfunction and V/Q mismatch in 
exercise intolerance in an animal model of CTEPH. This model emulates critical 
features of patients with CTEPH, including V/Q mismatch and early RV 
dysfunction. The latter likely contributed to the reduced SVi that was present at 
rest. Both the V/Q mismatch and the cardiac dysfunction were aggravated by 
exercise. Prolonged increases in RV afterload were associated with adaptive RV 
hypertrophy, while the V/Q mismatch remained present. This animal model can 
be further utilized to investigate disease development, early diagnostic markers 
and interventions that interfere with microvascular remodeling in the field of 
Exercise to predict cardiac and vascular remodeling in CTEPH 
111 
CTEPH research. Finally, this model may also be used to delineate sex-differences 
that are known to exist in development and progression of CTEPH (50). 
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Abstract 
Purpose 
The purpose of this study was to compare invasively measured aorta flow with 2D 
phase contrast flow and 4D flow measurements by cardiovascular magnetic 
resonance (CMR) imaging in a large animal model. 
Methods 
Nine swine (mean weight 63±4 kilograms) were included in the study. 4D flow 
CMR exams were performed on a 1.5T MRI scanner. Flow measurements were 
performed on 4D flow images at the aortic valve level, in the ascending aorta, and 
main pulmonary artery. Simultaneously, flow was measured using an invasive flow 
probe, placed around the ascending aorta. Additionally, standard 2D phase 
contrast flow and 2D left ventricular (LV) volumetric data were used for 
comparison. 
Results 
The correlations of cardiac output (CO) between the invasive flow probe, and 
CMR modalities were strong to very strong. CO measured by 4D flow CMR 
correlated better with the CO measured by the invasive flow probe than 2D flow 
CMR flow and volumetric LV data (4D flow CMR: Spearman’s rho 0.86 at the aortic 
valve level and 0.90 at the ascending aorta level; 2D flow CMR: 0.67 at aortic valve 
level; LV measurements: 0.77). In addition, there tended to be a correlation 
between mean pulmonary artery flow and aorta flow with 4D flow (Spearman’s 
rho=0.65, P=0.07), which was absent in measurements obtained with 2D flow 
CMR (Spearman’s rho=0.40, P=0.33). 
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Conclusion 
This study shows that aorta flow can be accurately measured by 4D flow CMR 
compared to simultaneously measured invasive flow. This helps to further 
validate the quantitative reliability of this technique. 
Validation of 4D flow CMR 
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Introduction 
Cardiovascular magnetic resonance (CMR) imaging has been used for flow 
visualization and quantification in daily clinical practice for several decades. (15, 
21) CMR is the gold standard for non-invasive quantification of left and especially 
right heart function and shunt fraction. (20, 22) Nowadays, standard imaging 
protocols consists of the acquisition of cine imaging and 2D phase contrast flow 
measurements in multiple planes using numerous breath-holds. Especially, in 
complex congenital heart disease patients this can be challenging and time 
consuming.  
A promising and rapidly evolving CMR technique is 4D flow imaging: a 
volumetric, free-breathing acquisition technique of flow velocity data with 
simultaneous assessment of anatomic structures. (24) 4D flow CMR allows flow 
quantification at any level within the acquired field of view and calculation of 
cardiac volumes and biventricular function. (10, 13) Until now, several studies 
have evaluated the use of 4D flow CMR for visualization and quantification of 
cardiac shunts. (4, 11, 14, 23) 4D flow CMR was previously validated against 
echocardiography (5) and standard 2D flow CMR in humans (6, 12). In addition, 
the 4D flow determined pulmonary vascular resistance was validated against in 
vivo measurements in a canine study. (16) 
In this study, we sought to validate this promising 4D flow CMR technique 
by direct, simultaneous comparison with 2D flow CMR and invasive flow 
measurements using a validated flow probe positioned around the ascending 
aorta in a large animal model.  
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Methods 
Study design 
Studies were performed in accordance with the “Guiding Principles in the Care 
and Use of Laboratory Animals” as approved by the Council of the American 
Physiological Society, and with approval of the Animal Care Committee of the 
Erasmus Medical Center Rotterdam (3158, 109-13-09). Nine Yorkshire x Landrace 
swine (5-6 months old, 21 ± 1 kg at the time of surgery, 63 ± 4 kg at the time of 
the CMR scan) of either sex were included in the study. The swine included in this 
study were part of previously published studies. (17, 18) 
Chronic instrumentation of the swine 
The swine were chronically catheterized for hemodynamic monitoring 
approximately two to three months prior to the scanning procedure. Surgical 
details have been extensively described previously. (7) In short, swine were 
sedated with an intramuscular injection of tiletamine/zolazepam (5 mg/kg), 
xylazine (2.25 mg/kg) and atropine (1 mg), intubated and ventilated with a 
mixture of O2 and N2 (1:2 v/v) to which 2% (v/v) isoflurane was added to maintain 
anesthesia. Under sterile conditions, the chest was opened via a left thoracotomy 
in the fourth intercostal space and fluid-filled polyvinylchloride catheters (B Braun 
Medical Inc., Bethlehem, PA, USA) were placed in the right ventricle, pulmonary 
artery, aorta and left atrium. A flow probe (Transonic Systems Inc., Ithaca, NY, 
USA) was positioned around the ascending aorta for measurement of aorta flow. 
The catheters were tunneled to the back and animals received analgesia (0.015 
mg/kg buprenorphine i.m. and a slow-release fentanyl patch 12 μg/h for 48 hours) 
on the day of the surgery and daily antibiotic prophylaxis (25 mg/kg amoxicillin 
i.v.) for 7 days.  
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CTEPH induction 
CTEPH was induced in awake state as describe previously (17). In short, following 
the recovery week, on the first day, the CTEPH animals (n=6), were given the 
eNOS-inhibitor L-Nω-Nitroarginine methyl ester (LNAME) (10 mg/kg i.v., Enzo Life 
Sciences International Inc, NY, USA) as a bolus infusion which was increased by 10 
mg/kg per day up to 30 mg/kg i.v., which was maintained until 2 weeks before the 
end of the study. Four days after the start of LNAME administration, microsphere 
infusions were started. Polyethylene microspheres (diameter 600-710 μm, density 
1.13 g/cm3, 500 mg, corresponding to ∼2500 microspheres, Cospheric LLC, Santa 
Barbara, California, US) were suspended in 50 mL autologous blood with 2500 I.U. 
heparin and slowly infused into the right ventricle over 10 minutes while 
monitoring mean pulmonary artery pressure (PAP). Microsphere infusions were 
repeated until the PAP reached ~60 mmHg, or the arterial PaO2 dropped below 
~40 mmHg, as measured 30 min after infusion at rest, or when a maximum of 3 
gram (∼15000) microspheres was infused on one day. In the subsequent four 
weeks, hemodynamics were weekly assessed, and microsphere infusions were 
repeated when PAP was <25 mmHg and PaO2 >70 mmHg, as described above. 
During the final 5 weeks of follow-up, no microsphere infusions were performed.  
The control animals (n=4) were healthy chronically instrumented swine.  
CMR protocol 
CMR examination was performed on a 1.5T clinical scanner with a dedicated 
receive-only 32-channel phased-array cardiac surface coil (Discovery MR450, GE 
Healthcare, Milwaukee, WI, USA). The animals were sedated, and intubated as 
described above. Anesthesia during imaging was maintained with pentobarbital 
sodium (6-12 mg/kg/h). Mechanical ventilation and breath-holds were performed 
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using a mobile ventilator (Carina™, Dräger Medical, Best, The Netherlands). Heart 
rate and blood pressures were monitored throughout the scan. When necessary, 
and always in absence of pain reflexes, muscle relaxation was achieved using 
pancuronium bromide (2–4 mg bolus). The image protocol consisted of 2D 
balanced Steady-State Free Precession (SSFP) cine imaging, 4D flow, and 2D phase 
contrast flow measurements. Standard long-axis and short-axis images with full 
left ventricular (LV) coverage were acquired using retrospectively ECG-gated SSFP 
cine imaging with breath-holding (FIESTA, GE Healthcare acronym). Typical scan 
parameters were slice thickness 6.0 mm, slice gap 0 mm, TR/TE 3.4/1.4 ms, flip 
angle (FA) 75°, field of view (FOV) 320×240 mm, acquired matrix 128×180, and 
reconstructed to a pixel size of 1.3x1.3 mm. The free-breathing, retrospectively 
ECG-gated 4D flow acquisition was performed directly after administration of a 
gadolinium-based contrast agent (Gadovist 1,0 mmol/mL, Bayer, Mijdrecht, The 
Netherlands, single dose of up to 15 mL). The 4D flow sequence has been 
described before (4-6), in short the sequence was prescribed in axial plane, 
including the entire thorax in the field of view. The k-space was filled with 
variable-density Poisson-disc undersampling with acceleration factors of 1.8×1.8 
(phase x slice) and the parallel imaging algorithm used was ESPIRiT. The following 
imaging parameters were used: matrix 192x160x78, acquired resolution 
2.1x1.7x2.8 mm, reconstructed resolution 2.1x1.7x1.4 mm, TR/TE 3.8/1.5 ms, FA 
15°, views per segment 4, bandwidth 63kHz, number of reconstructed phases 20 
per cardiac cycle, and a velocity encoded value set at 250 cm/s. Scan time ranged 
between 5.57 and 8.51 minutes. Finally, one-directional through plane 2D phase 
contrast flow measurements of the aorta (at the level of the aortic valve or just 
above) and pulmonary artery were performed during an end-expiratory breath-
hold. The imaging planes were planned perpendicular to the great vessels. Typical 
scan parameters were slice thickness 6.0 mm, matrix 256x166, TR/TE 4.0/2.2 ms, 
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FA 18°, FOV 340x220, velocity encoding value set at 180 cm/s. The invasive flow 
probe was attached to the amplifier and a flow signal was obtained immediately 
before and after the 4D flow CMR sequence. 
Post-processing and data analysis 
To assess left ventricular volumes, endocardial contours were drawn manually on 
end-diastolic and end-systolic 2D short axis SSFP cine images, and stroke volume 
and ejection fraction were calculated. No substantial mitral regurgitation was 
visually noted on CMR in any of the animals, therefore stroke volume (mL/beat) 
and cardiac output (CO, L/min) of the left ventricle were also compared to 
invasive measurements. To analyze the 2D phase contrast images a region of 
interest was manually traced around the aorta and pulmonary valve. Both 2D flow 
CMR and left ventricular function were analyzed with Medis software (QMass and 
QFlow analytical software version 8.1, Medis, Leiden, The Netherlands).  
The 4D flow data were analyzed using a dedicated cloud-based post-
processing software (ArterysInc, San Francisco, CA, USA). Semi-automatic eddy-
current correction was applied. (6) Data were visualized, and flow quantification 
was performed at the level of aortic valve and at the level of the sinotubular 
junction/proximal part of the ascending aorta below the flow probe. Also the 
pulmonary flow was determined by measuring in the main pulmonary artery 
(MPA). For both 2D and 4D flow shunt fractions (Qp/Qs) were calculated. 
Digital recording and offline analysis of heart rate (HR) and aorta flow 
were performed with MatLab (MathWorks, Natick, MA, USA) and have been 
described in detail elsewhere. (8, 19)Briefly, HR and aorta flow were analyzed 
offline using a proprietary program written in MatLab. Over at least 10 
consecutive seconds, both before and after the 4D flow CMR sequence, CO and SV 
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were determined from each individual beat and averaged. HR was calculated as 
the ratio of the number of beats and time. The end-diastolic time point was used 
to align the (average) phasic flow signals obtained with the different methods.  
All measurements were performed independently from each other (2D 
flow and left ventricular function measurements by NvdV and AH, 4D flow CMR by 
RC, and invasive flow probe measurements by KS).  
Statistics 
Statistical analysis was performed with SPSS software version 21 (IBM, New York, 
US) and Graphpad Prism 4 Project (San Diego, CA, US). Correlation between 
measurements was evaluated using Spearman’s (rho) coefficient for 
nonparametric data, and agreement was analyzed with Bland-Altman plots. The 
Spearman rho coefficient was classified as “very weak” for values of 0.00–0.19, 
“weak” for 0.20–0.39, “moderate” for 0.40–0.59, “strong” for 0.60–0.79 and “very 
strong” for 0.80–1.0. (1, 4) 
Results 
A total of nine animals were scanned, but not all animals were included in every 
method of CO determination: two animals had a malfunctioning invasive flow 
probe, in all nine animals CO could be determined with 4D flow CMR at the level 
of the aortic valve, while susceptibility artefacts from the invasive flow probe 
precluded measurement of CO at the ascending aorta level in two animals. Finally, 
one animal was excluded due to technical problems for measurement of CO with 
2D flow CMR as well as LV functional measurements. Typical examples of the 4D 
flow CMR images and measurements are shown in Figure 1 and supplemental 
video’s. 
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Figure 1. Example of 4D flow CMR images and measurement. 
Example of 4D flow CMR with a flow measurement in the ascending aorta. The magnitude 
images are shown with a color velocity overlay (red: velocity >150 cm/s). (A) 3 chamber 
view (online supplementary file 1 for movie), (B) coronal view, (C) corresponding short-axis 
view of the aorta with tracing for flow measurement, and (D) overview of both aortic and 
pulmonary flow (online supplementary file 2 for movie). (*) susceptibility artefacts from 
the invasive flow probe around the ascending aorta. 
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Figure 2. Individual aorta flow curves per heartbeat.   
Individual aorta flow curves per heartbeat of the invasive flow probe, 4D flow CMR 
(measured at level of the aortic valve), and 2D flow CMR superimposed per animal. 2D 
flow CMR measurements of Control 3 and invasive flow probe measurements of CTEPH 1 
and Control 1 are missing due to technical problems. CTEPH animals are ordered on 
disease severity, CTEPH 1 presented with the most severe PH and CTEPH 6 with the 
mildest.  
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The shape of the individual aorta flow patterns measured by all three 
methods showed good agreement and individual flow curves per animal are 
depicted in Figure 2. Indeed, the correlation between the CO measured by the 
invasive flow probe and 4D flow CMR was very strong (Spearman’s rho=0.86 at 
the aortic valve level and 0.90 at the ascending aorta level) (Table 1 and Figure 3). 
Relative to the invasive flow probe measurements, the flow measured by 4D flow 
CMR was overestimated by 0.8 L/min at the aortic valve level and by 0.6 L/min at 
the ascending aorta level (Bland-Altman, Table 1 and Figure 3). The correlation 
between the invasive flow probe and 2D flow CMR and volumetric LV 
measurements were strong (2D flow CMR: Spearman’s rho=0.67 and volumetric 
LV measurements: Spearman’s rho=0.77). Relative to the invasive flow probe 
measurements, the flow measured by 2D flow CMR was overestimated by 1.1 
L/min and by 1.3 L/min with the LV parameters (Bland-Altman, Table 1 and Figure 
2). 
The shape of the individual pulmonary flow patterns measured by 4D flow 
CMR and 2D flow CMR showed good agreement and individual flow curves per 
animal are depicted in Figure 4. The correlation between the 4D flow CMR and 2D 
flow CMR MPA CO measurement was very strong (Spearman’s rho=0.81) (Table 
1). Relative to the 4D flow CMR measurements, the MPA CO measured by 2D flow 
CMR was underestimated by 0.4 L/min. Although the correlation between MPA 
and aorta flow at the aortic valve level as measured with 4D flow CMR only 
tended to be significant (Spearman’s rho=0.65, P=0.07), no correlation was found 
between MPA and aorta flow measured with 2D flow CMR (Spearman’s rho=0.40, 
P=0.33) (Figure 5). 
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Figure 3. Comparison of cardiac output in the aorta measured by the invasive flow 
probe, 4D flow and 2D flow CMR. 
Correlation between the invasive flow probe, 4D flow CMR (A, n=7), and 2D flow CMR (C, 
n=6) measurements of the aortic flow. Line of identity is indicated as the dotted line and 
Spearman’s rho (ρ) and P-value are indicated in the legends (A&C). Bland-Altman plots of 
the cardiac output (CO), with the mean, 1.96 standard deviation (SD) and -1.96 SD lines 
indicated as the dotted lines. (B) invasive flow probe and 4D flow CMR measurements 
(n=7), and (D) invasive flow probe and 2D flow CMR measurements (n=6). 
To investigate any differences in flow between the CTEPH and Control animals, 
and investigate any differences in flow through the aorta and pulmonary artery, 
we superimposed the MPA and aorta flow pattern measured by 4D flow CMR of 
each animal (Figure 6). In this figure, the CTEPH animals were ordered by disease 
Validation of 4D flow CMR 
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severity, in which CTEPH 1 was most affected and CTEPH 6 presented with the 
mildest PH. Although the MPA and aorta flow were almost perfectly aligned in the 
control animals while the peak MPA flow appears to be decreased compared to 
the peak aorta flow in the CTEPH animals, this is not significantly different. In 
addition, the flow pattern appears to be more elongated in the control animals 
when compared to the more steep, sharp flow pattern of the CTEPH animals, but 
this is also not significantly different. 
Figure 4. Individual pulmonary artery flow curves per heartbeat. 
Individual Pulmonary Flow (PuF) curves per heartbeat of 4D flow and 2D flow CMR 
superimposed per animal. 2D flow CMR measurements of Control 3 are missing due to 
technical problems.  CTEPH animals are ordered on disease severity, CTEPH 1 presented 
with the most severe PH and CTEPH 6 with the mildest. 
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addition, the flow pattern appears to be more elongated in the control animals 
when compared to the more steep, sharp flow pattern of the CTEPH animals, but 
this is also not significantly different. 
Figure 4. Individual pulmonary artery flow curves per heartbeat. 
Individual Pulmonary Flow (PuF) curves per heartbeat of 4D flow and 2D flow CMR 
superimposed per animal. 2D flow CMR measurements of Control 3 are missing due to 
technical problems.  CTEPH animals are ordered on disease severity, CTEPH 1 presented 
with the most severe PH and CTEPH 6 with the mildest. 
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Figure 5. Comparison of pulmonary and aorta flow measured by 4D flow CMR and 2D 
flow CMR. 
Correlation between the aorta and pulmonary measured by 4D flow CMR (A, n=9) and 2D 
flow CMR (B, n=8). Line of identity is indicated as the dotted line. Spearman’s rho (ρ) and P-
value are indicated in the legends.  
Figure 6 Individual pulmonary artery and aorta flow curves per heart beat 
superimposed. 
Individual flow curves, measured by 4D flow CMR, superimposed per animal. CTEPH 
animals are ordered on disease severity, CTEPH 1 presented with the most severe PH and 
CTEPH 6 with the mildest.  
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Discussion 
The main findings of this study were that (1) CO measured by 4D flow CMR 
showed a very strong correlation with invasively measured aortic flow, although 
there was an overestimation of the CO by 4D flow CMR of ~15%, (2) the 
correlation between 2D flow CMR and volumetric LV measurements in relation to 
invasively measured flow was less strong with a larger overestimation of the flow, 
and (3) the difference between MPA and aorta flow was much smaller with 4D 
flow compared to 2D flow CMR. 
4D flow CMR is a relatively new technique but increasingly used in clinical 
practice due to its simplicity. The application of 4D flow CMR in the clinical setting 
provides many benefits as the technique is patient and operator friendly, less 
operator dependent and any flow in any plane can be selected retrospectively 
since the whole field of interest is acquired. (5, 9, 11) The latter is not the case for 
2D flow CMR, in which flow measurements are limited to preselected planes. (3, 
5, 9) Importantly, 4D flow CMR is in most cases more patient friendly than 2D flow 
CMR. One important benefit for the patients is that the sequence can be 
performed without breath holds (free breathing), which is not only more 
comfortable but will be an advantage in children, decompensated and importantly 
pulmonary hypertension patients in which breath holds are mostly impossible. (4, 
5, 9) In addition, data on flow and anatomic structures can be obtained 
simultaneously which can shorten the scan time for the patients, especially in 
patients with a difficult anatomy. (2, 4, 6, 9) However, it is important to note that 
there are some existing challenges with the 4D flow CMR technique such as long 
scan time, reliability of respiratory gating and lower resolution. Given the benefits 
and existing challenges, it is important to assess accuracy of 4D flow CMR 
measurements. Our data show that indeed, 4D flow CMR measurements correlate 
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strongly with flow measured with an invasive flow probe, and overestimation of 
flow with this technique is less than measurements obtained using 2D flow CMR 
as well as compared to CO determined from volumetric LV measurements. 
This is the first study to validate 4D flow CMR against both 2D flow CMR 
and invasively measured flow within the same animal, at the same time. Thus far, 
4D flow CMR has only been validated against 2D flow CMR (6, 12) and ultrasound 
(5) measurements in humans. Although data are obtained in a relatively small 
group of animals, and magnetic interference of the metal in the flow probe could 
not be completely ruled out (two animals were excluded due to artifacts and in 
the other animals there were no noticeable imaging artifacts), both flow pattern 
and average flow showed a very strong correlation between invasively measured 
flow and 4D flow CMR. Although the invasively measured flow is considered the 
gold standard in validation studies, according to the manufacturer’s specifications, 
this technique has an absolute accuracy of 10%. Both 2D flow CMR and 4D flow 
CMR overestimated CO as compared to the invasively measured flow by 25% and 
16% respectively. When comparing the individual flow patterns between the 
different techniques (Figure 2) we do not see a consistent difference between the 
CMR and invasively measured flow, suggesting that there is no systematic bias. 
Consistent with data obtained in a canine model of acute thromboembolic 
pulmonary hypertension, 4D flow CMR resulted in slightly lower values of CO as 
compared to 2D flow CMR measurements (16), suggesting that determination of 
flow using 4D CMR is slightly more accurate than 2D CMR. The higher accuracy of 
4D flow CMR vs 2D flow CMR can also be inferred from the comparison between 
aorta flow and MPA flow. Also here, there tended to be a correlation of the 
measurements with 4D flow CMR while no correlation was found with 2D flow 
CMR. 
Validation of 4D flow CMR 
143 
In conclusion, this study shows that aorta flow and pulmonary flow can be 
accurately and simultaneously measured by 4D flow CMR. This helps to further 
validate the quantitative reliability of this technique for implementation of 4D 
flow CMR in routine clinical practice. Unfortunately, we did not observe any 
significant distinctions in flow patterns in the CTEPH swine. 
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Abstract 
Rationale: Pulmonary vascular remodeling in pulmonary arterial hypertension 
involves perturbations in the nitric oxide (NO) and endothelin-1 (ET-1) pathways. 
However, the implications of pulmonary vascular remodeling and these pathways 
remain unclear in chronic thrombo-embolic pulmonary hypertension (CTEPH). 
Objectives: The objective of the present study was to characterize changes in 
microvascular morphology and function, focussing on the ET-1 and NO pathways, 
in a CTEPH swine model. 
Methods: Swine were chronically instrumented and received up to 5 pulmonary 
embolizations by microsphere infusion, while endothelial dysfunction was induced 
by daily administration of the eNOS inhibitor L-Nω-Nitroarginine methyl ester, 
until two weeks prior to the end of study. Swine were subjected to exercise and 
the pulmonary vasculature was investigated by hemodynamic, histological, qPCR 
and myograph experiments. 
Results: In swine with CTEPH, the increased RV-afterload, decreased cardiac index 
and mild ventilation-perfusion mismatch were exacerbated during exercise. These 
findings suggest that pulmonary microvascular remodeling was evidenced by 
increased muscularization which was accompanied by an increased maximal 
vasoconstriction. Although ET-1-induced vasoconstriction was increased in CTEPH 
pulmonary small arteries, the ET-1-sensitivity was decreased. Moreover, the 
contribution of the ETA receptor to ET-1 vasoconstriction was increased, while the 
contribution of the ETB receptor was decreased and the contribution of Rho-
Kinase was lost. A reduction in endogenous NO-production was compensated in 
part by a decreased PDE5-activity resulting in an apparent increased NO-
sensitivity in CTEPH pulmonary small arteries.  
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Conclusions: Pulmonary microvascular remodeling with a reduced activity of PDE5 
and Rho-kinase may contribute to the lack of therapeutic efficacy of PDE5-
inhibitors and Rho-kinase inhibitors in CTEPH.  
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Introduction 
Chronic thrombo-embolic pulmonary hypertension (CTEPH) is a form of 
pulmonary hypertension (PH) initiated by thrombo-emboli in the pulmonary 
vasculature (9). The obstructions in the pulmonary vascular bed cause a direct 
increase in pulmonary vascular resistance, which results in an increase in 
pulmonary artery pressure (PAP). CTEPH is defined as a PAP ≥ 25 mmHg at rest 
persisting for at least six weeks (26). Both the increase in pressure and a 
redistribution of flow through the unobstructed parts of the pulmonary 
vasculature have been proposed to contribute to pathological processes including 
endothelial dysfunction, thrombophilia, inflammation, vasoconstriction and 
impaired vasodilation (36), eventually resulting in structural pulmonary vascular 
remodeling of both the obstructed and unobstructed pulmonary vasculature (17, 
42). This remodeling encompasses both the pulmonary small arteries as well as 
the microvasculature.  
It is well known that perturbations in the endothelin-1 (ET-1) and the 
nitric oxide (NO) pathways play an important role in the dysregulation of 
pulmonary vascular tone as well as in microvascular remodeling in pulmonary 
arterial hypertension (PAH) (14, 52). Plasma markers of oxidative stress and the 
endogenous endothelial NO synthase (eNOS) inhibitor asymmetric dimethyl 
arginine (ADMA) are increased in patients with CTEPH (59). Moreover, circulating 
ET-1 levels are elevated in patients with CTEPH and correlate with clinical severity 
of the disease as well as with hemodynamic outcome after pulmonary 
endarterectomy (47). Nevertheless, therapeutic agents that modulate the NO and 
the ET-1 pathways, including phosphodiesterase 5 (PDE5)-inhibitors and ET-
receptor antagonists, which are the cornerstones of PAH therapy, are not as 
effective in CTEPH (13, 22, 45). The only approved therapy for CTEPH is the 
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soluble guanylate cyclase (sGC) stimulator Riociguat (13, 22, 45), suggesting that 
indeed the NO-pathway is compromised in CTEPH. However, the contribution of 
alterations in the NO and ET-1 pathways to pulmonary microvascular 
(dys)function have not been investigated to date in CTEPH. 
We recently developed and hemodynamically characterized a swine 
model of CTEPH, using a combination of repeated micro-embolizations and eNOS-
inhibition to mimic endothelial dysfunction (54). In this study, micro-
embolizations alone resulted in transient elevations in pulmonary artery pressure 
but did not induce sustained PH. In contrast, in animals in which repeated micro-
embolizations were combined with eNOS-inhibition, PH persisted for several 
weeks, even after discontinuation of micro-embolization and eNOS-inhibition. In 
the present study, we characterized changes in pulmonary microvascular 
morphology and hypothesized that microvascular remodeling is associated with 
altered regulation of pulmonary microvascular function through the ET-1- and NO-
pathways in this CTEPH model. 
Methods 
Animal studies were performed following the “Guide for the Care and Use of 
Laboratory Animals” as approved by the Council of the American Physiological 
Society, and with approval of the Animal Care Committee of the Erasmus 
University Medical Center (EMC3158, 109-13-09). Twenty-four swine (2-3 months 
old, 21±1 kg) entered the study. Lungs from seven additional swine were obtained 
at a local slaughterhouse for in vitro control experiments.  
CTEPH induction 
Animals were chronically instrumented as previously described (8, 54). In short, 
swine were sedated with an intramuscular injection (i.m.) of 
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tiletamine/zolazepam (5 mg/kg), xylazine (2.25 mg/kg) and atropine (1 mg), 
intubated and ventilated with a mixture of O2 and N2 (1:2 v/v) to which 2% (v/v) 
isoflurane was added to maintain anesthesia (8, 54). Under sterile conditions, the 
chest was opened via a left thoracotomy in the fourth intercostal space and fluid-
filled polyvinylchloride catheters (Braun Medical Inc., Bethlehem, PA, USA) were 
placed in the right ventricle, pulmonary artery, aorta and left atrium for blood 
sampling and measurement of pressures. A flow probe (Transonic Systems Inc., 
Ithaca, NY, USA) was positioned around the ascending aorta for measurement of 
cardiac output. The catheters were tunneled to the back and animals were 
allowed to recover for one week, receiving analgesia (0.015 mg/kg buprenorphine 
i.m. and a slow-release fentanyl patch 12 μg/h for 48 hours) on the day of the 
surgery and daily intravenous (i.v.) antibiotic prophylaxis (25 mg/kg amoxicillin) 
for 7 days (8).  
Following the recovery week, on the first day, the CTEPH animals (n=11), 
were given the eNOS-inhibitor L-Nω-Nitroarginine methyl ester (LNAME) (10 
mg/kg i.v., Enzo Life Sciences International Inc, NY, USA) as a bolus infusion. On 
subsequent days, the dose of LNAME was increased by 10 mg/kg per day up to 30 
mg/kg i.v., which was maintained until 2 weeks before the end of the study (35, 
46, 54). Four days after the start of LNAME administration, microsphere infusions 
were started. Polyethylene microspheres (diameter 600-710 μm, density 1.13 
g/cm3, 500 mg, corresponding to ∼2500 microspheres, Cospheric LLC, Santa 
Barbara, California, US) were suspended in 50 mL autologous blood with 2500 I.U. 
heparin and slowly infused into the right ventricle over 10 minutes while 
monitoring mean pulmonary artery pressure (PAP). Microsphere infusions were 
repeated until the PAP reached ~60 mmHg, or the arterial PaO2 dropped below 
~40 mmHg, as measured 30 min after infusion at rest, or when a maximum of 3 
gram (∼15000) microspheres was infused on one day (54). In the subsequent four 
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weeks, hemodynamics were weekly assessed, and microsphere infusions were 
repeated when PAP was <25 mmHg and PaO2 >70 mmHg, as described above. 
During the final 5 weeks of follow-up, no microsphere infusions were performed.  
Seven sham-operated animals which did not receive LNAME or 
microspheres served as controls. A third group of six swine did receive LNAME but 
no microspheres and also served as controls (54). Similar to the CTEPH group, 
LNAME was discontinued two weeks before the end of the study. 
Mortality due to acute cardiopulmonary failure after CTEPH induction 
occurred in 2 out of 11 animals. In addition, 2 animals were excluded due to 
catheter failure (1 CTEPH and 1 Control) and 2 animals had to be euthanized 
following infections (1 CTEPH and 1 Control). 
In vivo experiments 
Hemodynamic studies were performed nine weeks after surgery. With swine 
standing quietly on a motor-driven treadmill and during exercise at 4 km/h, 
cardiac output, PAP, aorta pressure, left atrial pressure and right ventricular 
pressure, were continuously recorded, and blood samples were taken when 
hemodynamics had reached a steady-state. Measurements of arterial and mixed 
venous pO2, pCO2, O2 saturation, pH and lactate were performed immediately 
with a blood gas analyzer (ABL 800, Radiometer, Denmark) (8, 12). Furthermore, 
EDTA plasma was stored for measurement of endothelin-1 (ET-1) levels with an 
enzyme-linked immunoassay (ELISA; Enzo Life Sciences International Inc, NY, USA) 
and D-Dimer levels with a particle-enhanced, immunoturbidimetric assay 
(INNOVANCE®, Siemens Healtineers, Erlangen, Duitsland) following the standard 
protocols.  
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Euthanasia 
After completion of the experiments (week 9), the animals were re-anaesthetized 
with pentobarbital sodium (6-12 mg/kg/h iv), intubated and ventilated as 
described before (8, 54). Following sternotomy, the heart was arrested and 
immediately excised together with the lungs. Parts of one lung were snap frozen 
in liquid nitrogen for molecular analyses, and one lung lobe was placed in cold 
Krebs buffer for dissection of pulmonary small arteries for wire-myograph 
experiments to delineate changes in microvascular function (2, 18, 41, 43). The 
accessory lobe was obtained for histological analyses.  
Quantitative PCR of lung tissue 
Lung tissue was excised and immediately snap frozen in liquid nitrogen for the 
measurement of mRNA levels of prepro-endothelin 1 (PPET-1), endothelin 
converting enzyme 1 (ECE-1), endothelin receptor A (ETA), endothelin receptor B 
(ETB), endothelial nitric oxide synthase (eNOS), Ras homolog gene family, member 
A (RhoA), rho-associated, coiled-coil-containing protein kinase 1 (ROCK1), Rho 
associated coiled-coil containing protein kinase 2 (ROCK2),Platelet endothelial cell 
adhesion molecule (CD31), vascular cell adhesion molecule 1 (VCAM-1), vascular 
endothelial cadherin (VE-cadherin, CD144), interleukin-6 (Il-6), interferon-γ, tumor 
necrosis factor α (TNF-α) and transforming growth factor β1 (TGF-β). Small pieces 
of lung tissue (<30 mg) were homogenized by adding RLT lysisbuffer (Qiagen, 
Venlo, The Netherlands) and 2-mercaptoethanol (Sigma-Aldrich, Zwijndrecht, The 
Netherlands) using a homogenizer (PRO Scientific Inc., Oxford, Connecticut, USA). 
After a proteinase K (Invitrogen, Breda, The Netherlands) treatment at 55 °C for 
10 min, total RNA was isolated using RNeasy Fibrous Tissue Mini Kit (Qiagen, 
Venlo, The Netherlands). RNA was eluted in RNase-free water and the 
concentration was determined by using a NanoDrop (NanoDrop1000, Thermo 
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weeks, hemodynamics were weekly assessed, and microsphere infusions were 
repeated when PAP was <25 mmHg and PaO2 >70 mmHg, as described above. 
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LNAME was discontinued two weeks before the end of the study. 
Mortality due to acute cardiopulmonary failure after CTEPH induction 
occurred in 2 out of 11 animals. In addition, 2 animals were excluded due to 
catheter failure (1 CTEPH and 1 Control) and 2 animals had to be euthanized 
following infections (1 CTEPH and 1 Control). 
In vivo experiments 
Hemodynamic studies were performed nine weeks after surgery. With swine 
standing quietly on a motor-driven treadmill and during exercise at 4 km/h, 
cardiac output, PAP, aorta pressure, left atrial pressure and right ventricular 
pressure, were continuously recorded, and blood samples were taken when 
hemodynamics had reached a steady-state. Measurements of arterial and mixed 
venous pO2, pCO2, O2 saturation, pH and lactate were performed immediately 
with a blood gas analyzer (ABL 800, Radiometer, Denmark) (8, 12). Furthermore, 
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enzyme-linked immunoassay (ELISA; Enzo Life Sciences International Inc, NY, USA) 
and D-Dimer levels with a particle-enhanced, immunoturbidimetric assay 
(INNOVANCE®, Siemens Healtineers, Erlangen, Duitsland) following the standard 
protocols.  
Pulmonary vascular remodeling in CTEPH swine 
159 
Euthanasia 
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described before (8, 54). Following sternotomy, the heart was arrested and 
immediately excised together with the lungs. Parts of one lung were snap frozen 
in liquid nitrogen for molecular analyses, and one lung lobe was placed in cold 
Krebs buffer for dissection of pulmonary small arteries for wire-myograph 
experiments to delineate changes in microvascular function (2, 18, 41, 43). The 
accessory lobe was obtained for histological analyses.  
Quantitative PCR of lung tissue 
Lung tissue was excised and immediately snap frozen in liquid nitrogen for the 
measurement of mRNA levels of prepro-endothelin 1 (PPET-1), endothelin 
converting enzyme 1 (ECE-1), endothelin receptor A (ETA), endothelin receptor B 
(ETB), endothelial nitric oxide synthase (eNOS), Ras homolog gene family, member 
A (RhoA), rho-associated, coiled-coil-containing protein kinase 1 (ROCK1), Rho 
associated coiled-coil containing protein kinase 2 (ROCK2),Platelet endothelial cell 
adhesion molecule (CD31), vascular cell adhesion molecule 1 (VCAM-1), vascular 
endothelial cadherin (VE-cadherin, CD144), interleukin-6 (Il-6), interferon-γ, tumor 
necrosis factor α (TNF-α) and transforming growth factor β1 (TGF-β). Small pieces 
of lung tissue (<30 mg) were homogenized by adding RLT lysisbuffer (Qiagen, 
Venlo, The Netherlands) and 2-mercaptoethanol (Sigma-Aldrich, Zwijndrecht, The 
Netherlands) using a homogenizer (PRO Scientific Inc., Oxford, Connecticut, USA). 
After a proteinase K (Invitrogen, Breda, The Netherlands) treatment at 55 °C for 
10 min, total RNA was isolated using RNeasy Fibrous Tissue Mini Kit (Qiagen, 
Venlo, The Netherlands). RNA was eluted in RNase-free water and the 
concentration was determined by using a NanoDrop (NanoDrop1000, Thermo 
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Fisher Scientific, Bleiswijk, The Netherlands). RNA integrity was confirmed using a 
Bioanalyzer (2100 Bioanalyzer, Agilent, Santa Clara, California, USA). cDNA was 
synthesized from 500 ng of total RNA with the SensiFAST cDNA Synthesis Kit 
(Bioline, London, UK). qPCR (CFX-96, Bio-Rad, Hercules, California, USA) was 
performed with SensiFAST SYBR & Fluorescein Kit (Bioline, London, UK). Target 
gene mRNA levels were normalized against β-actin, glyceraldehyde-3-phosphate 
dehydrogenase (GADPH), and Cyclophilin using the CFX manager software (Bio-
Rad, Hercules, California, USA). Relative gene expression data were calculated 
using the ΔΔCt method. All primer sequences are presented in Table 1. 
Myograph studies of isolated pulmonary small arteries 
Myograph studies have been extensively described before (43, 54, 60). Unless 
otherwise mentioned, all chemicals were obtained from Sigma Aldrich, 
Zwijndrecht, The Netherlands. Pulmonary small arteries (diameter ~300μm) were 
dissected from the lung and stored overnight in cold, oxygenated (95% O2/5% 
CO2) Krebs bicarbonate solution (composition in mM: 118 NaCl, 4.7 KCl, 2.5 CaCl2, 
1.2 MgSO4, 1.2 KH2PO4, 25 NaHCO3, and glucose 8.3; pH 7.4). The next day, 
pulmonary small arteries were cut into segments of ~2 mm length and mounted 
in microvascular myographs (Danish MyoTechnology) with separated 6-ml organ 
baths containing Krebs bicarbonate solution aerated with 95% O2-5% CO2 and 
maintained at 37°C. Changes in contractile force were recorded with a Harvard 
isometric transducer. Following a 30-min stabilization period, the internal 
diameter was set to a tension equivalent to 0.9 times the estimated diameter at 
20 mmHg effective transmural pressure (18, 60). The vessels were subsequently 
exposed to 30 mM KCl twice. Endothelial integrity was ascertained by measuring 
the dilation response to 10 nM substance P after preconstriction with 100 nM of 
the stable thromboxane-A2 analog 9,11-dideoxy-11α,9α 
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epoxymethanoprostaglandin F2α (U46619). Then, after washout, vessels were 
subjected to 100 mM KCl to determine maximal vascular contraction. Thereafter, 
vessels were allowed to equilibrate in fresh Krebs solution for 30 min before 
different experimental protocols were started. Only one protocol was performed 
per vessel segment, and each vessel segment within an experimental protocol was 
obtained from a different animal with a minimum of five per experiment per 
group.  
Following preconstriction with 100 nM U46619, vessel segments were 
exposed to incremental concentrations of the Rho-kinase inhibitor Y-27632 (10-8-
3⋅10-5M), the cGMP analogue 8Br-cGMP (10-7-3⋅10-4M), the PDE5-inhibitor 
Sildenafil (10-10-3⋅10-5M), the NO-donor sodium nitroprusside (SNP) (10-9-3⋅10-5M), 
or the endothelium dependent-vasodilator Bradykinin (10-10-3⋅10-7M), in the 
absence and presence of 30 minutes pre-incubation with LNAME(10-4M). 
In pulmonary small artery segments from a subgroup of seven CTEPH 
animals and eleven Control animals, concentration-response curves to Endothelin-
1 (ET-1) were constructed, by subjecting these segments to incremental 
concentrations of ET-1 (10-10-3⋅10-7M) in the absence and presence of the ETA 
receptor antagonist BQ123 (10−6M), the ETB receptor antagonist BQ788 (10−8M), a 
combination of both BQ123 and BQ788, or the Rho-kinase inhibitor Y-27632 (10-
5M) (2, 18, 41). 
Histology of the lung tissue 
The accessory lobe was flushed with saline, and fixed by bronchial installation of 
3.5-4% buffered formaldehyde at a physiological pressure of 18 mmHg (34). 
Tissues were processed and embedded in paraffin. Sections (4.5 µm) were cut, 
stained with Resorcin Fuchsin von Gieson (RF) and evaluated by light microscopy 
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(NDP slide scanner, Hamamatsu Nanozoomer 2.0HT, Hamamatsu Photonics K.K., 
Japan). 
Data analysis and statistics 
Digital recording and offline analysis of hemodynamic data were performed as 
described previously (12, 56). To account for differences in growth between 
animals, cardiac output was corrected for bodyweight, yielding cardiac index (CI). 
Total pulmonary vascular resistance index (tPVRi) was calculated as PAP/CI and 
body oxygen consumption index (BVO2i) as CI⋅(arterial-mixed venous oxygen 
content) i.e. CI·(CaO2-CmvO2). Alveolar-arterial oxygen gradient (AaDO2) was 
calculated as: 
𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴2 = �𝐹𝐹𝐹𝐹𝑖𝑖𝑖𝑖𝐴𝐴𝐴𝐴2 ∙ (𝑃𝑃𝑃𝑃𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴 − 𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝2𝐴𝐴𝐴𝐴)− 𝑃𝑃𝑃𝑃𝑎𝑎𝑎𝑎𝐶𝐶𝐶𝐶𝐴𝐴𝐴𝐴2𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅 � − 𝑃𝑃𝑃𝑃𝑎𝑎𝑎𝑎𝐴𝐴𝐴𝐴2 
With FIO2=0.21; PATM=760 mmHg; pH20=47 mmHg; RER=0.9 at rest (based on the 
assumption that pig chow contains predominantly protein and carbohydrates) and 
1.15 at 4km/h (27) and PaCO2 and PaO2 were measured in the blood gases 
obtained from the animals. 
Vascular responses to ET-1 in the myograph experiments were normalized 
to 100 mM KCl. Vasorelaxation was expressed as the percentage of contraction to 
U46619.  
Morphometric measurements of pulmonary small arteries and 
microvasculature were performed using NanoZoomer Digital Pathology (NDP) 
viewer (Hamamatsu Photonics K.K., Japan). To ensure that pulmonary veins were 
excluded for analysis, vessels within, or in close proximity to the lung septae were 
not included in the analysis. Only transversely cut vessels (ratio largest/ smallest 
diameter <1.5) of predetermined diameters (<50, 50-100, 100-300 µm) were 
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analyzed. All vessels complying with these conditions were analyzed resulting in 
an average of 68 vessels per animal. Assuming circularity of the vessels, inner and 
outer radius were calculated as r = perimeter/2*π. Wall-to-lumen ratio was 
calculated as (outer – inner radius)/inner radius. 
Data analysis of the concentration-response curves in the isolated 
pulmonary small arteries was performed using Prism (version 5.0, Graphpad 
Software, Inc., La Jolla, CA, USA)and StatView (version 5.0, SAS Institute, Cary, 
North Carolina, USA). SPSS (version 21.0 IBM, Armonk, NY, USA)was used for 
statistical analysis of exercise responses and qPCR data.Statistical analysis was 
performed using a two-way ANOVA for repeated measures or one-way ANOVA 
when applicable. Statistical significance was accepted when P≤0.05. Data are 
presented in box and whisker plots with the whiskers reflecting min to max, 
median presented as line and means are presented as +. 
Results 
CTEPH and exercise response in vivo 
As the hemodynamic responses over time were not different between the sham-
operated animals with and without LNAME, these were pooled into one single 
Control group. Repeated embolizations combined with LNAME resulted in CTEPH 
as evidenced by a PAP > 25 mmHg (43±6 mmHg vs 20±1 mmHg in Control, 
p<0.001) as a result of an increased tPVRi (266±56 mmHg L-1minkg vs 119±10 
mmHg L-1 minkg in Control, p=0.007) (Figure 1) (54).  
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Table 1. Primer sequences used for the qPCR. 
IL-6, interleukin-6; IFN-γ, interferon-γ; TNF-α, tumor necrosis factor α; TGF-β, transforming 
growth factor β1; PPET-1, prepro endothelin 1; ECE-1, endothelin converting enzyme 1; 
ETA, endothelin receptor A; ETB, endothelin receptor B; eNOS, endothelial nitric oxide 
synthase; CD31,Platelet endothelial cell adhesion molecule; VCAM-1, vascular cell 
adhesion molecule 1; CD144, vascular endothelial cadherin (VE-cadherin); RhoA, Ras 
homolog gene family member A; ROCK1, rho-associated, coiled-coil-containing protein 
kinase 1; ROCK2, Rho associated coiled-coil containing protein kinase 2. 
 Sequence 
Genes Forward Reverse 
IL-6 CTCCAGAAAGAGTATGAGAGC AGCAGGCCGGCATTTGTGGTG 
IFN-γ GAAGAATTGGAAAGAGGAGAGTGAC TGCTCCTTTGAATGGCCTGG 
TNF-α TGCACTTCGAGGTTATCGGCC CCCACTCTGCCATTGGAGCTG 
TGF-β GTGGAAAGCGGCAACCAAAT CACTGAGGCGAAAACCCTCT 
PPET-1 TCATCGGCAGCTGGTGATGGG GGCTTTCAGCTTGGCGATGTG 
ECE-1 TGGGGGACCTTCAGCAACCT GGGTGTCCTGGAAGTTGTCCTTG 
ETA ACAGGTACAGAGCAGTTGCC TCTCGACGCTGTTTCAGGTG 
ETB CCCCTTCATCTCAGCAGGATT GCACCAGCAGCATAAGCATG 
eNOS GGACACACGGCTAGAAGAGC TCCGTTTGGGGCTGAAGATG 
CD31 AGTGTACAGTGAAATCCGGAAA TCTCAGAATGCGGTGTCTCC 
VCAM-1 TGTGAAGGGATTAACCAGGCT CAGTGTCCCCTTCCTTGACG 
CD144 AGGGAGAAGAACACTTCCGC GGGCATCTTGTGTTTCCACC 
RhoA AGGACCAATTCCCGGAGGTA AGCCAACTCTACCTGCTTTCC 
ROCK1 ATCAAACGATATGGCTGGAAG CCATAGACGGATTGGATTGTTCC 
ROCK2 TTCGACCAGTTACACAGACAG TAAATTCATGTCCCTTGTGGC 
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Figure 1. Pulmonary hemodynamics and oxygenation during exercise.  
Effect of exercise after 9 weeks of CTEPH. Shown are data obtained at rest and during 
maximal exercise at 4 km h-1 in Control swine (white boxes, n=10) and CTEPH swine (grey 
boxes, n=6) A) Mean pulmonary artery pressure (PAP), B) Cardiac Index (CI), C) total 
pulmonary vascular resistance index (tPVRi), D) arterial oxygen pressure (PaO2), E) arterial 
carbon dioxide pressure (PaCO2), F) arterial oxygen content (CaO2), G) mixed venous oxygen 
pressure (PmvO2), H) mixed venous carbon dioxide pressure (PmvCO2), I) mixed venous 
oxygen content (CmvO2), J) arterial lactate concentration (CaLac), K) body oxygen 
consumption index (BVO2i), L) alveolar-arterial oxygen gradient (AaDO2). Whiskers denote 
min to max and means are presented as +. * P < 0.05 CTEPH vs Control; $ P ≤ 0.10 CTEPH 
vs Control; § P ≤ 0.05 Effect of exercise vs Control; ‡ ≤ 0.1 Effect of exercise vs Control. 
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Although the exercise-induced increase in CI was reduced in CTEPH, the 
higher tPVRi resulted in an exaggerated exercise-induced increase in PAP in CTEPH 
as compared to Control swine. Ventilation-perfusion (V/Q)-mismatch was 
suggested by a lower PaO2 in CTEPH compared to Control at rest, and the 
reduction in PaO2 was exacerbated during exercise. The lower PaO2 and arterial O2 
content (CaO2) during exercise were partially due to a reduction in PmvO2 and 
CmvO2 as a consequence of the diminished exercise-induced increase in CI, and in 
part due to widening of the AaDO2, but were not accompanied by significant 
changes in arterial or mixed venous CO2 (Figure 1). The impaired oxygen uptake in 
the lungs resulted in an attenuation of the exercise-induced increase in BVO2i in 
CTEPH compared to Control, which was accompanied by a trend towards an 
increase in lactate, particularly during exercise (Figure 1), reflecting a lower 
anaerobic threshold. Furthermore, CTEPH was not accompanied by increased D-
Dimer concentrations, indicating that contribution of endogenous clot formation 
to CTEPH induction is minimal in this swine model (Figure 3 C).  
Figure 3. Maximal vasoconstriction of pulmonary small arteries and plasma Endothelin-1 
and D-Dimer. 
Maximal vasoconstriction response of CTEPH and Control isolated pulmonary small 
arteries to KCl (100mM) and U46619 (100nM) (A). Plasma endothelin-1 (B) and plasma D-
Dimer levels (C). Whiskers denote min to max and means are presented as +. Control n=12, 
CTEPH n=6 (A); Control n=11, CTEPH n=5 (B); Control n=11, CTEPH n=6 (C). * P < 0.05 
CTEPH vs Control. 
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Although the exercise-induced increase in CI was reduced in CTEPH, the 
higher tPVRi resulted in an exaggerated exercise-induced increase in PAP in CTEPH 
as compared to Control swine. Ventilation-perfusion (V/Q)-mismatch was 
suggested by a lower PaO2 in CTEPH compared to Control at rest, and the 
reduction in PaO2 was exacerbated during exercise. The lower PaO2 and arterial O2 
content (CaO2) during exercise were partially due to a reduction in PmvO2 and 
CmvO2 as a consequence of the diminished exercise-induced increase in CI, and in 
part due to widening of the AaDO2, but were not accompanied by significant 
changes in arterial or mixed venous CO2 (Figure 1). The impaired oxygen uptake in 
the lungs resulted in an attenuation of the exercise-induced increase in BVO2i in 
CTEPH compared to Control, which was accompanied by a trend towards an 
increase in lactate, particularly during exercise (Figure 1), reflecting a lower 
anaerobic threshold. Furthermore, CTEPH was not accompanied by increased D-
Dimer concentrations, indicating that contribution of endogenous clot formation 
to CTEPH induction is minimal in this swine model (Figure 3 C).  
Figure 3. Maximal vasoconstriction of pulmonary small arteries and plasma Endothelin-1 
and D-Dimer. 
Maximal vasoconstriction response of CTEPH and Control isolated pulmonary small 
arteries to KCl (100mM) and U46619 (100nM) (A). Plasma endothelin-1 (B) and plasma D-
Dimer levels (C). Whiskers denote min to max and means are presented as +. Control n=12, 
CTEPH n=6 (A); Control n=11, CTEPH n=5 (B); Control n=11, CTEPH n=6 (C). * P < 0.05 
CTEPH vs Control. 
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Pulmonary microvascular morphometry 
The increase in PAP in CTEPH resulted in pulmonary microvascular remodeling. 
The pulmonary small arteries of both 50-100 µm and 100-300 µm in lumen 
diameter showed a higher wall thickness, wall to lumen ratio and lower relative 
lumen area in CTEPH compared to Control animals (Figure 2). The remodeling of 
the pulmonary small arteries encompassed predominantly an increased 
muscularization in the tunica media. In the pulmonary microvasculature (vessel 
diameter <50 µm), remodeling was also predominantly present in the tunica 
media. The wall thickness (6.2±0.4 µm vs 5.2±0.3 µm, p=0.08) as well as the wall 
to lumen ratio (0.32±0.03 vs 0.25±0.02, p<0.06) tended to be higher in CTEPH 
compared to Control, while the relative lumen area tended to be smaller in the 
CTEPH compared to the Control microvasculature (0.63±0.02 vs 0.68±0.01, 
p=0.07) (Figure 2). 
The changes in microvascular morphology were not accompanied by an 
overt inflammatory response, as IFN-γ, TNF-α and TGF-β were unaltered and IL-6 
showed only a trend towards an increase in the CTEPH lung tissue (Figure 4 A). 
Consistent with the unaltered inflammatory state, neither CD31, VCAM-1 or 
CD144 were altered in the CTEPH swine lung tissue, indicating that vascular 
integrity was preserved (Figure 4 B).  
Pulmonary small artery vasoreactivity in vitro: endothelin pathway 
The increased muscularization of the pulmonary small arteries in CTEPH animals 
as observed histologically, was associated with an increase in pulmonary small 
artery vasoconstriction to both potassium chloride and the thromboxane 
analogue U46619 in CTEPH compared to Control vessels (Figure 3 A). The absolute 
vasoconstriction in response to ET-1 was also augmented (17.7±2.4 mN in CTEPH 
Pulmonary vascular remodeling in CTEPH swine 
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vs 12.8±1.4 mN in Control, p<0.05). However, when normalized to KCl, the 
concentration-response curve to ET-1 was shifted to the right, reflecting a 
reduced sensitivity in CTEPH compared to Control vessels. The reduced sensitivity 
inversely correlated (R2=0.49) with the elevated plasma levels of ET-1 in CTEPH 
animals. 
Figure 4. Gene expression in lung tissue. 
Gene expression measured by a quantitativepolymerase chain reaction (qPCR) of 
interleukin-6 (Il-6), interferon-γ (IFN- γ), tumor necrosis factor α (TNF-α) and transforming 
growth factor β1 (TGF-β) (A), endothelial nitric oxide synthase (eNOS), Platelet endothelial 
cell adhesion molecule (CD31), vascular cell adhesion molecule 1 (VCAM-1) and vascular 
endothelial cadherin (VE-cadherin, CD144)(B), prepro endothelin (PPET-1), endothelin 
converting enzyme (ECE-1), endothelin receptor A (ETA) and endothelin receptor B (ETB) (C), 
Ras homolog gene family, member A (RhoA), rho-associated, coiled-coil-containing protein 
kinase 1 (ROCK1), Rho associated coiled-coil containing protein kinase 2 (ROCK2) (D) in 
Control and CTEPH lung tissue. Whiskers denote min to max and means are presented as +. 
Control n=13, CTEPH n=5. * P < 0.05 CTEPH vs Control; $ P < 0.10 CTEPH vs Control. 
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Consistent with the higher plasma ET-1 levels (Figure 3 B), expression of the ETB 
receptor, which is the clearance receptor for ET-1, was reduced, while neither 
expression of PPET-1 nor that of ECE-1 in lung tissue was different in CTEPH as 
compared to Control animals (Figure 4 C), suggesting that ET-1 clearance rather 
than ET-1 production was altered in CTEPH. To investigate the contributions of the 
ETA and ETB receptors to the ET-induced vasoconstriction, concentration response 
curves to ET-1 were also performed in pulmonary small arteries in the presence of 
ETA and ETB receptor blockers alone as well as their combination. ETA blockade by 
BQ123 resulted in an attenuation of ET-1-induced vasoconstriction that appeared 
relatively more pronounced in CTEPH compared to Control vessels. In contrast, 
ETB blockade with BQ788 did not affect the vasoconstrictor response to ET-1 in 
either Control or CTEPH pulmonary small arteries. The effect of ETA blockade was 
maintained in the presence of ETB blockade (ETA/ETB vs ETB) in both CTEPH and 
Control vessels, but only in Control vessels combined ETA/ETB blockade further 
attenuated the ET-1-induced vasoconstriction compared to ETA blockade. In the 
CTEPH vessels there was no difference between ETA/ETB and ETA blockade, 
suggesting a reduced contribution of the ETB receptor and increased contribution 
of the ETA receptor to the ET-vasoconstrictor response in the CTEPH pulmonary 
small arteries (Figure 5 A-C). These observations are consistent with the lower ETB 
gene expression in CTEPH lung tissues (Figure 4 C) and higher ETA/ETB ratio 
(2.9±0.1 in CTEPH vs 1.7±0.4 in Control, p<0.05). 
To further investigate the lower ET-sensitivity in CTEPH pulmonary small 
arteries, the contribution of Rho-kinase was examined. After pre-constriction to 
U46619, CTEPH-vessels showed a reduced vasodilator response to Rho-kinase 
inhibition with Y-27632 compared to Control (Figure 5 D). 
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Consistent with the higher plasma ET-1 levels (Figure 3 B), expression of the ETB 
receptor, which is the clearance receptor for ET-1, was reduced, while neither 
expression of PPET-1 nor that of ECE-1 in lung tissue was different in CTEPH as 
compared to Control animals (Figure 4 C), suggesting that ET-1 clearance rather 
than ET-1 production was altered in CTEPH. To investigate the contributions of the 
ETA and ETB receptors to the ET-induced vasoconstriction, concentration response 
curves to ET-1 were also performed in pulmonary small arteries in the presence of 
ETA and ETB receptor blockers alone as well as their combination. ETA blockade by 
BQ123 resulted in an attenuation of ET-1-induced vasoconstriction that appeared 
relatively more pronounced in CTEPH compared to Control vessels. In contrast, 
ETB blockade with BQ788 did not affect the vasoconstrictor response to ET-1 in 
either Control or CTEPH pulmonary small arteries. The effect of ETA blockade was 
maintained in the presence of ETB blockade (ETA/ETB vs ETB) in both CTEPH and 
Control vessels, but only in Control vessels combined ETA/ETB blockade further 
attenuated the ET-1-induced vasoconstriction compared to ETA blockade. In the 
CTEPH vessels there was no difference between ETA/ETB and ETA blockade, 
suggesting a reduced contribution of the ETB receptor and increased contribution 
of the ETA receptor to the ET-vasoconstrictor response in the CTEPH pulmonary 
small arteries (Figure 5 A-C). These observations are consistent with the lower ETB 
gene expression in CTEPH lung tissues (Figure 4 C) and higher ETA/ETB ratio 
(2.9±0.1 in CTEPH vs 1.7±0.4 in Control, p<0.05). 
To further investigate the lower ET-sensitivity in CTEPH pulmonary small 
arteries, the contribution of Rho-kinase was examined. After pre-constriction to 
U46619, CTEPH-vessels showed a reduced vasodilator response to Rho-kinase 
inhibition with Y-27632 compared to Control (Figure 5 D). 
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Furthermore, pre-incubation with Y-27632 attenuated ET-1-induced 
vasoconstriction in the Control arteries while it did not affect the response in 
arteries from CTEPH animals, so that Rho-kinase inhibition abrogated the 
difference in ET-1-response between Control and CTEPH. However, Rho-kinase 
gene expression level was unaltered in CTEPH (Figure 4 D). These findings suggest 
that reduced Rho-kinase activity, but not gene expression, in CTEPH pulmonary 
small arteries underlies the decreased ET-1 vasoconstriction in CTEPH compared 
to Control (Figure 5 E&F). 
 
Figure 6. Pulmonary vasoreactivity: NO pathway. 
Effect of Bradykinin with or without eNOS-inhibition (LNAME) (A), the NO-donor sodium 
nitroprusside (SNP) (B), 8-bromo-cyclic guanosine monophosphate (8Br-cGMP) (C) and 
phosphodiesterase 5 (PDE5) inhibition (Sildenafil) (D). Control n=12, CTEPH n=5 (A); Control 
n=11, CTEPH n=6 (B); Control n=9, CTEPH n=6 (C); Control n=12, CTEPH n=6 (D). * P < 0.05 
CTEPH vs Control; § Effect blocker CTEPH vs effect blocker Control. 
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Pulmonary small artery vasoreactivity in vitro: nitric oxide pathway 
The vasodilator response to bradykinin (BK) was reduced in CTEPH as compared to 
Control pulmonary small arteries (Figure 6), consistent with endothelial 
dysfunction. Surprisingly however, eNOS gene expression was increased (Figure 4 
B), while NOS-inhibition attenuated BK-induced vasodilation to a similar extent in 
pulmonary small arteries from CTEPH and Control. The NO-donor SNP resulted in 
vasodilation that was more pronounced in CTEPH compared to Control, indicating 
that sensitivity to NO was increased. To further assess NO signaling, the responses 
to the stable cGMP analogue 8Br-cGMP and PDE5-inhibition were investigated. 
The unaltered response to 8Br-cGMP indicates that protein kinase G (PKG) 
responsiveness to cGMP was maintained. However, the response to PDE5-
inhibition was reduced, suggestive of a reduced PDE5-activity (Figure 6). 
Altogether, the reduced response to PDE5-inhibition, increased SNP-induced 
vasodilation and the maintained contribution of NO to BK-induced vasodilation, 
suggest that loss of endogenous NO production is compensated in part by a 
decreased PDE5 activity resulting in an increased NO-responsiveness. 
Discussion 
The main findings of the present study in swine with CTEPH are that (i) the 
exercise-induced increase in PAP was exaggerated while the exercise-induced 
increase in CI was reduced in CTEPH as compared to Control swine, (ii) the mild 
drop in arterial oxygen content that was already present at rest was exacerbated 
during exercise, (iii) inward microvascular remodeling with increased 
muscularization was present in the pulmonary microvessels of all sizes, (iv) the 
increased muscularization was accompanied by an increase in maximal 
vasoconstriction to KCl, ET-1 and U46619, (v) although absolute vasoconstriction 
to ET-1 was increased in CTEPH pulmonary small vessels, the sensitivity to ET-1 
Kelly Stam Dissertatie V5.indd   172 12-8-2019   09:52:07
5Chapter 5. 
172 
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Figure 6. Pulmonary vasoreactivity: NO pathway. 
Effect of Bradykinin with or without eNOS-inhibition (LNAME) (A), the NO-donor sodium 
nitroprusside (SNP) (B), 8-bromo-cyclic guanosine monophosphate (8Br-cGMP) (C) and 
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n=11, CTEPH n=6 (B); Control n=9, CTEPH n=6 (C); Control n=12, CTEPH n=6 (D). * P < 0.05 
CTEPH vs Control; § Effect blocker CTEPH vs effect blocker Control. 
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Pulmonary small artery vasoreactivity in vitro: nitric oxide pathway 
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increased muscularization was accompanied by an increase in maximal 
vasoconstriction to KCl, ET-1 and U46619, (v) although absolute vasoconstriction 
to ET-1 was increased in CTEPH pulmonary small vessels, the sensitivity to ET-1 
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was reduced with an increased contribution of the ETA receptor but decreased 
contribution of the ETB receptor and complete loss of the contribution of Rho-
kinase to ET-1 vasoconstriction, (vi) an apparant reduction in endogenous NO 
production was compensated in part by a decreased PDE5 activity resulting in an 
increased NO-sensitivity in CTEPH pulmonary small arteries. These findings will be 
discussed in detail below. 
Exercise intolerance in CTEPH 
CTEPH is characterized by exercise intolerance which is principally caused by an 
exacerbated increase in PAP and thereby in RV afterload during exercise, in 
combination with a significant V/Q-mismatch in the lungs (4, 6, 7). Our CTEPH 
swine model recapitulates these characteristics of CTEPH. Thus, PAP was 
disproportionally increased in CTEPH as compared to Control animals in response 
to exercise. The increased afterload of the right ventricle limited the exercise-
induced increase in CI. In humans with CTEPH, physiological dead space is 
increased in proportion to the increase in PVR, resulting in a lower PaO2, which is 
accompanied by a reduction in PaCO2, as a result of compensatory 
hyperventilation (38). Similarly, the slightly lower PaO2 and higher AaDO2 in 
CTEPH-swine compared to Control are consistent with a mild V/Q-mismatch and 
dead space ventilation at rest. Contrary to humans with CTEPH, PaCO2 was not 
significantly affected in our porcine CTEPH-model neither at rest, nor during 
exercise. This discrepancy in CO2 response between humans and swine is not 
readily explained, but may in part be because swine lack collateral ventilation and 
therefore are less capable of ameliorating intraregional V/Q differences between 
alveoli as compared to humans (27). Furthermore, as healthy quadrupeds already 
ventilate and perfuse a major part of their lungs at rest (40), an increase in 
ventilation with CTEPH cannot further recruit hypoventilated lung areas and 
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improve V/Q mismatch, and hence their hyperventilatory response may not be 
capable of reducing PaCO2 levels below normal as occurs in humans.  
The AaDO2 in CTEPH animals was exacerbated during exercise, which is 
partially attributable to a lower PmvO2 (31.7±0.7 mmHg in Controls and 26.2±2.2 
mmHg in CTEPH) as a consequence of the lower CI, and in part reflects a further 
worsening of the V/Q mismatch due to the faster passage of blood through the 
pulmonary capillaries upon the exercise-induced increase in CI (27).  
Maximal body oxygen consumption was reduced and arterial lactate 
concentration was increased by more than 2 mmol/L, indicating that, consistent 
with patient data (19, 23, 29, 48), the anaerobic threshold was reached in CTEPH 
but not sham-operated swine during exercise at 4km/h. Particularly the decreased 
CI (27% lower in CTEPH as compared to Control) and to a lesser extent the 
decreased CaO2 (10% lower as compared to Control), limited the increase in body 
oxygen delivery during exercise. These findings suggest that exercise intolerance 
in CTEPH is principally caused by the increased pulmonary vascular resistance, and 
thereby the afterload of the RV, that limits the exercise induced increase in CI. The 
V/Q-mismatch that hampers arterial oxygenation also contributes to exercise 
intolerance, but to a lesser extent. However, the relative contributions of cardiac 
and pulmonary dysfunction to the exercise intolerance in patients with more 
severe RV dysfunction remains to be established. Cardiopulmonary exercise 
testing in CTEPH patients will therefore yield valuable data to help determine the 
cause(s) of their exercise intolerance (37). 
Pulmonary microvascular remodeling 
CTEPH occurs in a minority of patients after acute pulmonary embolism. However, 
also patients that did not experience (or did not notice to) an acute pulmonary 
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embolism have been reported to develop CTEPH (51). In these patients, it is 
proposed that CTEPH is the consequence of multiple micro-embolisms (17, 55). 
Our swine model with repeated micro-embolization procedures is similar to the 
second group of patients. It is increasingly recognized that, not only proximal 
obstructions, but also distal remodeling of the unobstructed pulmonary 
microvasculature contributes to the pathogenesis of CTEPH (17, 42). In 
accordance with previous studies in humans and animals (5, 11, 42), we observed 
inward remodeling of both pulmonary small arteries and the pulmonary 
microvasculature. This remodeling encompassed muscularization and thickening 
of the vascular wall and resulted in a relative reduction of the vascular lumen 
(Figure 2 & Figure 8-10). The changes in microvascular morphology were not 
accompanied by an overt pulmonary inflammatory response at this stage, as only 
IL-6 showed a trend towards an increase, consistent with the increase in IL-6 in 
CTEPH patients (49, 57, 58), while IFN- γ, TNF-α and TGF-β were unaltered. 
Although the existence of pulmonary microvascular remodeling is known since 
1993 (42), the consequences of this remodeling for pulmonary microvascular 
function have not been investigated to date. The present study shows that, 
consistent with the increased vascular muscularization in CTEPH, the maximal 
contraction of these vessels was also increased. In addition, microvascular 
remodeling was accompanied by alterations in two major endothelial signaling 
pathways, i.e. ET and NO, that are also implicated in development and 
progression of pulmonary hypertension (3), as will be further discussed below.  
Endothelial dysfunction in CTEPH 
Endothelial dysfunction was characterized by an imbalance between endothelial 
production of the vasodilator NO and the vasoconstrictor ET-1 while vascular 
integrity was intact at this stage. Perturbations in the NO-pathway have been 
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implicated in the pathogenesis of PH (3, 31, 59). Indeed, we have previously 
shown that chronic eNOS-inhibition is required to successfully produce stable 
CTEPH in swine, as microsphere embolizations alone do not result in sustained PH 
(54). To preclude a direct effect of eNOS-inhibition on both the in vivo and the in 
vitro measurements, eNOS inhibition was discontinued two weeks before the end 
of study. Moreover, control animals with and without chronic eNOS-inhibition 
were included. In accordance with our previous study, which showed no effect of 
chronic eNOS-inhibition on hemodynamics in control animals (54), in the present 
study, chronic eNOS-inhibition in control animals had no effect on vasoreactivity, 
plasma ET-levels and pulmonary gene expression (Figure 7). 
In pulmonary small arteries from CTEPH the vasodilator response to BK 
was reduced as compared to Control. Surprisingly however, eNOS-inhibition 
attenuated the BK-induced vasodilation to a similar degree in CTEPH and Control, 
indicating that either NO production was maintained or a decreased NO 
production was compensated by an increased sensitivity to NO. The increased 
vasodilation in response to the NO-donor SNP in CTEPH compared to Control is 
consistent with an increased sensitivity to NO. This increased vasodilator response 
to NO is in line with vasodilation observed during treatment with inhaled NO in 
CTEPH patients (1). The response to the stable cGMP analogue 8Br-cGMP was 
similar in CTEPH compared to Control vessels, indicating that PKG responsiveness 
to cGMP was preserved in CTEPH. 
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Figure 7. Pulmonary vasoreactivity: Comparison of Control with or without LNAME. 
Effect of endothelin (ET-1) (A), Rho-kinase inhibition (Y-27632) (B), Bradykinin (C), 8-
bromo-cyclic guanosine monophosphate (8Br-cGMP) (D), phosphodiesterase 5 (PDE5) 
inhibition (Sildenafil) (E) and the NO-donor sodium nitroprusside (SNP) (F) on the 
vasoconstriction or vasodilation of pulmonary small arteries, plasma ET-1 levels (G) and 
gene expression in lung tissue (H) of Control animals with (LNAME Control) and without 
(Control) LNAME. Whiskers denote min to max and means are presented as +. Control n=8, 
LNAME Control n=3 (A); Control n=7, LNAME Control n=4 (B&F); Control n=8, LNAME 
Control n=4 (C&E); Control n=5, LNAME Control n=4 (D); Control n=6, LNAME Control n=5 
(G); Control n=9, LNAME Control n=5 (H). No significant differences were observed. 
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Finally, the response to PDE5-inhibition was reduced in the CTEPH arteries, 
suggesting that reduced PDE5-activity acted to compensate, in part, for a blunted 
endogenous NO production, resulting in an increase in NO-sensitivity. The 
reduced response to Sildenafil provides a potential explanation for the failure of 
single treatment with Sildenafil as a therapeutic strategy for CTEPH and 
underscores the importance of intervening more upstream in the NO-pathway 
either by administering NO (1) or stimulating sGC. Indeed, beneficial therapeutic 
effects have been reported for Riociguat, a sGC stimulator, which was recently 
approved for therapeutic use in CTEPH (22, 30, 33, 50).  
Endothelin receptor antagonists (ERAs) are an established therapy for PAH 
(16, 32), but conflicting results of ERA therapy have been reported in CTEPH 
patients (24, 25, 44). The 40% higher plasma ET-1 in our porcine model is slightly 
less than the doubling observed in patient studies. However, clinically, our 
animals represent New York Heart Association (NYHA) class II or III, in which the 
elevation in ET-1 is less than in patients with NYHA class IV (21, 47). Although 
plasma ET-1 levels correlate well with clinical severity (21, 47), the contribution of 
changes in ET signaling to structural and functional changes in the pulmonary 
microvasculature has not been established. The present study shows that the 
increase in circulating ET-1 is accompanied by a decreased sensitivity of the 
pulmonary microvasculature to ET-1, as evidenced by a rightward shift in the ET-1 
response in pulmonary small arteries of animals with CTEPH as compared to 
Control. The relative contribution of the ETA receptor to the ET-1-induced 
vasoconstriction was slightly enhanced in pulmonary small arteries from animals 
with CTEPH as compared to Control. Moreover, ETB receptor blockade attenuated 
the contraction to ET-1 in the presence of ETA receptor blockade but it had no 
effect in pulmonary small arteries from animals with CTEPH. These data are in 
accordance with the increased ETA receptor expression in pulmonary 
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endarterectomy tissues (53) and in the lungs of swine with CTEPH (39), as well as 
with the increased ETA/ETB ratio observed in the present study. The latter was, 
however, primarily due to a decrease in ETB mRNA, which contrasts with another 
study in a different CTEPH- swine model that shows an increased ETB mRNA 
expression in the unobstructed areas of the lungs (39). However as both ETA and 
ETB receptors have also been shown to be present on bronchial smooth muscle 
(20), a change in mRNA expression may not solely reflect a change in expression in 
the pulmonary vasculature. These data suggest that CTEPH is accompanied by 
changes in ET-1 signaling in the pulmonary microvasculature and that the 
interaction between the ETA and the ETB receptor is altered in CTEPH. The loss of 
ETB mediated vasoactive effects observed in the present study suggests that dual 
ERA therapy may not be more effective as compared to ETA blockade alone. 
Moreover, in CTEPH the effect of ET-1 is already suppressed by a decreased 
sensitivity which would explain the observed inefficacy of ERA’s. 
ET-1 signaling occurs via two pathways, i.e. a calcium-dependent pathway 
involving phospholipase C (PLC)-mediated activation of myosin-light chain kinase 
and a calcium-independent pathway involving RhoA-Rho-kinase mediated 
inactivation of myosin phosphatase (28). Rho-kinase inhibition with Fasudil has 
been shown to be an effective therapy in some patients with PAH (15), but little is 
known about this pathway in the pathology of CTEPH. In the present study, Rho-
kinase inhibition caused vasodilation of pulmonary small arteries of Control 
animals, which was blunted in CTEPH as compared to Control. Moreover, ET-1-
induced contraction was attenuated by Rho-kinase inhibition in pulmonary small 
arteries from Control but not CTEPH swine. Although a reduction in Rho-kinase 
was not present at mRNA level in the CTEPH swine, mRNA levels of lung tissue 
may not reflect protein levels and/or enzyme activity in the vasculature. The data 
obtained from the isolated pulmonary small arteries indicate a complete loss of 
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the Rho-kinase contribution to ET-1-induced vasoconstriction in the CTEPH small 
arteries, and imply that, ET-1-induced vasoconstriction in CTEPH must therefore 
be mediated through the PLC-pathway. These results are very different from 
those obtained in PAH, where the contribution of Rho-kinase was found to be 
increased (10). Together, these data suggest that microvascular constriction and 
remodeling occur via different pathways in CTEPH as compared to PAH, and could 
be interpreted to suggest that the use of Rho-kinase inhibitors to alleviate 
pulmonary vasoconstriction may be useless in CTEPH patients.  
It is however, important to note that the present study investigated the 
contribution of endothelial dysfunction to the acute regulation of vascular tone, 
and that these results may not directly apply to the role of endothelial dysfunction 
in pulmonary microvascular remodeling and long-term effects of therapy. Future 
studies are thus required to investigate the pulmonary effects of chronic Rho-
kinase inhibition in CTEPH. 
Altogether, our study shows that alterations in microvascular structure 
contribute to the increase in pulmonary vascular resistance. These changes in 
microvascular structure are accompanied by  changes in microvascular function 
that may have therapeutic consequences in that the efficacy of therapeutic agents 
that are commonly applied in PAH, may not be as effective in CTEPH. 
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and that these results may not directly apply to the role of endothelial dysfunction 
in pulmonary microvascular remodeling and long-term effects of therapy. Future 
studies are thus required to investigate the pulmonary effects of chronic Rho-
kinase inhibition in CTEPH. 
Altogether, our study shows that alterations in microvascular structure 
contribute to the increase in pulmonary vascular resistance. These changes in 
microvascular structure are accompanied by  changes in microvascular function 
that may have therapeutic consequences in that the efficacy of therapeutic agents 
that are commonly applied in PAH, may not be as effective in CTEPH. 
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Abstract 
Right ventricular (RV) function is the most important determinant of survival and 
quality of life in patients with chronic thrombo-embolic pulmonary hypertension 
(CTEPH). This study investigated whether the increased cardiac afterload is 
associated with 1) cardiac remodeling and hypertrophic signalling, 2) changes in 
angiogenic factors and capillary density and 3) inflammatory changes associated 
with oxidative stress and interstitial fibrosis. 
CTEPH was induced in eight chronically instrumented swine by chronic 
NOS inhibition and up to 5-weekly pulmonary embolizations. Nine healthy swine 
served as control. After nine weeks, RV function was assessed by single beat 
analysis of RV-pulmonary artery (PA) coupling at rest and during exercise, and by 
cardiac magnetic resonance imaging. Subsequently, the heart was excised and RV 
and LV tissues were processed for molecular and histological analyses. 
Swine with CTEPH exhibited significant RV hypertrophy in response to the 
elevated PA pressure. RV-PA coupling was significantly reduced, correlated 
inversely with pulmonary vascular resistance and did not increase during exercise 
in CTEPH swine. Expression of genes associated with hypertrophy (BNP), 
inflammation (TGFβ), oxidative stress (ROCK2, NOX1 and NOX4), apoptosis (BCL2 
and Caspase-3) and angiogenesis (VEGFA), were increased in the RV of CTEPH 
swine and correlated inversely with RV-PA coupling during exercise. In the LV, 
only significant changes in ROCK2 gene-expression occurred.  
In conclusion, RV-remodeling in our CTEPH swine model is associated with 
increased expression of genes involved in inflammation and oxidative stress, 
suggesting that these processes contribute to RV remodeling and dysfunction in 
CTEPH and hence represent potential therapeutic targets.
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Introduction 
Chronic thrombo-embolic pulmonary hypertension (CTEPH) develops in a subset 
of patients after acute pulmonary embolism (31, 45). In CTEPH, pulmonary 
vascular resistance, which is initially elevated due to the obstructions in the larger 
pulmonary arteries, is further increased by pulmonary microvascular remodeling 
(31, 45). This increased pulmonary vascular resistance augments afterload of the 
right ventricle (RV), thereby resulting in RV dilation and RV hypertrophy. RV 
structural and functional adaptability are important determinants of functional 
capacity and survival in patients with CTEPH (9, 25, 55). Thus, RV-pulmonary 
arterial uncoupling is associated with reduced exercise-capacity (9), and patients 
with RV dilation have a worse prognosis compared to patients with preserved RV 
function and geometry (2, 20). Furthermore, it has become increasingly 
recognized that RV dysfunction may also influence the left ventricle (LV), both 
mechanically, through direct mechanical interaction and changes in LV filling, by 
inducing interventricular asynchrony (35, 58) as well as through activation of 
inflammatory pathways, that may be the result of low grade systemic 
inflammation in combination with neurohumoral activation due to reduced 
cardiac output (13, 25, 39).  
In CTEPH, pulmonary obstructive lesions can be located both proximally 
and distally. Distal pulmonary lesions have recently been shown to be associated 
with worse prognosis, in part because distal pulmonary lesions are currently 
deemed inoperable, and in part because distal pulmonary emboli are associated 
with worse RV function (20). Furthermore, also in patients with chronic 
thromboembolic disease, even without overt pulmonary hypertension (PH), RV 
dysfunction has been observed (38), which is associated with an impaired exercise 
capacity (9).  
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It is currently unknown which factor(s) predispose(s) to RV failure. Unlike 
pulmonary arterial hypertension, which is usually only detected in a very 
advanced stage of the disease, CTEPH occurs mostly after acute pulmonary 
embolism, which despite the fact that this first pulmonary embolism may also go 
unnoticed (Ende-Verhaar et al, 2017), may allow earlier intervention in the 
process of RV remodeling and adaptation,. Mild RV dysfunction is characterized by 
a deterioration of RV diastolic function (i.e. relaxation), while RV contraction is still 
preserved (38). The main determinant of cardiac diastolic function is cardiac 
stiffness, which is negatively influenced by interstitial fibrosis as well as by 
changes in isoform- expression of the ‘cardiac spring protein’ titin (41). 
Furthermore, it has been proposed that the failure of angiogenesis to keep up 
with RV hypertrophy, resulting in reduced capillary densities and concommittant 
RV perfusion abnormalities, is a key determinant that discriminates between 
adaptive RV hypertrophy and RV failure (17).  
We have recently developed a swine model, in which a combination of 
endothelial dysfunction by NOS inhibition with pulmonary embolizations with 
microspheres of  ̴700 μm in diameter resulted in the development of CTEPH with 
distal pulmonary microvascular remodeling (47, 48). In CTEPH animals, the 
increased afterload was accompanied by RV hypertrophy, that resulted in 
preservation of RV function at rest, but stroke volume (SV) decreased with 
increasing exercise intensity, suggesting mild RV dysfunction (47).  
In the present study, we investigated the changes in RV and LV geometry 
and morphology in CTEPH as well as concomittant changes in gene expression 
that may contribute to these changes. Specifically, we studied whether the 
increased RV afterload is associated with 1) cardiac remodeling and hypertrophic 
Cardiac remodeling in CTEPH 
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signalling, 2) changes in angiogenic factors and capillary density and 3) 
inflammatory changes associated with oxidative stress and interstitial fibrosis. 
Methods 
Ethical approval 
Animal studies were performed following the “Guiding Principles for the Care and 
Use of Laboratory Animals” as approved by the Council of the American 
Physiological Society, and with approval of the Animal Care Committee of the 
Erasmus University Medical Center (EMC3158, 109-13-09). The authors 
understand the ethical principles under which the Journal of Physiology operates 
and hereby declare that this work complies with the animal ethics checklist 
outlined by Grundy (21). Twenty-three crossbred Landrace x Yorkshire swine of 
either sex obtained from a commercial breeder (3 months old, 22±1 kg) entered 
the study. Swine were individually housed in the animal facility of the Erasmus 
University Medical Center, fed twice a day and had free access to drinking water. 
Our experimental protocol consists of a chronic instrumentation, followed by 
induction of CTEPH in twelve animals through a combination of NOS-inhibition 
with L-Nω-Nitroarginine methyl ester (LNAME) and up to five weekly repeated 
embolizations with microspheres (see below for details). Mortality due to acute 
cardio-pulmonary failure upon CTEPH induction occurred in two animals. Two 
animals were excluded due to catheter failure (1 control, 1 CTEPH) whereas 2 
animals (1 control, 1 CTEPH) had to be euthanized following repeated infections 
due to the catheters and were not included. Only animals that completed the 
protocol are included in the N-numbers as described in the remainder of the 
manuscript. 
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manuscript. 
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Chronic instrumentation 
Animals were chronically instrumented as previously described (11, 47). In short, 
after an overnight fast, swine were sedated with an intramuscular injection (i.m.) 
of tiletamine/zolazepam (5 mg kg-1), xylazine (2.25 mg kg-1) and atropine (1 mg), 
intubated and ventilated with a mixture of O2 and N2 (1:2 v/v) to which 2% (v/v) 
isoflurane was added to maintain anesthesia. Under sterile conditions, a left 
thoracotomy in the fourth intercostal space was performed, the pericardium was 
opened and fluid-filled polyvinylchloride catheters (Braun Medical Inc., 
Bethlehem, PA, USA) were placed in the RV, pulmonary artery and aorta for blood 
pressure measurement. A flow probe (Transonic Systems Inc., Ithaca, NY, USA) 
was positioned around the ascending aorta for measurement of cardiac output 
(CO). The catheters were tunneled to the back, the chest was closed, and animals 
were allowed to recover for one week, receiving analgesia (0.015 mg kg-1 
buprenorphine i.m. and a slow-release fentanyl patch 12 μg h-1 for 48 hours) on 
the day of the surgery and daily intravenous (i.v.) antibiotic prophylaxis (25 mg kg-
1 amoxicillin) for 7 days (11).  
CTEPH induction 
Following the recovery week, CTEPH was successfully induced in eight animals (4 
male, 4 female) as described previously (47, 48). In short, on the first day, the 
animals were given the NOS-inhibitor LNAME (10 mg kg-1 i.v., Enzo Life Sciences 
International Inc, NY, USA) as a bolus infusion. On subsequent days, the dose of 
LNAME was increased by 10 mg kg-1 per day up to 30 mg kg-1 i.v., which was 
maintained until 1 week before the end of the study (36, 42). LNAME exhibits Ki 
values of 15 nM, 39 nM, and 4.4 µM for nNOS (bovine), eNOS (human), and iNOS 
(mouse) (4, 18, 19). Four days after the start of LNAME administration, 
microsphere infusions were started. Polyethylene microspheres (diameter 600-
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710 μm, density 1.13 g cm-3, 500 mg, corresponding to ∼2500 microspheres, 
Cospheric LLC, Santa Barbara, California, US) were suspended in 50 mL autologous 
blood with 2500 I.U. heparin and slowly infused into the RV while monitoring 
mean pulmonary artery pressure (mPAP). Microsphere infusions were repeated 
until the mPAP reached ~60 mmHg, or the arterial PaO2 dropped below ~40 
mmHg, as measured at rest 30 min after infusion, or when a maximum of 3 g 
(∼15000) microspheres was infused on one day based on the assumption that the 
porcine lungs contain approximately 25000 small arteries of this diameter. In the 
subsequent four weeks, hemodynamics were assessed weekly, and microsphere 
infusions were repeated when mPAP was <25 mmHg and PaO2 >70 mmHg, as 
described above. During the final 5 weeks of follow-up, no microsphere infusions 
were performed while LNAME administration was discontinued one week before 
sacrifice (47, 48).  
Seven sham-operated animals (3 male, 4 female), which did not receive 
LNAME or microspheres, and two additional healthy animals (2 female), that were 
not operated, served as controls. 
In vivo experiments 
Hemodynamic studies. Hemodynamic studies were performed ten weeks 
after surgery. With swine standing quietly on a motor-driven treadmill and during 
exercise at 4 km/h, CO, PAP, aorta pressure (AoP), and right ventricular pressure 
(RVP) were continuously recorded (11, 15). 
Digital recording and offline analysis of hemodynamic data were 
performed as described previously (15, 49). To account for differences in growth 
between animals, CO was corrected for body weight, yielding cardiac index (CI). 
Stroke volume index (SVi) was calculated as CI/heart rate. Total pulmonary 
vascular resistance index (tPVRi) and systemic vascular resistance index (SVRi) 
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were calculated as mPAP/CI and mAoP/CI respectively. RV function was measured 
by single beat analysis of RV-pulmonary artery (PA) coupling as described 
previously (3), using the median value of at least 10 consecutive beats, assuming 
that end-systolic PAP equals mPAP (3, 5). For calculation of Ees, a sine wave was 
fitted to the isovolumetric contraction and relaxation phases of RV contraction. 
The top of the sine wave has previously been shown to be a good approximation 
of Pmax, derived from isovolumetric contraction. Ees was subsequently calculated 
as (Pmax-mPAP)/SVi. Ea was calculated as mPAP/SVi. RV-PA coupling was 
assessed as the ratio of Ees and Ea (Figure 1). 
 
Figure 2. Typical example of RV-PA coupling analysis. 
Typical example of RV-PA coupling analysis showing hemodynamic signals (three beats) 
and their derivatives. Pmax was determined as the maximal value from a sine-fit of Right 
ventricular pressure (RVP), Pes was estimated to equal mean pulmonary artery pressure 
(mPAP), whereas stroke volume (SV) was calculated as the time-integral of aorta flow 
(AoF). 
Cardiovascular magnetic resonance imaging. After completion of the 
hemodynamic experiments, a cardiovascular magnetic resonance (CMR) 
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examination was performed on a 1.5T clinical scanner with a dedicated 32-
channel phased-array cardiac surface coil (Discovery MR450, GE Healthcare, 
Milwaukee, WI, US) in 5 Control (2 male, 3 female) and 6 CTEPH (4 male, 2 female) 
animals. For this purpose, animals were sedated and intubated as described 
above. During imaging, anesthesia was maintained with pentobarbital sodium (6-
12 mg kg-1 h-1 i.v.).Mechanical ventilation and breath-holds were performed using 
a mobile ventilator (Carina™, Dräger Medical, Best, The Netherlands). When 
necessary, and always in absence of pain reflexes, muscle relaxation was 
temporarily achieved using pancuronium bromide (2–4 mg i.v. bolus). The imaging 
protocol consisted of retrospectively ECG-gated balanced Steady-State Free 
Precession cine imaging with breath-holding (FIESTA, GE Medical System). 
Standard long-axis and short axis images with full LV and RV coverage were 
obtained. Typical scan parameters were slice thickness 6.0 mm, slice gap 0 mm, 
TR/TE 3.4/1.4 msec, flip angle 75°, field of view 320×240 mm, acquired matrix 
180×128, and reconstructed matrix 256×256. To assess dimensions, function and 
mass of both ventricles, LV and RV epi- and endocardial contours were drawn 
manually on end-diastolic and end-systolic short axis cine images. Volumes and 
masses were measured, and stroke volumes and ejection fractions (EF) calculated. 
All volumes were indexed for bodyweight. QMassMR analytical software (version 
8.1, Medis BV, Leiden) was used for analysis. 
Euthanasia 
After completion of the in vivo experiments, with animals intubated and under 
deep anesthesia (pentobarbital sodium, 6-12 mg kg-1 h-1 i.v.), a sternotomy was 
performed, ventricular fibrillation was induced using a 9 V battery, and the heart 
was immediately excised. To assess relative RV hypertrophy, the heart was 
sectioned into RV free wall and LV (including septum), and weighed. RV 
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hypertrophy was assessed using the Fulton index (RV/LV). Parts of the LV anterior 
wall and RV were snap frozen in liquid nitrogen within 10 minutes after excision 
for molecular analyses and fixated in formaldehyde for histological analysis.  
Histology 
LV and RV tissues were fixated in 3.5-4% buffered formaldehyde for a minimum of 
24 hours, and embedded in paraffin wax. Subsequently, 5µm sections were cut, 
and stained with 1) Gomori to assess cardiomyocyte cross-section area (CSA), 2) 
Lectin to assess capillary density, and 3) Picrosirius red (PSR) to assess collagen 
content (46). The stained sections were scanned using a Hamamatsu NDP scanner 
(Hamamatsu Nanozoomer 2.0 HT, Hamamatsu Photonics K.K., Hamamatsu City, 
Japan). Morphometric measurements of CSA and capillary density (expressed as 
number of capillaries per mm2 and per cardiomyocyte) were performed using 
Clemex Vision Professional Edition (Clemex Technologies inc. Corporate 
Headquarters, Quebec, Canada), while collagen content was analyzed using 
BioPixiQ (Gothenburg, Sweden) as previously described (46). 
Real time quantitative PCR 
Total RNA was extracted from snap frozen LV and RV tissues with the RNeasy 
Fibrous Tissue Mini Kit (Qiagen, Venlo, The Netherlands) as previously described 
(47). RNA integrity was confirmed by Bioanalyzer (2100 Bioanalyzer, Agilent, Santa 
Clara, California, USA). cDNA was synthesized from 500 ng of total RNA with 
SensiFAST cDNA Synthesis Kit (Bioline, London, UK). RT-qPCR (CFX-96, Bio-Rad, 
Hercules, California, USA) was performed with SensiFAST SYBR & Fluorescein Kit 
(Bioline, London, UK). Target genes mRNA expression levels were normalized 
against β-actin, glyceraldehyde-3-phosphate dehydrogenase (GADPH) and 
cyclophilin using the ΔΔCt method with the gene study function in CFX manager 
Cardiac remodeling in CTEPH 
205 
software (Bio-Rad, Hercules, California, USA). All primer sequences are presented 
in Table 1. 
Titin isoform composition 
Titin isoform protein composition (i.e. presence of the stiff  N2B and compliant 
N2BA isoforms) was analyzed as previously described (46). In short, snap frozen 
LV and RV tissues were weighed and pulverized in liquid nitrogen using a mortar 
and pestle. Cardiac tissue powder was solubilized in 8 mol L-1 urea buffer with 
dithiothreitol and 50% glycerol solution with protease inhibitors (4× Leupeptin, E-
64, and phenylmethanesulfonyl fluoride). Equal dilutions were calculated based 
on myosin heavy chain (MHC) content and homogenate samples were loaded on 
custom-made 1% agarose gels. Gels were stained with SYPRO Ruby. Samples were 
measured in triplicate. Only samples with ≦20% degradation were used. Titin 
isoforms N2B and N2BA were normalized to total titin amount, and the N2B/N2BA 
ratio was calculated. 
Statistical analysis 
SPSS (version 21.0 IBM, Armonk, NY, USA) was used for the statistical analysis. 
Statistical analysis was performed with a mixed-model ANOVA with exercise as a 
repeated measure and CTEPH as a between group comparison, and 
exercise*CTEPH as interaction term for the analysis of heamodynamics. ANOVA 
with CTEPH as a factor was performed for the MRI data, histology and gene-
expression. Bonferroni post-hoc testing was performed when appropriate. The 
correlation coefficient r2was calculated for the relations between two continuous 
variables. Statistical significance was accepted when P<0.05. Data are presented 
in box and whisker plots with the whiskers reflecting min to max and median 
presented as line. 
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Results 
Cardiac hypertrophy and function 
CTEPH resulted in an increased RV afterload, as evidenced by an increase in 
mPAP, tPVRi and Ea (Figure 2). This sustained increase in afterload resulted an 
increase in RV-BNP expression (Table 3), suggestive of increased RV wall stress. 
Indeed, trends towards RV dilation (P=0.15) and decreased EF (P=0.08) as 
measured with CMR were observed (Figure 3). However, end-systolic elastance 
(Ees), an index of RV contractility, was higher in CTEPH while RV dP/dtmax and RV 
dP/dtmin were unchanged (Figure 2). Although RV-PA coupling was reduced, CI was 
maintained in CTEPH (Figure 2). Furthermore, neither heart rate, mAoP (Table 2), 
LV volume, LVEF (Figure 3) nor LV-BNP expression (Table 3) were altered. 
Exercise resulted in increases in mPAP and Ea that were larger in CTEPH as 
compared to Control while the exercise induced increase in CI was blunted. 
Moreover, although Ees increased in both CTEPH and Control animals, Ees was no 
longer different between groups. Hence, RV-PA coupling, which increased with 
exercise in the Control swine did not change significantly during exercise in CTEPH 
animals (Figure 2). In fact, RV-PA coupling worsened with exercise in 4 out of 6 
CTEPH animals, and correlated inversely with tPVRi (Figure 4). Moreover, the 
CTEPH animal with the worst RV function was uncapable of performing exercise at 
4 km/h due to RV failure, evidenced by a significant reduction in mAoP during 
exercise (animal not included in figure). Altogether, these data are consistent with 
RV dysfunction that is still compensated at rest but that is excacerbated during 
exercise. 
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Figure 3. Hemodynamics at rest and during exercise after 9 weeks of CTEPH. 
Shown are data obtained at rest and during maximal exercise at 4 km h-1 in Control swine 
(n=7) and CTEPH swine (n=7). A) Mean pulmonary artery pressure (mPAP), B) Cardiac index 
(CI), C) total pulmonary vascular resistance index (tPVRi), D) Arterial elastance (Ea), E) End-
systolic elastance (Ees), F) RV-PA coupling (Ees/Ea), G) maximum rate of fall of RV pressure 
(RV dP/dtmin), H) maximum rate of rise of RV pressure (RV dP/dtmax), I) Stroke work at 
rest and during exercise. Whiskers denote min to max and median is presented by the line. 
* P < 0.05, (*) P <0.1 CTEPH vs corresponding Control; † P< 0.05, (†) P<0.1 Exercise vs 
corresponding rest; ‡ P<0.05, (‡) P < 0.1 Exercise*CTEPH, i.e. effect of exercise on variable 
is different in CTEPH from Control.  
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Table 2. Systemic hemodynamics at rest and during exercise. 
  
Control 
 
CTEPH 
 BW Instrumentation 20 ± 1 
 
23 ± 1 
 
 
End of Study 61 ± 2 
 
62 ± 3 
          HR Rest 136 ± 21 
 
131 ± 4 
  Exercise 235 ± 15 † 211 ± 8 †‡ 
          Svi Rest 1.28 ± 0.09 
 
1.17 ± 0.17 
  Exercise 1.07 ± 0.09 † 0.99 ± 0.13 
           mAoP Rest 91 ± 4 
 
100 ± 4 
  Exercise 96 ± 4 (†) 116 ± 4 *†(‡) 
          SVRi Rest 561 ± 24 
 
839 ± 205 
  Exercise 384 ± 25 † 752 ± 252 
 Bodyweight (BW) and systemic hemodynamic data at rest and during exercise. Heart 
rate (HR); stroke volume index (SVi); mean aorta pressure (mAoP); systemic vascular 
resistance index (SVRi). Data are mean ± SEM. Control N=7, CTEPH N=7. * P < 0.05 
CTEPH vs corresponding Control; † P< 0.05, (†) P<0.1 Exercise vs corresponding rest; ‡ 
P<0.05, (‡) P < 0.1 Exercise*CTEPH i.e. effect of exercise on variable is different in CTEPH 
from Control. 
As previously reported (47), the increased RV afterload resulted in RV 
hypertrophy, as evidenced by an increased RV/BW and Fulton index (Figure 5), 
as well as an increased RV cardiomyocyte CSA in CTEPH (Figure 6). RV 
cardiomyocte CSA of CTEPH animals resembled those of LV cardiomyocytes. LV 
cardiomyocytes were similar in size in LV of CTEPH as compared to Control 
animals (Figure 6), consistent with the maintained LVW/BW in CTEPH compared 
to Control swine (Figure 5). Expression of SERCA2a, its inhibitor phospholamban 
(PLN), and their ratio did not change in the RV (Table 3). However, there was a 
shift in RV titin isoform expression from the stiff N2B, to the more compliant 
N2BA isoform (Figure 6). The pro-apoptotic gene Caspase-3 was upregulated in 
the RV, while the anti-apoptotic gene BCL2 was also upregulated in the RV of 
CTEPH animals (Table 3). Expression of BCL2 correlated modestly and inversely 
with RV-PA coupling during exercise (Figure 7), but not with resting RV-PA 
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coupling (r2= 0.08, not shown). In the LV, none of the genes involved in cardiac 
hypertrophy and apoptosis were significantly affected in the CTEPH animals. 
 
Figure 3. 
Right (RV) and left (LV) ventricular dimensions and function measured by cardiovascular 
magnetic resonance (CMR) imaging. A) end-diastolic volume index (EDVi), B) end-systolic 
volume index (ESVi), C) stroke volume index (SVi), and D) ejection fraction (EF). Whiskers 
denote min to max and median is presented by the line. Control N=5, CTEPH N=6. (*) P < 
0.1 CTEPH vs Control. 
Angiogenesis  
We observed an increase in capillary density in the RV of swine with CTEPH as 
compared to Control (Figure 6), that correlated with the increased stroke work 
(Figure 6) and was consistent with the trend towards the increased VEGFA 
expression (Table 3). Moreover, VEGFA expression correlated inversely with RV-
PA coupling during exercise (Figure 7) but not with resting RV-PA coupling 
(r2=0.34, not shown). In contrast, no changes in capillary density or VEGFA 
expression were observed in the LV. 
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volume index (ESVi), C) stroke volume index (SVi), and D) ejection fraction (EF). Whiskers 
denote min to max and median is presented by the line. Control N=5, CTEPH N=6. (*) P < 
0.1 CTEPH vs Control. 
Angiogenesis  
We observed an increase in capillary density in the RV of swine with CTEPH as 
compared to Control (Figure 6), that correlated with the increased stroke work 
(Figure 6) and was consistent with the trend towards the increased VEGFA 
expression (Table 3). Moreover, VEGFA expression correlated inversely with RV-
PA coupling during exercise (Figure 7) but not with resting RV-PA coupling 
(r2=0.34, not shown). In contrast, no changes in capillary density or VEGFA 
expression were observed in the LV. 
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Figure 4.  
Correlation between total pulmonary vascular resistance (tPVRi) and RV-PA coupling 
during maximal exercise at 4 km h-1 in Control swine (n=7) and CTEPH swine (n=6). P-value 
denotes significance of slope from zero. 
Figure 5.  
Cardiac hypertrophy. A) The Fulton index calculated as the ratio of Right ventricular weight 
(RVW) and left ventricular weight (LVW) and B) RVW over bodyweight (BW) were 
increased at sacrifice in CTEPH swine while C) LVW over BW was similar in CTEPH and 
Control swine. Whiskers denote min to max and median is presented by the line. Control 
N=9, CTEPH N=8. * P < 0.05 CTEPH vs Control. 
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Figure 6.  
Histological analyses in Control and CTEPH animals of both the left ventricle (LV) and right 
ventricle (RV). A) Capillary density per mm2 (lectin staining), B) capillary-fibre ratio, C) 
correlation between stroke work during maximal exercise at 4 km h-1 and RV capillary-fibre 
ratio, D) Interstitial fibrosis (picrosirius red (PSR) staining), E) cardiomyocyte size, F) 
cardiomyocyte size normalized for bodyweight (Gomori staining, cross sectional area 
(CSA)).Myofilament composition in terms of the two different titin isoforms G) N2BA 
(N2BA/Titin) and H) N2B (N2B/Titin) and I) their ratio. Whiskers denote min to max and 
median is presented by the line. Control N=8, CTEPH N=6. * P < 0.05 CTEPH vs Control (*)P < 
0.1 CTEPH vs Control. 
Inflammation, oxidative stress, and interstitial fibrosis 
Although expression of the immune-modulatory genes TNF-α, IL-6, IFN-γ was not 
altered in the RV, TGF-β1 gene expression tended to be higher in the RV of CTEPH  
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swine, while BMPRII was not altered (Table 3). Consistent with a perturbation in 
the TGF-β – BMP balance, PAI also tended to be increased, while Id-1 did not 
change (Table 3). This shift in the TGF-β – BMP balance was accompanied by 
increased expression of ROCK2, NOX-1 and NOX-4 in the RV (Table 3), indicative of 
an increase in oxidative stress. Expression of ROCK2, NOX-1 and NOX-4 correlated 
inversely with RV-PA coupling during exercise (Figure 7), but not with resting RV-
PA coupling (r2= 0.29, 0.01 and 0.16 for ROCK2, NOX1 and NOX4, respectively). 
Figure 7.  
Correlation of the RV-PA coupling during exercise with expression of A) vascular 
endothelial growth factor A (VEGFA) , B) NADPH oxidase 1 (NOX1), C) NADPH oxidase 4 
(NOX4), D) Rho-associated protein kinase 2 (ROCK2), E) B-cell lymphoma 2 (BCL2), F) ratio 
of tissue inhibitor of metalloproteinases 2 (TIMP2) over matrix metalloproteinase-2 
(MMP2) in the RV. Control N=7, CTEPH N=4. P-value denotes significance of slope from 
zero. 
These changes in gene expression of pro-inflammatory genes and genes 
promoting oxidative stress did not result in overt changes in interstitial fibrosis, as 
collagen content was similar in the RV of CTEPH versus Control swine (Figure 6). 
Yet, although no change in interstitial fibrosis was observed, there was a trend 
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towards a shift in expression of Col3 to the stiffer Col1 isoform, that was 
accompanied by an increase in the ratio of TIMP2/MMP2 (Table 3) that correlated 
inversely with RV-PA coupling (Figure 7), suggesting reduced ECM turnover in the 
diseased RV. 
With the exception of an increase in ROCK2 and a trend towards an 
increase in NOX2 expression, no changes in genes involved in inflammation, 
oxidative stress and fibrosis were observed in the LV (Table 3), which is consistent 
with the absence of changes in LV myocardial interstitial collagen content. 
Discussion 
The present study investigated functional, histological and molecular 
changes in the RV and LV in swine with CTEPH. The main findings were that CTEPH 
resulted in 1) RV hypertrophy, both at the global and the myocyte level, 2) mild 
RV dysfunction as evidenced by decreased RV-PA coupling and elevated BNP 
expression, with trends towards an increased RV EDVi and a lower EF, 3) further 
decrease in RV-PA coupling during exercise that correlated with an increase in 
ROCK2, NOX1, NOX4 expression, 4) increased VEGFA expression that was 
accompanied by an increased capillary density in the RV. Finally, CTEPH did not 
result in changes in LV structure or function, and was associated with minor 
changes in LV gene expression in our swine model. 
Animal model 
CTEPH was induced in juvenile swine by first inducing endothelial 
dysfunction through chronic NOS-inhibition, followed by up to 5 repeated 
embolizations with microspheres. We previously showed that this combination 
was required as neither NOS-inhibition nor embolization alone were sufficient to 
induce chronically elevated pulmonary artery pressures, while the combination of 
Kelly Stam Dissertatie V5.indd   216 12-8-2019   09:52:17
6Chapter 6. 
216 
swine, while BMPRII was not altered (Table 3). Consistent with a perturbation in 
the TGF-β – BMP balance, PAI also tended to be increased, while Id-1 did not 
change (Table 3). This shift in the TGF-β – BMP balance was accompanied by 
increased expression of ROCK2, NOX-1 and NOX-4 in the RV (Table 3), indicative of 
an increase in oxidative stress. Expression of ROCK2, NOX-1 and NOX-4 correlated 
inversely with RV-PA coupling during exercise (Figure 7), but not with resting RV-
PA coupling (r2= 0.29, 0.01 and 0.16 for ROCK2, NOX1 and NOX4, respectively). 
Figure 7.  
Correlation of the RV-PA coupling during exercise with expression of A) vascular 
endothelial growth factor A (VEGFA) , B) NADPH oxidase 1 (NOX1), C) NADPH oxidase 4 
(NOX4), D) Rho-associated protein kinase 2 (ROCK2), E) B-cell lymphoma 2 (BCL2), F) ratio 
of tissue inhibitor of metalloproteinases 2 (TIMP2) over matrix metalloproteinase-2 
(MMP2) in the RV. Control N=7, CTEPH N=4. P-value denotes significance of slope from 
zero. 
These changes in gene expression of pro-inflammatory genes and genes 
promoting oxidative stress did not result in overt changes in interstitial fibrosis, as 
collagen content was similar in the RV of CTEPH versus Control swine (Figure 6). 
Yet, although no change in interstitial fibrosis was observed, there was a trend 
Cardiac remodeling in CTEPH 
217 
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inversely with RV-PA coupling (Figure 7), suggesting reduced ECM turnover in the 
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With the exception of an increase in ROCK2 and a trend towards an 
increase in NOX2 expression, no changes in genes involved in inflammation, 
oxidative stress and fibrosis were observed in the LV (Table 3), which is consistent 
with the absence of changes in LV myocardial interstitial collagen content. 
Discussion 
The present study investigated functional, histological and molecular 
changes in the RV and LV in swine with CTEPH. The main findings were that CTEPH 
resulted in 1) RV hypertrophy, both at the global and the myocyte level, 2) mild 
RV dysfunction as evidenced by decreased RV-PA coupling and elevated BNP 
expression, with trends towards an increased RV EDVi and a lower EF, 3) further 
decrease in RV-PA coupling during exercise that correlated with an increase in 
ROCK2, NOX1, NOX4 expression, 4) increased VEGFA expression that was 
accompanied by an increased capillary density in the RV. Finally, CTEPH did not 
result in changes in LV structure or function, and was associated with minor 
changes in LV gene expression in our swine model. 
Animal model 
CTEPH was induced in juvenile swine by first inducing endothelial 
dysfunction through chronic NOS-inhibition, followed by up to 5 repeated 
embolizations with microspheres. We previously showed that this combination 
was required as neither NOS-inhibition nor embolization alone were sufficient to 
induce chronically elevated pulmonary artery pressures, while the combination of 
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NOS-inhibition and embolization resulted in a progressive increase in tPVRi that 
continued to increase after the last embolization and was accompanied by 
pulmonary microvascular remodeling (47, 48). The required induction of 
endothelial dysfunction may be the result of the younger age of our animals, as 
endothelial NO-production decreases with age (32, 40). Also in humans, 
endothelial dysfunction is often present both in patients with acute pulmonary 
embolism as well as with CTEPH and correlates with disease severity (8, 29, 43). In 
humans, CTEPH prevalence is higher in females (30), but male patients typically 
have a worse prognosis (7). In the present study, male and female swine were 
used as we have previously shown that there are subtle differences in regulation 
of pulmonary vascular tone (10, 12), and hence it is possible that sex also affects 
development of CTEPH and subsequent RV remodeling in our animals. 
Unfortunately, the small group size precludes statistical assessment of the effect 
of sex. However, in supplemental figure 1-4 individual data are shown and 
different symbols are used for male and female swine. 
RV-function and remodeling 
RV afterload increases during development and progression of pulmonary 
hypertension. To cope with the increased afterload, the RV undergoes structural 
and functional changes to augment contractility, and there is evidence that this 
RV structural and functional adaptability are important determinants of functional 
capacity and survival in patients with CTEPH (9, 25, 55). The effects of CTEPH on 
cardiac structure, function and gene expression were therefore examined in our 
porcine model. CTEPH resulted in an increase in RV cardiomyocyte size and global 
RV hypertrophy, that was accompanied by activation of both pro- and anti-
apoptotic gene expression (increases in Caspase-3 and BCL2 respectively). 
Although these data suggest that apoptosis is likely altered in the remodeled RV, 
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apoptosis is determined by enzyme activity rather than expression. Future 
experiments examining activity of enzymes involved in apoptosis and TUNEL 
staining should be performed to elucidate whether the increased mRNA 
expression is indeed translated to alterations in apoptosis.  
Consistent with our previous study in which RV dimensions were assessed 
using echocardiography in awake swine (47), CTEPH resulted in trends towards RV 
dilation and a reduced RVEF. In the present study, RV resting function was still 
preserved, as evidenced by a maintained CI, but BNP expression was increased, 
suggestive of an increased wall stress (52). These findings are consistent with 
observations in another porcine CTEPH model, in which CTEPH is induced by 
ligation of the left pulmonary artery, in combination with embolization of the 
proximal segmental arteries with glue (22-24). In that model, RV dilation (24) and 
RV myocyte hypertrophy (22) were also accompanied by an increased BNP 
expression (22, 24), that correlated inversely with stroke volume and positively 
with global RV hypertrophy (22). Furthermore, RV-PA coupling, an index of how 
well the RV can cope with the increased afterload, was reduced in that study and 
a correlation was found between reduced coupling and a reduced SV reserve with 
dobutamine (24). Similarly, in the present study, severity of CTEPH reflected in the 
tPVRi, correlated inversely with RV-PA coupling during exercise. Importantly, 
recent studies in patients with CTEPH show that RV-PA coupling correlates with 
exercise capacity (9), which in turn is a strong prognosticator (2).  
It is increasingly recognized that not only RV systolic function, but also RV 
diastolic function correlates with prognosis in patients with pulmonary arterial 
hypertension (PAH) (53). Indeed, in pigs with type II PH, abnormalities in RV-PA 
coupling were accompanied by diastolic dysfunction (1). Diastolic RV chamber 
stiffness is determined by myocyte stiffness as well as interstitial collagen. In a rat 
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model of pulmonary artery banding, mild RV dysfunction was accompanied by an 
increase in myocyte stiffness, whereas interstitial fibrosis was only observed in the 
presence of severe RV dysfunction (41). In these rats, the increased myocyte 
stiffness was accompanied by a paradoxical increase in the more compliant titin 
N2BA isoform, possibly to blunt a further increase in myocyte stiffness. Consistent 
with these findings the mild RV dysfunction in our swine with CTEPH was 
accompanied by an increase in titin N2BA, while no changes in myocardial 
collagen content were observed histologically. Furthermore, no changes in Col1 
and Col3 expression were observed, although there was a change in the ratio 
between Col1 and Col3 indicating a relatively higher expression of the stiff Col1 
isoform. These data are also consistent with the isoform shift observed by Rain et 
al (41), and may have contributed to a stiffer RV.  
The transition from RV dysfunction to overt RV failure is associated with 
inflammation and activation of the immune response (14, 16, 50). Although 
expression of genes involved in immune modulation (TNF-α, IL-6, IFN-γ) was not 
altered, expression of TGF-β1 tended to be increased. Activation of the TGF-β 
pathway was further confirmed by the increase in expression of its downstream 
target PAI-1. Both activation of the TGF-β pathway and increased circulating levels 
of endothelin, as we previously showed to be present in our porcine CTEPH model 
(48), can result in activation of the Rho-kinase pathway (44, 54, 59). Indeed, 
ROCK2 expression was upregulated in CTEPH swine and showed a strong inverse 
correlation with RV-PA coupling. ROCK2 activation is involved in cardiac 
hypertrophy and oxidative stress, and plays a deleterious role in RV-remodeling 
(28, 51). ROCK2 phosphorylates protein phosphatase 1 (PP1), which regulates 
both myofilament sensitivity to Ca2+ as well as Ca2+-handling (26). Hence, although 
neither SERCA2a nor phospholamban gene expression were changed in the 
present study, it is possible that post-translational modifications in their 
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phosphorylation status contributed to altered Ca2+ handling. Indeed, it has been 
suggested that changes in Ca2+-handling may play a role in the development of RV 
dysfunction as diastolic dysfunction in swine with type II PH was associated with 
reduced SERCA2a-expression (1). Future studies in our CTEPH model are required 
to further investigate the post-translational modifications in contractile and Ca2+-
handling proteins. 
Another key factor that distinguishes adaptive RV remodeling from RV 
failure is myocardial angiogenesis (17). Angiogenesis allows RV perfusion to be 
enhanced commensurate with the increase in RV mass. Indeed, many studies 
have shown that RV failure is accompanied by a reduction in capillary density, 
whereas capillary density is preserved or even increased in adaptive RV 
remodeling (for an overview of angiogenesis in the RV in a variety of animal 
models with PH see (17)). Although chronic administration of LNAME could 
significantly reduce myocardial angiogenesis (37) and limit myocardial perfusion, 
capillary density was actually increased in the RV of CTEPH swine and correlated 
with stroke work during exercise. These data are in accordance with recent data in 
another porcine CTEPH model (33), and suggests a state of adaptive RV 
remodeling with sufficient myocardial perfusion and oxygenation under resting 
conditions. Nevertheless, VEGFA-expression was higher in swine with CTEPH 
(Loisel et al., 2019, present study) and correlated with RV-PA coupling during 
exercise, suggesting that, even though expression of HIF-1α and HIF-2α was 
unchanged, there was still a need for additional perfusion during stress. Indeed, 
myocardial perfusion reserve has been shown to be reduced in humans with 
CTEPH and PAH (56, 57). Furthermore, myocardial perfusion reserve correlated 
inversely with mPAP and RV work in these studies, suggesting that flow reserve is 
recruited as a result of the increased work (57) and maximal flow may be limited 
due to increased extravascular compression (56).  
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ROCK2 is not only expressed in the myocardium but also in the 
vasculature, where its expression correlates with oxidative stress and NOX-
expression (6). NOX1, NOX2 and NOX4 were upregulated in the right coronary 
artery of swine with pulmonary artery banding, which was accompanied by 
oxidative stress and endothelial dysfunction, despite maintained eNOS expression 
(34). The upregulation of NOX1 and NOX4, and the unaltered eNOS expression in 
the RV of CTEPH swine, as observed in the present study, are consistent with 
these data, although we did not determine the exact intramyocardial location of 
their expression. Furthermore, the upregulation of NOX4 is also consistent with 
recent data from patients with PAH, in which circulating NOX4 was increased (27). 
Finally, the correlation of NOX1 and NOX4 with RV-PA coupling suggest that 
oxidative stress in the myocardium may contribute to worsening of RV-function.  
Conclusion and clinical implications 
In swine with CTEPH, the increased afterload resulted in RV hypertrophy, that 
contributed to a maintained resting RV function, although a trend towards RV 
dilation and reduced RVEF was observed with CMR. Consistent with data obtained 
in CTEPH-patients without overt RV failure (25), neither LV function nor LV gene 
expression (perhaps with exception of ROCK2, NOX2 and BCL2) were altered. 
CTEPH is different from PAH in that patients often experience an acute 
thrombo-embolic event prior to development of the disease. This form of PH 
therefore has the potential for follow-up and earlier therapeutic interventions. 
Exercise unmasked mild RV dysfunction as evidenced by reduced RV-PA coupling, 
which may facilitate early diagnosis of patients at risk for developing persistent RV 
failure. The present study shows that this mild RV dysfunction correlates with 
changes in expression of genes involved in oxidative stress, apoptosis and 
angiogenesis. These changes in gene expression suggest activation of an 
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inflammatory response in the RV, promoting oxidative stress. Given that ROCK2 
shows a strong correlation with RV dysfunction and has been shown to play a 
detrimental role in inflammation, oxidative stress, interstitial fibrosis, cardiac 
hypertrophy and impaired myocardial perfusion, ROCK2 inhibition may provide a 
viable target for early therapeutic intervention. 
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therefore has the potential for follow-up and earlier therapeutic interventions. 
Exercise unmasked mild RV dysfunction as evidenced by reduced RV-PA coupling, 
which may facilitate early diagnosis of patients at risk for developing persistent RV 
failure. The present study shows that this mild RV dysfunction correlates with 
changes in expression of genes involved in oxidative stress, apoptosis and 
angiogenesis. These changes in gene expression suggest activation of an 
Cardiac remodeling in CTEPH 
223 
inflammatory response in the RV, promoting oxidative stress. Given that ROCK2 
shows a strong correlation with RV dysfunction and has been shown to play a 
detrimental role in inflammation, oxidative stress, interstitial fibrosis, cardiac 
hypertrophy and impaired myocardial perfusion, ROCK2 inhibition may provide a 
viable target for early therapeutic intervention. 
Acknowledgements 
The authors would like to acknowledge the expert technical assistance of 
Piotr Wielopolski, Esther van de Kamp, Annemarie Verzijl and Ruud Zaremba. We 
would like to thank Dylan van der Vusse, Brechje de Rapper and Paula Krul for 
their assistance. 
 
Kelly Stam Dissertatie V5.indd   223 12-8-2019   09:52:18
Chapter 6. 
224 
References 
1. Aguero J, Ishikawa K, Hadri L, Santos-Gallego C, Fish K, Hammoudi N, 
Chaanine A, Torquato S, Naim C, Ibanez B, Pereda D, Garcia-Alvarez A, Fuster V, 
Sengupta PP, Leopold JA, and Hajjar RJ. Characterization of right ventricular 
remodeling and failure in a chronic pulmonary hypertension model. Am J Physiol 
Heart Circ Physiol 307: H1204-1215, 2014. 
2. Blumberg FC, Arzt M, Lange T, Schroll S, Pfeifer M, and Wensel R. Impact 
of right ventricular reserve on exercise capacity and survival in patients with 
pulmonary hypertension. Eur J Heart Fail 15: 771-775, 2013. 
3. Brimioulle S, Wauthy P, Ewalenko P, Rondelet B, Vermeulen F, Kerbaul F, 
and Naeije R. Single-beat estimation of right ventricular end-systolic pressure-
volume relationship. Am J Physiol Heart Circ Physiol 284: H1625-1630, 2003. 
4. Buckner CK, Saban R, Castleman WL, and Will JA. Analysis of leukotriene 
receptor antagonists on isolated human intralobar airways. Ann N Y Acad Sci 524: 
181-186, 1988. 
5. Chemla D, Hebert JL, Coirault C, Salmeron S, Zamani K, and Lecarpentier Y. 
Matching dicrotic notch and mean pulmonary artery pressures: implications for 
effective arterial elastance. Am J Physiol 271: H1287-1295, 1996. 
6. Chen IC, Tan MS, Wu BN, Chai CY, Yeh JL, Chou SH, Chen IJ, and Dai ZK. 
Statins ameliorate pulmonary hypertension secondary to left ventricular 
dysfunction through the Rho-kinase pathway and NADPH oxidase. Pediatr 
Pulmonol 52: 443-457, 2017. 
7. Chen TX, Pudasaini B, Guo J, Gong SG, Jiang R, Wang L, Zhao QH, Wu WH, 
Yuan P, and Liu JM. Sex-specific cardiopulmonary exercise testing indices to 
estimate the severity of inoperable chronic thromboembolic pulmonary 
hypertension. Int J Chron Obstruct Pulmon Dis 13: 385-397, 2018. 
8. Chibana H, Tahara N, Itaya N, Ishimatsu T, Sasaki M, Sasaki M, Nakayoshi 
T, Ohtsuka M, Yokoyama S, Sasaki KI, Ueno T, and Fukumoto Y. Pulmonary artery 
dysfunction in chronic thromboembolic pulmonary hypertension. Int J Cardiol 
Heart Vasc 17: 30-32, 2017. 
9. Claeys M, Claessen G, La Gerche A, Petit T, Belge C, Meyns B, Bogaert J, 
Willems R, Claus P, and Delcroix M. Impaired Cardiac Reserve and Abnormal 
Vascular Load Limit Exercise Capacity in Chronic Thromboembolic Disease. JACC 
Cardiovasc Imaging 2018. 
Cardiac remodeling in CTEPH 
225 
10. de Beer VJ, de Graaff HJ, Hoekstra M, Duncker DJ, and Merkus D. 
Integrated control of pulmonary vascular tone by endothelin and angiotensin II in 
exercising swine depends on gender. Am J Physiol Heart Circ Physiol 298: H1976-
1985, 2010. 
11. De Wijs-Meijler DP, Stam K, van Duin RW, Verzijl A, Reiss IK, Duncker DJ, 
and Merkus D. Surgical Placement of Catheters for Long-term Cardiovascular 
Exercise Testing in Swine. J Vis Exp e53772, 2016. 
12. de Wijs-Meijler DPM, Danser AHJ, Reiss IKM, Duncker DJ, and Merkus D. 
Sex differences in pulmonary vascular control: focus on the nitric oxide pathway. 
Physiol Rep 5: 2017. 
13. Dell'Italia LJ. The forgotten left ventricle in right ventricular pressure 
overload. J Am Coll Cardiol 57: 929-930, 2011. 
14. Dewachter L, and Dewachter C. Inflammation in Right Ventricular Failure: 
Does It Matter? Front Physiol 9: 1056, 2018. 
15. Duncker DJ, Stubenitsky R, and Verdouw PD. Role of adenosine in the 
regulation of coronary blood flow in swine at rest and during treadmill exercise. 
Am J Physiol 275: H1663-1672, 1998. 
16. Frangogiannis NG. Fibroblasts and the extracellular matrix in right 
ventricular disease. Cardiovasc Res 113: 1453-1464, 2017. 
17. Frump AL, Bonnet S, de Jesus Perez VA, and Lahm T. Emerging role of 
angiogenesis in adaptive and maladaptive right ventricular remodeling in 
pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 314: L443-L460, 2018. 
18. Furfine ES, Harmon MF, Paith JE, and Garvey EP. Selective inhibition of 
constitutive nitric oxide synthase by L-NG-nitroarginine. Biochemistry 32: 8512-
8517, 1993. 
19. Garvey EP, Tuttle JV, Covington K, Merrill BM, Wood ER, Baylis SA, and 
Charles IG. Purification and characterization of the constitutive nitric oxide 
synthase from human placenta. Arch Biochem Biophys 311: 235-241, 1994. 
20. Grosse A, Grosse C, and Lang I. Evaluation of the CT imaging findings in 
patients newly diagnosed with chronic thromboembolic pulmonary hypertension. 
PLoS One 13: e0201468, 2018. 
21. Grundy D. Principles and standards for reporting animal experiments in 
The Journal of Physiology and Experimental Physiology. J Physiol 593: 2547-2549, 
2015. 
Kelly Stam Dissertatie V5.indd   224 12-8-2019   09:52:19
6Chapter 6. 
224 
References 
1. Aguero J, Ishikawa K, Hadri L, Santos-Gallego C, Fish K, Hammoudi N, 
Chaanine A, Torquato S, Naim C, Ibanez B, Pereda D, Garcia-Alvarez A, Fuster V, 
Sengupta PP, Leopold JA, and Hajjar RJ. Characterization of right ventricular 
remodeling and failure in a chronic pulmonary hypertension model. Am J Physiol 
Heart Circ Physiol 307: H1204-1215, 2014. 
2. Blumberg FC, Arzt M, Lange T, Schroll S, Pfeifer M, and Wensel R. Impact 
of right ventricular reserve on exercise capacity and survival in patients with 
pulmonary hypertension. Eur J Heart Fail 15: 771-775, 2013. 
3. Brimioulle S, Wauthy P, Ewalenko P, Rondelet B, Vermeulen F, Kerbaul F, 
and Naeije R. Single-beat estimation of right ventricular end-systolic pressure-
volume relationship. Am J Physiol Heart Circ Physiol 284: H1625-1630, 2003. 
4. Buckner CK, Saban R, Castleman WL, and Will JA. Analysis of leukotriene 
receptor antagonists on isolated human intralobar airways. Ann N Y Acad Sci 524: 
181-186, 1988. 
5. Chemla D, Hebert JL, Coirault C, Salmeron S, Zamani K, and Lecarpentier Y. 
Matching dicrotic notch and mean pulmonary artery pressures: implications for 
effective arterial elastance. Am J Physiol 271: H1287-1295, 1996. 
6. Chen IC, Tan MS, Wu BN, Chai CY, Yeh JL, Chou SH, Chen IJ, and Dai ZK. 
Statins ameliorate pulmonary hypertension secondary to left ventricular 
dysfunction through the Rho-kinase pathway and NADPH oxidase. Pediatr 
Pulmonol 52: 443-457, 2017. 
7. Chen TX, Pudasaini B, Guo J, Gong SG, Jiang R, Wang L, Zhao QH, Wu WH, 
Yuan P, and Liu JM. Sex-specific cardiopulmonary exercise testing indices to 
estimate the severity of inoperable chronic thromboembolic pulmonary 
hypertension. Int J Chron Obstruct Pulmon Dis 13: 385-397, 2018. 
8. Chibana H, Tahara N, Itaya N, Ishimatsu T, Sasaki M, Sasaki M, Nakayoshi 
T, Ohtsuka M, Yokoyama S, Sasaki KI, Ueno T, and Fukumoto Y. Pulmonary artery 
dysfunction in chronic thromboembolic pulmonary hypertension. Int J Cardiol 
Heart Vasc 17: 30-32, 2017. 
9. Claeys M, Claessen G, La Gerche A, Petit T, Belge C, Meyns B, Bogaert J, 
Willems R, Claus P, and Delcroix M. Impaired Cardiac Reserve and Abnormal 
Vascular Load Limit Exercise Capacity in Chronic Thromboembolic Disease. JACC 
Cardiovasc Imaging 2018. 
Cardiac remodeling in CTEPH 
225 
10. de Beer VJ, de Graaff HJ, Hoekstra M, Duncker DJ, and Merkus D. 
Integrated control of pulmonary vascular tone by endothelin and angiotensin II in 
exercising swine depends on gender. Am J Physiol Heart Circ Physiol 298: H1976-
1985, 2010. 
11. De Wijs-Meijler DP, Stam K, van Duin RW, Verzijl A, Reiss IK, Duncker DJ, 
and Merkus D. Surgical Placement of Catheters for Long-term Cardiovascular 
Exercise Testing in Swine. J Vis Exp e53772, 2016. 
12. de Wijs-Meijler DPM, Danser AHJ, Reiss IKM, Duncker DJ, and Merkus D. 
Sex differences in pulmonary vascular control: focus on the nitric oxide pathway. 
Physiol Rep 5: 2017. 
13. Dell'Italia LJ. The forgotten left ventricle in right ventricular pressure 
overload. J Am Coll Cardiol 57: 929-930, 2011. 
14. Dewachter L, and Dewachter C. Inflammation in Right Ventricular Failure: 
Does It Matter? Front Physiol 9: 1056, 2018. 
15. Duncker DJ, Stubenitsky R, and Verdouw PD. Role of adenosine in the 
regulation of coronary blood flow in swine at rest and during treadmill exercise. 
Am J Physiol 275: H1663-1672, 1998. 
16. Frangogiannis NG. Fibroblasts and the extracellular matrix in right 
ventricular disease. Cardiovasc Res 113: 1453-1464, 2017. 
17. Frump AL, Bonnet S, de Jesus Perez VA, and Lahm T. Emerging role of 
angiogenesis in adaptive and maladaptive right ventricular remodeling in 
pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 314: L443-L460, 2018. 
18. Furfine ES, Harmon MF, Paith JE, and Garvey EP. Selective inhibition of 
constitutive nitric oxide synthase by L-NG-nitroarginine. Biochemistry 32: 8512-
8517, 1993. 
19. Garvey EP, Tuttle JV, Covington K, Merrill BM, Wood ER, Baylis SA, and 
Charles IG. Purification and characterization of the constitutive nitric oxide 
synthase from human placenta. Arch Biochem Biophys 311: 235-241, 1994. 
20. Grosse A, Grosse C, and Lang I. Evaluation of the CT imaging findings in 
patients newly diagnosed with chronic thromboembolic pulmonary hypertension. 
PLoS One 13: e0201468, 2018. 
21. Grundy D. Principles and standards for reporting animal experiments in 
The Journal of Physiology and Experimental Physiology. J Physiol 593: 2547-2549, 
2015. 
Kelly Stam Dissertatie V5.indd   225 12-8-2019   09:52:19
Chapter 6. 
226 
22. Guihaire J, Haddad F, Boulate D, Capderou A, Decante B, Flecher E, 
Eddahibi S, Dorfmuller P, Herve P, Humbert M, Verhoye JP, Dartevelle P, Mercier 
O, and Fadel E. Right ventricular plasticity in a porcine model of chronic pressure 
overload. J Heart Lung Transplant 33: 194-202, 2014. 
23. Guihaire J, Haddad F, Boulate D, Decante B, Denault AY, Wu J, Herve P, 
Humbert M, Dartevelle P, Verhoye JP, Mercier O, and Fadel E. Non-invasive 
indices of right ventricular function are markers of ventricular-arterial coupling 
rather than ventricular contractility: insights from a porcine model of chronic 
pressure overload. Eur Heart J Cardiovasc Imaging 14: 1140-1149, 2013. 
24. Guihaire J, Haddad F, Noly PE, Boulate D, Decante B, Dartevelle P, 
Humbert M, Verhoye JP, Mercier O, and Fadel E. Right ventricular reserve in a 
piglet model of chronic pulmonary hypertension. Eur Respir J 45: 709-717, 2015. 
25. Hardziyenka M, Campian ME, Reesink HJ, Surie S, Bouma BJ, Groenink M, 
Klemens CA, Beekman L, Remme CA, Bresser P, and Tan HL. Right ventricular 
failure following chronic pressure overload is associated with reduction in left 
ventricular mass: evidence for atrophic remodeling. J Am Coll Cardiol 57: 921-928, 
2011. 
26. Hartmann S, Ridley AJ, and Lutz S. The Function of Rho-Associated Kinases 
ROCK1 and ROCK2 in the Pathogenesis of Cardiovascular Disease. Front Pharmacol 
6: 276, 2015. 
27. He J, Li X, Luo H, Li T, Zhao L, Qi Q, Liu Y, and Yu Z. Galectin-3 mediates the 
pulmonary arterial hypertension-induced right ventricular remodeling through 
interacting with NADPH oxidase 4. J Am Soc Hypertens 11: 275-289 e272, 2017. 
28. Ikeda S, Satoh K, Kikuchi N, Miyata S, Suzuki K, Omura J, Shimizu T, 
Kobayashi K, Kobayashi K, Fukumoto Y, Sakata Y, and Shimokawa H. Crucial role 
of rho-kinase in pressure overload-induced right ventricular hypertrophy and 
dysfunction in mice. Arterioscler Thromb Vasc Biol 34: 1260-1271, 2014. 
29. In E, Deveci F, and Kaman D. Assessment of heat shock proteins and 
endothelial dysfunction in acute pulmonary embolism. Blood Coagul Fibrinolysis 
27: 378-383, 2016. 
30. Kirson NY, Birnbaum HG, Ivanova JI, Waldman T, Joish V, and Williamson 
T. Prevalence of pulmonary arterial hypertension and chronic thromboembolic 
pulmonary hypertension in the United States. Curr Med Res Opin 27: 1763-1768, 
2011. 
Cardiac remodeling in CTEPH 
227 
31. Lang IM, Dorfmuller P, and Vonk Noordegraaf A. The Pathobiology of 
Chronic Thromboembolic Pulmonary Hypertension. Ann Am Thorac Soc 13 Suppl 3: 
S215-221, 2016. 
32. Liu SF, Hislop AA, Haworth SG, and Barnes PJ. Developmental changes in 
endothelium-dependent pulmonary vasodilatation in pigs. Br J Pharmacol 106: 
324-330, 1992. 
33. Loisel F, Provost B, Guihaire J, Boulate D, Arouche N, Amsallem M, 
Arthur-Ataam J, Decante B, Dorfmuller P, Fadel E, Uzan G, and Mercier O. 
Autologous endothelial progenitor cell therapy improves right ventricular function 
in a model of chronic thromboembolic pulmonary hypertension. J Thorac 
Cardiovasc Surg 157: 655-666 e657, 2019. 
34. Lu X, Dang CQ, Guo X, Molloi S, Wassall CD, Kemple MD, and Kassab GS. 
Elevated oxidative stress and endothelial dysfunction in right coronary artery of 
right ventricular hypertrophy. J Appl Physiol (1985) 110: 1674-1681, 2011. 
35. Marcus JT, Gan CT, Zwanenburg JJ, Boonstra A, Allaart CP, Gotte MJ, and 
Vonk-Noordegraaf A. Interventricular mechanical asynchrony in pulmonary 
arterial hypertension: left-to-right delay in peak shortening is related to right 
ventricular overload and left ventricular underfilling. J Am Coll Cardiol 51: 750-757, 
2008. 
36. Matsunaga T, Warltier DC, Weihrauch DW, Moniz M, Tessmer J, and 
Chilian WM. Ischemia-induced coronary collateral growth is dependent on 
vascular endothelial growth factor and nitric oxide. Circulation 102: 3098-3103, 
2000. 
37. Matsunaga T, Weihrauch DW, Moniz MC, Tessmer J, Warltier DC, and 
Chilian WM. Angiostatin inhibits coronary angiogenesis during impaired 
production of nitric oxide. Circulation 105: 2185-2191, 2002. 
38. McCabe C, White PA, Hoole SP, Axell RG, Priest AN, Gopalan D, Taboada 
D, MacKenzie Ross R, Morrell NW, Shapiro LM, and Pepke-Zaba J. Right 
ventricular dysfunction in chronic thromboembolic obstruction of the pulmonary 
artery: a pressure-volume study using the conductance catheter. J Appl Physiol 
(1985) 116: 355-363, 2014. 
39. Naeije R, and Badagliacca R. The overloaded right heart and ventricular 
interdependence. Cardiovasc Res 113: 1474-1485, 2017. 
Kelly Stam Dissertatie V5.indd   226 12-8-2019   09:52:19
6Chapter 6. 
226 
22. Guihaire J, Haddad F, Boulate D, Capderou A, Decante B, Flecher E, 
Eddahibi S, Dorfmuller P, Herve P, Humbert M, Verhoye JP, Dartevelle P, Mercier 
O, and Fadel E. Right ventricular plasticity in a porcine model of chronic pressure 
overload. J Heart Lung Transplant 33: 194-202, 2014. 
23. Guihaire J, Haddad F, Boulate D, Decante B, Denault AY, Wu J, Herve P, 
Humbert M, Dartevelle P, Verhoye JP, Mercier O, and Fadel E. Non-invasive 
indices of right ventricular function are markers of ventricular-arterial coupling 
rather than ventricular contractility: insights from a porcine model of chronic 
pressure overload. Eur Heart J Cardiovasc Imaging 14: 1140-1149, 2013. 
24. Guihaire J, Haddad F, Noly PE, Boulate D, Decante B, Dartevelle P, 
Humbert M, Verhoye JP, Mercier O, and Fadel E. Right ventricular reserve in a 
piglet model of chronic pulmonary hypertension. Eur Respir J 45: 709-717, 2015. 
25. Hardziyenka M, Campian ME, Reesink HJ, Surie S, Bouma BJ, Groenink M, 
Klemens CA, Beekman L, Remme CA, Bresser P, and Tan HL. Right ventricular 
failure following chronic pressure overload is associated with reduction in left 
ventricular mass: evidence for atrophic remodeling. J Am Coll Cardiol 57: 921-928, 
2011. 
26. Hartmann S, Ridley AJ, and Lutz S. The Function of Rho-Associated Kinases 
ROCK1 and ROCK2 in the Pathogenesis of Cardiovascular Disease. Front Pharmacol 
6: 276, 2015. 
27. He J, Li X, Luo H, Li T, Zhao L, Qi Q, Liu Y, and Yu Z. Galectin-3 mediates the 
pulmonary arterial hypertension-induced right ventricular remodeling through 
interacting with NADPH oxidase 4. J Am Soc Hypertens 11: 275-289 e272, 2017. 
28. Ikeda S, Satoh K, Kikuchi N, Miyata S, Suzuki K, Omura J, Shimizu T, 
Kobayashi K, Kobayashi K, Fukumoto Y, Sakata Y, and Shimokawa H. Crucial role 
of rho-kinase in pressure overload-induced right ventricular hypertrophy and 
dysfunction in mice. Arterioscler Thromb Vasc Biol 34: 1260-1271, 2014. 
29. In E, Deveci F, and Kaman D. Assessment of heat shock proteins and 
endothelial dysfunction in acute pulmonary embolism. Blood Coagul Fibrinolysis 
27: 378-383, 2016. 
30. Kirson NY, Birnbaum HG, Ivanova JI, Waldman T, Joish V, and Williamson 
T. Prevalence of pulmonary arterial hypertension and chronic thromboembolic 
pulmonary hypertension in the United States. Curr Med Res Opin 27: 1763-1768, 
2011. 
Cardiac remodeling in CTEPH 
227 
31. Lang IM, Dorfmuller P, and Vonk Noordegraaf A. The Pathobiology of 
Chronic Thromboembolic Pulmonary Hypertension. Ann Am Thorac Soc 13 Suppl 3: 
S215-221, 2016. 
32. Liu SF, Hislop AA, Haworth SG, and Barnes PJ. Developmental changes in 
endothelium-dependent pulmonary vasodilatation in pigs. Br J Pharmacol 106: 
324-330, 1992. 
33. Loisel F, Provost B, Guihaire J, Boulate D, Arouche N, Amsallem M, 
Arthur-Ataam J, Decante B, Dorfmuller P, Fadel E, Uzan G, and Mercier O. 
Autologous endothelial progenitor cell therapy improves right ventricular function 
in a model of chronic thromboembolic pulmonary hypertension. J Thorac 
Cardiovasc Surg 157: 655-666 e657, 2019. 
34. Lu X, Dang CQ, Guo X, Molloi S, Wassall CD, Kemple MD, and Kassab GS. 
Elevated oxidative stress and endothelial dysfunction in right coronary artery of 
right ventricular hypertrophy. J Appl Physiol (1985) 110: 1674-1681, 2011. 
35. Marcus JT, Gan CT, Zwanenburg JJ, Boonstra A, Allaart CP, Gotte MJ, and 
Vonk-Noordegraaf A. Interventricular mechanical asynchrony in pulmonary 
arterial hypertension: left-to-right delay in peak shortening is related to right 
ventricular overload and left ventricular underfilling. J Am Coll Cardiol 51: 750-757, 
2008. 
36. Matsunaga T, Warltier DC, Weihrauch DW, Moniz M, Tessmer J, and 
Chilian WM. Ischemia-induced coronary collateral growth is dependent on 
vascular endothelial growth factor and nitric oxide. Circulation 102: 3098-3103, 
2000. 
37. Matsunaga T, Weihrauch DW, Moniz MC, Tessmer J, Warltier DC, and 
Chilian WM. Angiostatin inhibits coronary angiogenesis during impaired 
production of nitric oxide. Circulation 105: 2185-2191, 2002. 
38. McCabe C, White PA, Hoole SP, Axell RG, Priest AN, Gopalan D, Taboada 
D, MacKenzie Ross R, Morrell NW, Shapiro LM, and Pepke-Zaba J. Right 
ventricular dysfunction in chronic thromboembolic obstruction of the pulmonary 
artery: a pressure-volume study using the conductance catheter. J Appl Physiol 
(1985) 116: 355-363, 2014. 
39. Naeije R, and Badagliacca R. The overloaded right heart and ventricular 
interdependence. Cardiovasc Res 113: 1474-1485, 2017. 
Kelly Stam Dissertatie V5.indd   227 12-8-2019   09:52:19
Chapter 6. 
228 
40. Parker TA, le Cras TD, Kinsella JP, and Abman SH. Developmental changes 
in endothelial nitric oxide synthase expression and activity in ovine fetal lung. Am 
J Physiol Lung Cell Mol Physiol 278: L202-208, 2000. 
41. Rain S, Andersen S, Najafi A, Gammelgaard Schultz J, da Silva Goncalves 
Bos D, Handoko ML, Bogaard HJ, Vonk-Noordegraaf A, Andersen A, van der 
Velden J, Ottenheijm CA, and de Man FS. Right Ventricular Myocardial Stiffness in 
Experimental Pulmonary Arterial Hypertension: Relative Contribution of Fibrosis 
and Myofibril Stiffness. Circ Heart Fail 9: 2016. 
42. Rees DD, Palmer RM, Schulz R, Hodson HF, and Moncada S. 
Characterization of three inhibitors of endothelial nitric oxide synthase in vitro 
and in vivo. Br J Pharmacol 101: 746-752, 1990. 
43. Reesink HJ, Meijer RC, Lutter R, Boomsma F, Jansen HM, Kloek JJ, and 
Bresser P. Hemodynamic and clinical correlates of endothelin-1 in chronic 
thromboembolic pulmonary hypertension. Circ J 70: 1058-1063, 2006. 
44. Shimizu T, and Liao JK. Rho Kinases and Cardiac Remodeling. Circ J 80: 
1491-1498, 2016. 
45. Simonneau G, Torbicki A, Dorfmuller P, and Kim N. The pathophysiology 
of chronic thromboembolic pulmonary hypertension. Eur Respir Rev 26: 2017. 
46. Sorop O, Heinonen I, van Kranenburg M, van de Wouw J, de Beer VJ, 
Nguyen ITN, Octavia Y, van Duin RWB, Stam K, van Geuns RJ, Wielopolski PA, 
Krestin GP, van den Meiracker AH, Verjans R, van Bilsen M, Danser AHJ, Paulus 
WJ, Cheng C, Linke WA, Joles JA, Verhaar MC, van der Velden J, Merkus D, and 
Duncker DJ. Multiple common comorbidities produce left ventricular diastolic 
dysfunction associated with coronary microvascular dysfunction, oxidative stress, 
and myocardial stiffening. Cardiovasc Res 114: 954-964, 2018. 
47. Stam K, van Duin RWB, Uitterdijk A, Cai Z, Duncker DJ, and Merkus D. 
Exercise facilitates early recognition of cardiac and vascular remodeling in chronic 
thromboembolic pulmonary hypertension in swine. Am J Physiol Heart Circ Physiol 
314: H627-H642, 2018. 
48. Stam K, van Duin RWB, Uitterdijk A, Krabbendam-Peters I, Sorop O, 
Danser AHJ, Duncker DJ, and Merkus D. Pulmonary microvascular remodeling in 
chronic thrombo-embolic pulmonary hypertension. Am J Physiol Lung Cell Mol 
Physiol 2018. 
Cardiac remodeling in CTEPH 
229 
49. Stubenitsky R, Verdouw PD, and Duncker DJ. Autonomic control of 
cardiovascular performance and whole body O2 delivery and utilization in swine 
during treadmill exercise. Cardiovasc Res 39: 459-474, 1998. 
50. Sun XQ, Abbate A, and Bogaard HJ. Role of cardiac inflammation in right 
ventricular failure. Cardiovasc Res 113: 1441-1452, 2017. 
51. Sunamura S, Satoh K, Kurosawa R, Ohtsuki T, Kikuchi N, Elias-Al-Mamun 
M, Shimizu T, Ikeda S, Suzuki K, Satoh T, Omura J, Nogi M, Numano K, Siddique 
MAH, Miyata S, Miura M, and Shimokawa H. Different roles of myocardial ROCK1 
and ROCK2 in cardiac dysfunction and postcapillary pulmonary hypertension in 
mice. Proc Natl Acad Sci U S A 115: E7129-E7138, 2018. 
52. Torbicki A, and Fijałkowska A. Role of cardiac biomarkers in assessment of 
RV function and prognosis in chronic pulmonary hypertension. European Heart 
Journal Supplements 9: H41-H47, 2007. 
53. Trip P, Rain S, Handoko ML, van der Bruggen C, Bogaard HJ, Marcus JT, 
Boonstra A, Westerhof N, Vonk-Noordegraaf A, and de Man FS. Clinical 
relevance of right ventricular diastolic stiffness in pulmonary hypertension. Eur 
Respir J 45: 1603-1612, 2015. 
54. Tsai SH, Lu G, Xu X, Ren Y, Hein TW, and Kuo L. Enhanced endothelin-
1/Rho-kinase signalling and coronary microvascular dysfunction in hypertensive 
myocardial hypertrophy. Cardiovasc Res 113: 1329-1337, 2017. 
55. van de Veerdonk MC, Bogaard HJ, and Voelkel NF. The right ventricle and 
pulmonary hypertension. Heart Fail Rev 21: 259-271, 2016. 
56. van Wolferen SA, Marcus JT, Westerhof N, Spreeuwenberg MD, Marques 
KM, Bronzwaer JG, Henkens IR, Gan CT, Boonstra A, Postmus PE, and Vonk-
Noordegraaf A. Right coronary artery flow impairment in patients with pulmonary 
hypertension. Eur Heart J 29: 120-127, 2008. 
57. Vogel-Claussen J, Skrok J, Shehata ML, Singh S, Sibley CT, Boyce DM, 
Lechtzin N, Girgis RE, Mathai SC, Goldstein TA, Zheng J, Lima JA, Bluemke DA, 
and Hassoun PM. Right and left ventricular myocardial perfusion reserves 
correlate with right ventricular function and pulmonary hemodynamics in patients 
with pulmonary arterial hypertension. Radiology 258: 119-127, 2011. 
58. Vonk Noordegraaf A, Westerhof BE, and Westerhof N. The Relationship 
Between the Right Ventricle and its Load in Pulmonary Hypertension. J Am Coll 
Cardiol 69: 236-243, 2017. 
Kelly Stam Dissertatie V5.indd   228 12-8-2019   09:52:20
6Chapter 6. 
228 
40. Parker TA, le Cras TD, Kinsella JP, and Abman SH. Developmental changes 
in endothelial nitric oxide synthase expression and activity in ovine fetal lung. Am 
J Physiol Lung Cell Mol Physiol 278: L202-208, 2000. 
41. Rain S, Andersen S, Najafi A, Gammelgaard Schultz J, da Silva Goncalves 
Bos D, Handoko ML, Bogaard HJ, Vonk-Noordegraaf A, Andersen A, van der 
Velden J, Ottenheijm CA, and de Man FS. Right Ventricular Myocardial Stiffness in 
Experimental Pulmonary Arterial Hypertension: Relative Contribution of Fibrosis 
and Myofibril Stiffness. Circ Heart Fail 9: 2016. 
42. Rees DD, Palmer RM, Schulz R, Hodson HF, and Moncada S. 
Characterization of three inhibitors of endothelial nitric oxide synthase in vitro 
and in vivo. Br J Pharmacol 101: 746-752, 1990. 
43. Reesink HJ, Meijer RC, Lutter R, Boomsma F, Jansen HM, Kloek JJ, and 
Bresser P. Hemodynamic and clinical correlates of endothelin-1 in chronic 
thromboembolic pulmonary hypertension. Circ J 70: 1058-1063, 2006. 
44. Shimizu T, and Liao JK. Rho Kinases and Cardiac Remodeling. Circ J 80: 
1491-1498, 2016. 
45. Simonneau G, Torbicki A, Dorfmuller P, and Kim N. The pathophysiology 
of chronic thromboembolic pulmonary hypertension. Eur Respir Rev 26: 2017. 
46. Sorop O, Heinonen I, van Kranenburg M, van de Wouw J, de Beer VJ, 
Nguyen ITN, Octavia Y, van Duin RWB, Stam K, van Geuns RJ, Wielopolski PA, 
Krestin GP, van den Meiracker AH, Verjans R, van Bilsen M, Danser AHJ, Paulus 
WJ, Cheng C, Linke WA, Joles JA, Verhaar MC, van der Velden J, Merkus D, and 
Duncker DJ. Multiple common comorbidities produce left ventricular diastolic 
dysfunction associated with coronary microvascular dysfunction, oxidative stress, 
and myocardial stiffening. Cardiovasc Res 114: 954-964, 2018. 
47. Stam K, van Duin RWB, Uitterdijk A, Cai Z, Duncker DJ, and Merkus D. 
Exercise facilitates early recognition of cardiac and vascular remodeling in chronic 
thromboembolic pulmonary hypertension in swine. Am J Physiol Heart Circ Physiol 
314: H627-H642, 2018. 
48. Stam K, van Duin RWB, Uitterdijk A, Krabbendam-Peters I, Sorop O, 
Danser AHJ, Duncker DJ, and Merkus D. Pulmonary microvascular remodeling in 
chronic thrombo-embolic pulmonary hypertension. Am J Physiol Lung Cell Mol 
Physiol 2018. 
Cardiac remodeling in CTEPH 
229 
49. Stubenitsky R, Verdouw PD, and Duncker DJ. Autonomic control of 
cardiovascular performance and whole body O2 delivery and utilization in swine 
during treadmill exercise. Cardiovasc Res 39: 459-474, 1998. 
50. Sun XQ, Abbate A, and Bogaard HJ. Role of cardiac inflammation in right 
ventricular failure. Cardiovasc Res 113: 1441-1452, 2017. 
51. Sunamura S, Satoh K, Kurosawa R, Ohtsuki T, Kikuchi N, Elias-Al-Mamun 
M, Shimizu T, Ikeda S, Suzuki K, Satoh T, Omura J, Nogi M, Numano K, Siddique 
MAH, Miyata S, Miura M, and Shimokawa H. Different roles of myocardial ROCK1 
and ROCK2 in cardiac dysfunction and postcapillary pulmonary hypertension in 
mice. Proc Natl Acad Sci U S A 115: E7129-E7138, 2018. 
52. Torbicki A, and Fijałkowska A. Role of cardiac biomarkers in assessment of 
RV function and prognosis in chronic pulmonary hypertension. European Heart 
Journal Supplements 9: H41-H47, 2007. 
53. Trip P, Rain S, Handoko ML, van der Bruggen C, Bogaard HJ, Marcus JT, 
Boonstra A, Westerhof N, Vonk-Noordegraaf A, and de Man FS. Clinical 
relevance of right ventricular diastolic stiffness in pulmonary hypertension. Eur 
Respir J 45: 1603-1612, 2015. 
54. Tsai SH, Lu G, Xu X, Ren Y, Hein TW, and Kuo L. Enhanced endothelin-
1/Rho-kinase signalling and coronary microvascular dysfunction in hypertensive 
myocardial hypertrophy. Cardiovasc Res 113: 1329-1337, 2017. 
55. van de Veerdonk MC, Bogaard HJ, and Voelkel NF. The right ventricle and 
pulmonary hypertension. Heart Fail Rev 21: 259-271, 2016. 
56. van Wolferen SA, Marcus JT, Westerhof N, Spreeuwenberg MD, Marques 
KM, Bronzwaer JG, Henkens IR, Gan CT, Boonstra A, Postmus PE, and Vonk-
Noordegraaf A. Right coronary artery flow impairment in patients with pulmonary 
hypertension. Eur Heart J 29: 120-127, 2008. 
57. Vogel-Claussen J, Skrok J, Shehata ML, Singh S, Sibley CT, Boyce DM, 
Lechtzin N, Girgis RE, Mathai SC, Goldstein TA, Zheng J, Lima JA, Bluemke DA, 
and Hassoun PM. Right and left ventricular myocardial perfusion reserves 
correlate with right ventricular function and pulmonary hemodynamics in patients 
with pulmonary arterial hypertension. Radiology 258: 119-127, 2011. 
58. Vonk Noordegraaf A, Westerhof BE, and Westerhof N. The Relationship 
Between the Right Ventricle and its Load in Pulmonary Hypertension. J Am Coll 
Cardiol 69: 236-243, 2017. 
Kelly Stam Dissertatie V5.indd   229 12-8-2019   09:52:20
Chapter 6. 
230 
59. Zeidan A, Gan XT, Thomas A, and Karmazyn M. Prevention of RhoA 
activation and cofilin-mediated actin polymerization mediates the 
antihypertrophic effect of adenosine receptor agonists in angiotensin II- and 
endothelin-1-treated cardiomyocytes. Mol Cell Biochem 385: 239-248, 2014. 
 
 
 
 
  
Kelly Stam Dissertatie V5.indd   230 12-8-2019   09:52:20
  
 
  
 
 
Chapter 7 
Summary and General discussion 
 
Kelly Stam Dissertatie V5.indd   232 12-8-2019   09:52:20
  
 
  
Chapter 7
Summary and General discussion
Kelly Stam Dissertatie V5.indd   233 12-8-2019   09:52:20
  
 
Summary and General discussion 
235 
Chronic thromboembolic pulmonary hypertension (CTEPH) develops in about 3-
4% of patients after acute pulmonary embolism (PE), although the disease is 
probably highly underdiagnosed. CTEPH is associated with a poor quality life, high 
mortality and although pulmonary endarterectomy and balloon angioplasty may 
initially provide symptom relief by removing the proximal obstructions, there is no 
curative treatment for the pulmonary microvasculopathy. Furthermore, it is 
unclear why only a subpopulation of patients develops chronic pulmonary 
hypertension after an acute PE, and what the underlying mechanism(s) are for this 
transition from acute to chronic pulmonary disease. There are some risk factors 
such as genetics, ineffective endogenous fibrinolysis, hypercoagulability, deficient 
angiogenesis, inflammation and platelet endothelial cell adhesion molecule-1 
deficiency linked and hypothesized to play a role in the development of CTEPH 
(53, 82).  
In this thesis, we proposed that (pulmonary) endothelial dysfunction is a 
key mechanism in the transition from acute PE to development of CTEPH. With a 
dysfunctional endothelium, emboli cannot be properly resolved and the 
remodeling of the pulmonary vasculature, both functional as structural, cannot be 
prevented. A healthy pulmonary endothelium is characterized by production of 
nitric oxide (NO) and prostacyclin, while production of endothelin (ET) is kept low 
and circulating ET is largely cleared in the lungs. Pulmonary endothelial 
dysfunction and/or high pulmonary pressure are associated with perturbations in 
the prostacyclin, nitric oxide (NO) and endothelin (ET) pathways. These 
perturbations lead to pulmonary vascular vasoconstriction and, together with the 
high blood pressure, contribute to muscularization of the pulmonary vessels. Both 
vasoconstriction and muscularization of the pulmonary vessels cause an increase 
in vascular resistance, increasing the right ventricular afterload. The RV responds 
to this chronic increase in afterload by an initially adaptive response, 
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encompassing cardiomyocyte hypertrophy to increase contractile capacity, 
fibrosis to prevent cardiomyocyte overstretch and maintain RV shape for optimal 
function and angiogenesis to maintain blood supply to the thickened ventricular 
wall. However, eventually there is an inflammatory response and maladaptive 
(increased diastolic stiffness) fibrosis. However, although these adaptations are 
initially enabling the RV to cope with the increased afterload, they are eventually 
not sufficient, and can even be contributing to RV dysfunction/failure (5, 77, 82).  
The aim of the current thesis was to develop a CTEPH swine model in which both 
the emboli and the endothelial dysfunction are simulated in order to establish the 
role of pulmonary endothelial (dys)function in the development and progression 
of CTEPH and characterize (molecular) pathways involved in cardiac remodeling 
with the emphasis on hypertrophy, contractility, inflammation, oxidative stress, 
apoptosis and angiogenesis. In addition, we investigated the effects of acute 
exercise and the possibilities of exercise as a stress test for early detection in this 
CTEPH model.  
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Figure 1. Pathophysiology of CTEPH. 
The key pathways involved in the pathophysiology of CTEPH. CTEPH is a pulmonary and 
cardiac disease. The pulmonary changes are characterized by vascular obstructions due to 
emboli, vascular muscularization, vasoconstriction and endothelial dysfunction and 
inflammation which all interfere with each other. The cardiac changes are caused by the 
increased afterload and characterized by hypertrophy, inflammation, angiogenesis and 
fibrosis and lead to RV dysfunction and failure. NO, nitric oxide; ET, endothelin; RV, right 
ventricle (adapted from(94)).  
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Characterization of a new CTEPH swine model 
Applicability, interpretation and limitations of chronically instrumenting swine 
The use of chronically instrumented animals allows serial assessment of 
cardiopulmonary function either during development of disease or evaluation of 
treatment, thereby increasing statistical power and limiting the number of 
animals required for a study. In addition, chronic instrumentation of swine allow 
for awake monitoring of changes in regulation of the cardiopulmonary system 
during exercise testing. Therefore, we presented this chronic instrumentation of 
swine in Chapter 2, and explained its implications in cardiopulmonary monitoring 
and stress testing. 
A potential drawback is that, when commercially available swine breeds 
such as Yorkshire, Landrace, Large White etc, are used for chronic 
instrumentation, adult swine are very large and may therefore be difficult to 
handle. Therefore, juvenile swine are often used. The heart and pulmonary 
endothelium of juvenile swine are still very adaptable to stress and damage. An 
alternative is the use of adult miniature swine, such as Yucatan or Göttingen 
swine, of which the adult weight is 40 - 60 kg (8). Several swine models of 
cardiopulmonary disease, such as and pulmonary hypertension are available (56, 
66) or being developed and could be combined, and thereby significantly 
improved, with chronic instrumentation. 
Induction of CTEPH requires both repeated embolizations and endothelial 
dysfunction 
In order to combine the strengths and circumvent the shortcomings of the 
previous large animal models (2, 10, 24, 27, 29, 46, 57, 60, 61, 67, 68, 74, 75, 78, 
88, 95, 100) (see Table 1 of Chapter 3) we developed and characterized a new 
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CTEPH swine model in Chapter 3. CTEPH induction required both repeated 
embolizations by means of microsphere infusion via the inserted RV catheter, and 
endothelial dysfunction by means of eNOS inhibition, as either intervention alone 
did not result in sustained CTEPH. In this model we could monitor hemodynamics 
and perform echocardiography and exercise testing, all in the awake state.  
During the embolization procedures, microspheres were slowly injected 
into the RV, assuming that microspheres flow to perfused, non-embolized vessels 
to ensure full coverage of the pulmonary vasculature. A total of approximately 
36000 microspheres with a diameter of ~700 μm were infused per animal. When 
compared to the number of branches of the corresponding size present in the 
pulmonary vascular bed, it is likely that 60% of the pulmonary small arteries were 
obstructed. Since it has been suggested that 40-60% of the lung vasculature needs 
to be obstructed for CTEPH to develop (7, 18), the infused microspheres should be 
sufficient to induce CTEPH in the swine. Nevertheless, as we show in Chapter 3, 
with microspheres alone, no sustained CTEPH developed. 
In addition however, CTEPH occurs only in a minority of patients after 
acute pulmonary embolism while also patients that did not (notice to) experience 
an acute pulmonary embolism have been reported to develop CTEPH (82). In 
these patients, it is proposed that CTEPH is the consequence of multiple micro-
embolisms (23, 85). Since CTEPH patients present with dysfunctional endothelium 
as evidenced by alterations in coagulation, inflammation, angiogenesis and 
vasoregulation (4, 54, 69, 82, 83), this could be the second hit present in the 
group of patients that develop CTEPH. We therefore induced endothelial 
dysfunction as a second hit by inhibiting eNOS by chronic LNAME administration 
in our swine model to produce sustained CTEPH in Chapter 3, 4, 5 and 6. Nitric 
oxide is an important endothelium-derived anti-coagulatory, anti-inflammatory, 
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pro-angiogenic, vasodilator which are all factors leading to progression of CTEPH. 
We observed in our animal model that endothelial dysfunction in combination 
with multiple microsphere infusions resulted in a sustained increase in PAP and 
tPVRi. This increase in PAP above 25mmHg for a prolonged period of time after 
embolizations and in the awake state is evidence for successful induction of 
chronic PH (2, 29, 46, 57, 60, 67, 68, 75, 78, 95, 100). Our findings are in 
accordance with a recent study in rats, that show that sustained CTEPH developed 
when combining embolizations with endothelial dysfunction produced by VEGF-
inhibition (63) which also signals through the NO pathway. Importantly, in the 
studies presented in this thesis, CTEPH persisted when eNOS inhibition was 
discontinued, which implies that vascular remodeling and endothelial dysfunction 
developed as a consequence of high blood pressure and increased vascular shear 
stress in our swine. 
Characterization of pulmonary remodeling in CTEPH swine 
It is well established that secondary to pulmonary embolism, worsening of PH 
results from progressive microvascular remodeling of the non-obstructed distal 
pulmonary small arteries (23, 41, 59). Indeed, we also observed microvascular 
remodeling as evidenced by an increased wall thickness of the non-obstructed 
pulmonary small arteries and exaggerated vasoconstriction to both KCl and the 
thromboxane analogue U46619. Although the exact time-course of microvascular 
remodeling may not be exactly  determined from our data, as the increase in 
resistance due to embolizations cannot be distinguished from the increase in 
resistance due to microvascular remodeling during the embolization period, 
pulmonary vascular resistance continued to increase after cessation of the 
embolization procedures, which is consistent with remodeling of the distal 
vasculature. Even after cessation of the eNOS inhibitor, which may also have 
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contributed by increasing microvascular tone, the high pulmonary pressure and 
resistance persisted.  
Pulmonary microvascular remodeling 
In accordance with previous studies in humans and animals (10, 17, 59), we 
observed in Chapter 5 inward remodeling of both pulmonary small arteries and 
the pulmonary microvasculature. This remodeling encompassed muscularization 
and thickening of the vascular wall and resulted in a relative reduction of the 
vascular lumen which would be contributing to a worsening of PH by further 
increasing the PAP. The changes in microvascular morphology in our CTEPH swine 
were not accompanied by an overt pulmonary inflammatory response at the 
disease stage, as only IL-6 showed a trend towards an increase, while this increase 
in IL-6 was consistent with the increase in CTEPH patients (76, 96, 97). However, 
since we measured inflammation on gene expression level, further investigations 
such as on the protein level could reveal even more specifics. Although the 
existence of pulmonary microvascular remodeling in CTEPH is known since 1993 
(59), the consequences of this remodeling for pulmonary microvascular function 
had not been investigated. In contrast to the lack of evidence of overt 
inflammation in our model of CTEPH, microvascular remodeling was accompanied 
by alterations in two major endothelial signaling pathways, i.e. ET and NO, that 
are also implicated in development and progression of pulmonary hypertension 
(6), and will be further discussed below.  
Pulmonary vascular endothelium 
Perturbations in the NO-pathway have been implicated in the pathogenesis of PH 
(6, 48, 99). Indeed, we observed that chronic eNOS-inhibition is required as a 
second hit, in addition to embolizations, to successfully produce stable CTEPH in 
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swine, as repeated microsphere embolization alone does not result in sustained 
PH (Chapter 3). We investigated the endothelial dysfunction in our CTEPH animals 
in Chapter 5, which was characterized by an imbalance between endothelial 
production of the vasodilator NO and the vasoconstrictor ET-1, while vascular 
integrity was intact.  
We observed in Chapter 5 that, in accordance with inhaled NO treatment 
in patients (1), NO sensitivity was increased in pulmonary small arteries from 
CTEPH animals. This increase in NO sensitivity was evidenced by an enhanced 
vasodilatory response to the NO-donor SNP, reduced vasodilator response to 
bradykinin although there was a similar attenuation of BK-induced vasodilation by 
eNOS-inhibition. The increased NO sensitivity was therefore most likely caused by 
a decrease in NO production, although we did not directly measure NO plasma 
levels. In addition, the response to PDE5-inhibition with Sildenafil was reduced in 
the CTEPH arteries, suggesting that reduced PDE5-activity acted to compensate, in 
part, for a blunted endogenous NO production, resulting in an apparently 
increased NO-sensitivity. Such reduced response to PDE5-inhibition provides a 
potential explanation for the failure of single treatment with PDE5-inhibition as a 
therapeutic strategy for CTEPH and underscores the importance of intervening 
more upstream in the NO-pathway either by administering NO (1) or 
stimulating/activating sGC. Indeed, beneficial therapeutic effects have been 
reported for Riociguat, a sGC stimulator, which was recently approved for 
therapeutic use in CTEPH (31, 47, 50, 81).  
Consistent with endothelial dysfunction, we observed a 40% higher 
plasma ET-1 in our porcine model in Chapter 5. Clinically, it has been shown that 
plasma ET-1 levels correlate well with clinical severity (30, 71), and that patients 
with NYHA class IV show a doubling of circulating ET (30, 71). Hence the 40% 
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elevation in circulating ET-levels are consistent with the clinical phenotype of our 
animals representing NYHA class II or III. As ET can induce vasoconstriction and 
vascular remodeling, we investigated the contribution of changes in ET signaling 
to functional changes in the pulmonary microvasculature. In Chapter 5 we show 
that the increase in circulating ET-1 is accompanied by a decreased sensitivity of 
the pulmonary microvasculature to ET-1. Endothelin receptor antagonists (ERAs) 
are an established therapy in PAH (22, 49), but conflicting results of ERA therapy 
have been reported in CTEPH patients (39, 40, 64). For example, the randomized, 
double-blind, placebo-controlled BENEFIT study, which investigated dual ERA 
therapy with Bosentan, showed no statistically significant effects of Bosentan in 
CTEPH patients (45). In Chapter 5 we observed an increased ETA, decreased ETB 
contribution to ET-1 vasoconstriction and increased ETA/ETB gene expression ratio 
which are in accordance with the increased ETA receptor expression in human 
pulmonary endarterectomy tissues (84) and in the lungs of swine with CTEPH (57). 
These data suggest that CTEPH is accompanied by changes in ET-1 signaling in the 
pulmonary microvasculature and that the interaction between the ETA and the ETB 
receptor is altered in CTEPH. The loss of ETB mediated vasoactive effects observed 
in Chapter 5 suggests that specific ETA blockade alone would be more 
therapeutically efficacious. Moreover, in CTEPH the effect of ET-1 is already 
suppressed by a decreased sensitivity which could explain inefficacy of ERA 
therapy. Although the AMBER studies, which investigated the ETA specific ERA 
Ambrisentan was terminated early (ClinicalTrials.gov NCT02021292, 
NCT02060721), there are ongoing studies to ETA specific ERA’s such as Macitentan 
(MERIT) which is an ERA with high specificity for ETA(25), which is consistent with 
our data that ETA blockade alone would be more therapeutically efficient than 
dual ERA therapy.  
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ET-1 signaling occurs via two pathways, i.e. a calcium-dependent pathway 
involving phospholipase C (PLC)-mediated activation of myosin-light chain kinase 
and a calcium-independent pathway involving RhoA-Rho-kinase mediated 
inactivation of myosin phosphatase (42). Rho-kinase inhibition with Fasudil has 
been shown to be an effective therapy in some patients with PAH (21), but little is 
known about this pathway in the pathology of CTEPH. As we show in Chapter 5, 
the data obtained from the isolated pulmonary small arteries indicate a complete 
loss of the Rho-kinase contribution to ET-1-induced vasoconstriction in the CTEPH 
small arteries, and imply that, ET-1-induced vasoconstriction in CTEPH must 
therefore be mediated through the PLC-pathway. Although a reduction in Rho-
kinase was not present at mRNA level in the CTEPH swine, mRNA levels of lung 
tissue may not reflect protein levels and/or enzyme activity in the vasculature. 
These results are very different from those obtained in PAH, where the 
contribution of Rho-kinase was found to be increased (16). Together, these data 
suggest that microvascular constriction and remodeling occur via different 
pathways in CTEPH as compared to PAH, and suggest that the use of Rho-kinase 
inhibitors to alleviate pulmonary vasoconstriction and remodeling may not be 
efficacious in CTEPH patients. 
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Figure 2. Cardiac remodeling in CTEPH at rest and during exercise. 
Cardiac remodeling in CTEPH, and the effects of exercise on the heart. CTED, chronic 
thrombo-embolic disease; CTEPH, chronic thrombo-embolic pulmonary hypertension; 
RVESV, right ventricular end-systolic volume; RVEF, right ventricular ejection fraction. 
Reprinted and adapted from (14), with permission from Elsevier. 
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Characterization of cardiac remodeling in CTEPH swine 
Cardiac dimensions and function 
It has been shown that RV structural and functional adaptability are 
important determinants of functional capacity and survival in patients with CTEPH 
(14, 32, 91). The RV afterload increases during development and progression of 
PH. To cope with this increased afterload, the RV exhibits structural and functional 
changes to augment contractility (Figure 2). The effects of CTEPH on cardiac 
structure, function and gene expression were therefore examined in our porcine 
model in Chapter 3 and 6. We observed a trend towards RV dilation and a 
reduced RV ejection fraction both by echocardiography (Chapter 3) and by cardiac 
magnetic resonance imaging (Chapter 6). In addition, the CTEPH animals 
presented with an increase in RV cardiomyocyte size and global RV hypertrophy, 
that was accompanied by activation of both pro- and antiapoptotic gene 
expression (increases in Caspase-3 and BCL2 respectively). RV resting function was 
preserved in our animals, but BNP expression was increased, suggestive of an 
increased wall stress. Our findings are consistent with observations in another 
porcine CTEPH model, in which CTEPH is induced by ligation of the left pulmonary 
artery, in combination with embolization of the proximal segmental arteries with 
glue (27-29). In that model, RV dilation (29) and RV myocyte hypertrophy (27) 
were also accompanied by an increased BNP expression (27, 29), that correlated 
inversely with stroke volume and positively with global RV hypertrophy (27). In 
addition, we aimed to identify differences and/or correlations between CTEPH 
severity and PA flow patterns with the promosing new 4D flow CMR technique in 
Chapter 4. It appeared from the 4D CMR flow measurements that the pulmonary 
acceleration time was prolonged in the animals with the most severe CTEPH, 
although this was not statistically significant (Figure 3).  
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Figure 3. Pulmonary and aorta flow measured with 4D CMR 
Pulmonary and aorta flow patterns of swine with severe, mild or no CTEPH in which the 
acceleration time appears to be prolonged in the most severe CTEPH animal.  
It is increasingly recognized that not only RV systolic function, but also RV 
diastolic function correlates with prognosis in patients with PAH (89). Indeed, in 
pigs with type II pulmonary hypertension, changes in RV-PA coupling were 
accompanied by diastolic dysfunction (3). Diastolic stiffness is determined by 
passive myocyte stiffness as well as interstitial fibrosis. Consistent with the 
findings in a rat model of pulmonary artery banding (70), the mild RV dysfunction 
in our CTEPH swine was accompanied by an increase in the stiff titin isoform N2BA 
but not with changes in myocardial fibrosis as measured histologically. 
Furthermore, there was a change in the ratio between Col1 and Col3 in the RV, 
suggesting relatively more expression of the stiff Col1 isoform. These data, 
investigated in Chapter 6, are also consistent with the isoform shift observed by 
Rain et al (70), and may have contributed to a stiffer RV. Although neither SERCA 
nor phospholamban gene expression were changed in our CTEPH swine, it is 
possible that changes in their phosphorylation may play a role in altered Ca2+ 
handling, which is in turn implied to play a role in the development of RV 
dysfunction (3). Hence, future studies should investigate contractile function of 
individual cardiomyocytes as well as expression and phosphorylation of the 
contractile and calcium handling proteins SERCA, phospholamban, smooth muscle 
actin, titin, troponin kinase-A and -C and troponins. 
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Furthermore, there was a change in the ratio between Col1 and Col3 in the RV, 
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Cardiac inflammation, oxidative stress, apoptosis and angiogenesis  
A key factor that distinguishes compensated RV remodeling from RV 
failure is adequate myocardial perfusion (20). Angiogenesis allows the RV 
perfusion to be enhanced commensurate with the increase in RV mass. Indeed, 
many studies show that RV failure is accompanied by a reduction in capillary 
density, whereas capillary density is preserved or even increased in adaptive RV 
remodeling (20). Furthermore, myocardial perfusion reserve has been shown to 
be reduced in humans with both CTEPH and PAH (92, 93). As presented in Chapter 
6, capillary density was increased in our CTEPH swine, in accordance with another 
porcine CTEPH model (51), which is beneficial for myocardial perfusion and 
oxygenation, and suggests a state of adaptive RV remodeling. Nevertheless, 
VEGFA-expression was higher in swine with CTEPH, suggesting that there was still 
a need for additional perfusion, although we did not actually measure myocardial 
perfusion in these animals. Hence, future studies should address the myocardial 
perfusion and coronary flow reserve in different stages of RV (mal) adaptation. 
The transition from compensated RV remodeling to RV failure is also 
associated with inflammation and activation of the immune response (15, 19, 86). 
Although the RV expression of genes involved in immune modulation (TNF-α, IL-6, 
IFN-γ) was not altered, expression of TGF-β was increased in our CTEPH swine 
(Chapter 6). Activation of the TGF-β pathway is increasingly recognized to play a 
pivotal role in de development in PH (65, 73)and was further confirmed in our 
animals by the increase in expression of its downstream target PAI-1. Both 
activation of the TGF-β pathway and increased circulating levels of endothelin can 
result in activation of the Rho-kinase pathway (80, 90, 98). Indeed, ROCK2 
expression was upregulated in the RV of CTEPH swine. Importantly, ROCK2 
activation is involved in cardiac hypertrophy, oxidative stress, angiogenesis, 
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apoptosis and fibrosis and therefore may present a major deleterious factor in RV-
remodeling (33, 43, 87) (Figure 3), particularly given the observation that ROCK2 
phosphorylates protein phosphatase 1 (PP1), which regulates both myofilament 
sensitivity to Ca2+ as well as Ca2+ handling (33).  
ROCK2 is not only expressed in the myocardium but also in the 
vasculature, where its expression correlates with oxidative stress and NOX-
expression (11). NOX1, NOX2 and NOX4 were upregulated in the right coronary 
artery of swine with pulmonary artery banding, which was accompanied by 
oxidative stress and endothelial dysfunction, despite unaltered eNOS expression 
(52). The upregulation of NOX1 and NOX4, and the unaltered eNOS expression in 
the RV of our CTEPH swine are consistent with these data, although we did not 
determine the exact location of their expression (Chapter 6). Furthermore, the 
upregulation of NOX4 is consistent with recent data from patients with PAH, in 
which circulating NOX4 was increased (35). Finally, the negative correlation of 
NOX1 and NOX4 with RV-PA coupling, as observed in Chapter 6, suggests that 
oxidative stress in the myocardium contributes to worsening of RV-function.  
Hence, although therapeutic Rho-kinase inhibition may not be beneficial 
for the pulmonary vascular tone and remodeling, it may prevent adverse cardiac 
remodeling.  
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Figure 4. ROCK2 involvement in RV remodeling.
ROCK2 is associated with the mentioned factors and plays a major deleterious role in RV-
remodeling. Between parentheses are the genes that are altered in our CTEPH swine.
Cardiopulmonary stress testing 
Exercise testing after pulmonary embolism is predictive of development 
of PH and/or patient outcome in established CTEPH (34, 36, 37, 72). We presented 
in Chapter 3, 5 and 6 that CTEPH is characterized by exercise intolerance (Figure 
4). This impaired exercise capacity is principally caused by an exacerbated 
increase in PAP and pulmonary vascular resistance during exercise, that further 
increases RV afterload and the V/Q-mismatch in the lungs (9, 12, 13). 
In humans with CTEPH, physiological dead space is increased in 
proportion to the increase in PVR, resulting in a lower PaO2, which is accompanied 
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by a reduction in PaCO2, as a result of compensatory hyperventilation (55). 
Similarly, the slightly lower PaO2 in our CTEPH swine is consistent with a mild V/Q-
mismatch and dead space ventilation at rest. However, contrary to humans with 
CTEPH, PaCO2 was not significantly affected in our porcine CTEPH-model neither at 
rest, nor during exercise. This discrepancy in CO2 response may in part be due to 
the observation that swine lack collateral ventilation and therefore are less 
capable of ameliorating intraregional V/Q differences between alveoli as 
compared to humans. Furthermore, as healthy quadrupeds already ventilate and 
perfuse their entire lungs at rest (58), an increase in ventilation with CTEPH 
cannot further recruit hypoventilated lung areas and improve V/Q mismatch, and 
hence their hyperventilatory response may not be capable of reducing PaCO2 
levels below normal as occurs in humans. The lower PmvO2 observed in CTEPH is 
partly a consequence of the lower PaO2 due to the V/Q mismatch, and in part 
reflects the decreased blood flow due to a lower CI, forcing the body to extract 
more oxygen. 
 In accordance with the studies of Claessen et al. 2015 in CTEPH patients 
(12, 13), we observed in our CTEPH swine that the right ventricle was not able to 
cope with this increased afterload evidenced by the limited exercise-induced 
increase in stroke volume and CI (Figure 2). Furthermore, RV-PA coupling, an 
index of how well the RV can cope with the increased afterload, is reduced in 
CTEPH and a correlation was found between reduced coupling and a reduced SV 
reserve with dobutamine in swine (29). Similarly, in Chapter 6, severity of CTEPH 
indicated by the PVR, correlated inversely with RV-PA coupling. Importantly, 
recent studies in patients with CTEPH show that RV-PA coupling correlates with 
exercise capacity (14), which in turn is a strong predictor of outcome (9).  
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Figure 5. Effects of exercise in CTEPH.
The pathway after exercise that eventually leads to a decrease in exercise capacity in 
CTEPH. PAP, pulmonary artery pressure; PVR, pulmonary vascular resistance; RV, right 
ventricle; V/Q-mismatch, ventilation/perfusion-mismatch; PmvO2, mixed venous oxygen 
pressure; PaO2, arterial oxygen pressure; PaCO2, arterial carbon dioxide pressure.
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During exercise, maximal body oxygen consumption was reduced and 
arterial lactate concentration was increased by more than 2 mmol/L, indicating 
that, consistent with patient data (26, 38, 44, 72), the anaerobic threshold was 
reached in CTEPH swine during exercise at 4 km/h. Particularly the decreased CI 
(27%) and to a lesser extent the decreased CaO2 (10%), limited the increase in 
body oxygen delivery during exercise. These findings in Chapter 5 suggest that 
exercise intolerance in CTEPH is principally caused by the increased pulmonary 
vascular resistance, and thereby the afterload of the RV, that limits the exercise 
induced increase in CI. The V/Q-mismatch that hampers arterial oxygenation also 
contributes to exercise intolerance, but to a lesser extent. However, the relative 
contributions of cardiac and pulmonary dysfunction to the exercise intolerance in 
patients with more severe RV dysfunction remains to be established.  
Methodological limitations 
In the clinic, CTEPH occurs as a result of thrombo-emboli with different 
sizes which are not adequately resolved in the pulmonary vasculature. In the 
swine model described and characterized in this thesis, CTEPH is induced by 
artificial non-degradable microspheres with a diameter of ~700 μm. The absence 
of endogenous emboli in our studies could have altered the inflammatory 
response and vascular remodeling. In addition, the hypercoagulable state and/or 
inadequate endogenous fibrinolysis, often observed in CTEPH patients, are not 
present in our animal model. 
Future perspectives 
Although we show in Chapter 3 that the double-hit model is necessary to 
induce CTEPH in the relatively young Yorkshire x Landrace swine, recent studies 
suggest that microsphere infusion only is enough to induce PH in Göttinger 
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Figure 5. Effects of exercise in CTEPH.
The pathway after exercise that eventually leads to a decrease in exercise capacity in 
CTEPH. PAP, pulmonary artery pressure; PVR, pulmonary vascular resistance; RV, right 
ventricle; V/Q-mismatch, ventilation/perfusion-mismatch; PmvO2, mixed venous oxygen 
pressure; PaO2, arterial oxygen pressure; PaCO2, arterial carbon dioxide pressure.
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Minipigs (unpublished work from our laboratory) and beagles (61). These findings 
suggest an influence of age on pulmonary vascular function, resulting in a 
biological “second hit” to induce CTEPH (62). Chronic instrumentation of these 
minipigs according to the methods as described in Chapter 2, will allow for 
prolonged serial assessment of cardiopulmonary function in more adult CTEPH 
swine. 
Our CTEPH animal model can be further utilized to investigate disease 
development for possible discovery of potential early diagnostic markers to 
facilitate early detection of disease in patients, and interventions that interfere 
with microvascular remodeling to get more insight in the pathways involved in 
this remodeling and get more specific targeted therapy for inoperable CTEPH 
patients or patients with residual PH after surgery. In addition, this swine model 
may also be used to delineate sex-differences that are known to exist in 
development, progression and possibly interventions of CTEPH (79) and shed 
more light on the importance and implications of cardiopulmonary exercise 
testing in CTEPH patients. Secondary to diagnostic cardiopulmonary exercise 
testing, therapeutic long term exercise training can be performed in the CTEPH 
swine model presented in this thesis. 
Finally, it is important to note that we investigated the contribution of 
endothelial dysfunction to the acute regulation of vascular tone, and that, 
although vasoconstriction likely contributes to the elevated pulmonary vascular 
resistance in CTEPH, microvascular remodeling is also an important contributor. 
Although vasoconstriction and vascular remodeling in part share the same 
signaling pathways, and endothelial dysfunction plays a key role in both, the acute 
response to blockade of vasoactive pathways may not be identical to chronic 
blockade of such pathways, which may also impact vascular remodeling. Hence, 
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long-term effects of therapy, with future studies investigating chronic 
administration of therapeutic agents, for example the effects of chronic Rho-
kinase inhibition, activation of the prostacyclin pathway, ETA antagonists and sGC 
stimulation in CTEPH, are required to study the impact of these agents on 
(pulmonary) vascular as well as cardiac remodeling in CTEPH. Some of these 
agents are indeed currently being investigated in clinical trials (ClinicalTrials.gov 
NCT03689244, NCT01416636, NCT03809650, NCT03273257, NCT02634203, 
NCT00910429). Importantly, both acute and chronic administration of these 
agents could be studied in our CTEPH animal model since real time monitoring 
during administration or after long term administration is possible in awake 
animals. In addition, the effects of acute or chronic therapy such as ERA’s, 
phosphodiesterase inhibitors, NO donors, sGC stimulators or Rho-kinase inhibitors 
on acute exercise can be obtained in our CTEPH swine.  
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Het hart en de longen behoren tot de meest belangrijke organen van het 
menselijk lichaam. Ze zijn essentieel in de toevoer van zuurstof en 
voedingsstoffen en afvoer van koolstofdioxide en andere afvalstoffen van en naar 
organen. Aandoeningen aan het hart en de longen zorgen dan ook voor zowel een 
sterk verminderde kwaliteit van leven als een verkorte levensverwachting. 
Het hart en bloedvatenstelsel is verdeeld in twee circulaties. De systeem 
circulatie welke aangestuurd wordt door de linker harthelft, deze pompt 
zuurstofrijk bloed met voedingsstoffen naar de organen en zorgt ervoor dat 
zuurstofarm bloed met afvalstoffen van de organen afgevoerd wordt. De 
pulmonaal circulatie wordt juist aangestuurd door de rechter harthelft en deze 
pompt het teruggekomen zuurstof arme bloed door de longvaten waar 
koolstofdioxide wordt afgegeven aan, en zuurstof wordt opgenomen uit de 
longblaasjes, zodat dit zuurstofrijke bloed vervolgens weer via de systemische 
circulatie naar de organen getransporteerd kan worden. 
Wanneer er een te hoge bloeddruk in pulmonaal circulatie optreedt, 
>25mmHg in de longslagader (PAP, pulmonary artery pressure), spreekt men van 
pulmonale hypertensie (PH). Patiënten met PH hebben erg vervelende maar 
algemene symptomen zoals kortademigheid, ernstige ongewone moeheid, 
flauwvallen, hartkloppingen en een verminderde inspanningscapaciteit. Doordat 
de symptomen zo algemeen zijn wordt de ziekte vaak pas in een laat stadium 
gediagnosticeerd, wat een negatieve invloed heeft op de prognose. 
PH is een verzamelnaam van chronische aandoeningen met verschillende 
oorzaken waarbij de bloeddruk in de pulmonaal circulatie te hoog is. Een van deze 
oorzaken zijn longemboliën. Deze vorm van pulmonale hypertensie wordt dan ook 
wel chronische thrombo-embolische pulmonale hypertensie (CTEPH) genoemd.  
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Omdat de ziekte nog incompleet begrepen wordt, therapeutische 
interventies gelimiteerd zijn en er nog geen genezende medicaties zijn 
goedgekeurd voor CTEPH, ontrafelen we enkele mechanismen achter deze ziekte 
in dit proefschrift. Om dit te kunnen doen hebben we een groot CTEPH 
proefdiermodel ontwikkeld waarbij we chronische katheters in en rondom het 
hart hebben geplaatst waardoor we de bloeddrukken, hartminuutvolume en 
zuurstofopname in de dieren serieel, wakker en zelf tijdens inspanning kunnen 
meten (Hoofdstuk 2). CTEPH wordt geïnduceerd in deze varkens middels een 
double-hit, namelijk door 1) pulmonale vaatdysfunctie te induceren middels 
chronische administratie van de endotheliaal stikstofoxide-synthase remmer L-
NAME en 2) herhaaldelijke embolisaties van de longvaten met microsferen, 
aangezien beide als enkele toediening niet resulteerde in PH (Hoofdstuk 3). 
Alhoewel CTEPH in eerste instantie veroorzaakt wordt door obstructies in 
het longvaatbed door embolieën, is algemeen bekend dat secundair verergering 
van PH het gevolg is van progressieve microvasculaire remodellering van de niet-
geblokkeerde distale pulmonale kleine slagaders. Wij zien dan ook in Hoofstuk 5 
dat, in onze CTEPH varkens, de wand van deze distale pulmonale kleine slagaders 
en microvasculatuur verdikt en sterk gemusculariseerd is wat leidt tot een 
vernauwing van het lumen waar het bloed door stroomt. Deze muscularisatie in 
combinatie met lumen vernauwing zorgt voor een nog hogere vaatweerstand wat 
op zijn beurt de PAP nog verder verhoogt. Daarnaast zijn twee grote spelers in de 
endotheel regulatie van pulmonale vaattonus, namelijk vasodilator stikstofoxide 
(NO) en de vasoconstrictor endotheline (ET), ook uit balans waardoor de 
pulmonale vaten nog meer samentrekken en de PAP nog verder verhoogd 
(Hoofdstuk 5). Dit bij elkaar zorgt ervoor dat de longen in een vicieuze cirkel 
terechtkomen waarbij een hoge bloeddruk zorgt voor remodellering van de vaten 
en verdere endotheel dysfunctie wat op zijn beurt weer een hogere bloeddruk 
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veroorzaakt. In Hoofdstuk 5 hebben laten zien wat er precies mis gaat in het 
signaleringspad van NO en ET in het CTEPH longvaatbed, waardoor we een stap 
dichter zijn bij het ontrafelen van de mechanismen en wordt het duidelijker welke 
nieuwe therapieën effectief zullen zijn in de behandeling van CTEPH. 
Naast veranderingen in het pulmonale vaatbed zijn er ook verandering in 
het hart, voornamelijk het rechter ventrikel (RV), ten gevolge van de hoge 
weerstand (afterload) waar het rechter ventrikel tegen moet pompen. Het is 
bewezen dat het aanpassingsvermogen van het RV een belangrijke determinant is 
voor de functionele capaciteit en levensverwachting van de patiënt met CTEPH. In 
Hoofdstuk 3 en 6 laten we zien dat er een trend is dat het RV dilateert in 
combinatie met een verminderde ejectie fractie (fractie uitgepompt bloed) ten 
gevolge van CTEPH. Daarnaast laten we zien dat het CTEPH RV, om te 
compenseren voor de verhoogde afterload, is verdikt op zowel macroscopisch als 
microscopisch niveau. De snelheid waarmee de bloedstroom in de longslagader 
vanuit het RV stroomt, gemeten met de nieuwe 4D flow CMR techniek, Hoofdstuk 
4, leek ook lager in de dieren met de meest ernstige CTEPH, alhoewel dit niet 
statistisch significant was. Dit kan veroorzaakt zijn door een stijver RV, omdat we 
in Hoofdstuk 6 hebben laten zien dat er een verandering was in het RV weefsel 
richting de stijvere collageen isoform. 
In Hoofdstuk 6 hebben we ook laten zien dat er een aantal genexpressies 
veranderd zijn in het RV weefsel van de CTEPH dieren. Een van de belangrijkste 
hierin is ROCK2, dat een rol speelt in hypertrofie, apoptose, fibrose, inflammatie 
en oxidatieve stress. Dit zijn allemaal factoren waardoor het RV op negatieve 
wijze remodelleert en uiteindelijk niet meer naar behoren zal functioneren. Deze 
bevindingen suggereren dat therapie gericht op ROCK2 inhibitie de nadelige RV 
remodellering tegen kan gaan. 
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Ondanks dat de patiënten met CTEPH in het dagelijks leven last hebben 
van een verminderde inspanningscapaciteit, zijn inspanningstesten een goede 
voorspeller voor zowel de kans op CTEPH na een acute longembolie als de 
prognose van de CTEPH patiënt. In Hoofdstuk 3, 5 en 6 hebben we laten zien dat 
ook in ons varkensmodel, CTEPH gekarakteriseerd wordt door 
inspanningsintolerantie. Deze verminderde inspanningscapaciteit wordt 
voornamelijk veroorzaakt door een sterk verhoogde toename in PAP en 
pulmonale vasculaire weerstand tijdens inspanning, wat ervoor zorgt dat de RV 
afterload nog meer toeneemt en de ventilatie/perfusie mismatch in de longen ook 
alleen maar groter wordt. De bevindingen in Hoofdstuk 5 laten zien dat de 
inspanningsintolerantie in CTEPH voornamelijk veroorzaakt wordt door een 
toename in RV afterload, en daarbij een gelimiteerde toename in RV functie 
tijdens inspanning, en in een kleinere mate wordt veroorzaakt door de 
ventilatie/perfusie mismatch in de longen waardoor de arteriële oxygenatie 
belemmert wordt.  
Concluderend, het onderzoek in dit proefschrift schijnt meer licht op de 
onderliggende mechanismen welke zorgen voor de aanpassingen van het 
pulmonale vaatbed en het hart. De bevindingen laten zien dat specifiek onderzoek 
binnen globale signaleringspaden zoals NO, ET en Rho-kinase erg belangrijk zijn 
voor de ontwikkeling van effectievere behandelingen voor CTEPH. Daarnaast laten 
we het belang van inspanningstesten, voornamelijk in een vroeg stadium voor 
snellere diagnose, bij PH zien. Alles tezamen is er in dit proefschrift veel kennis 
vergaard over de pathofysiologie van CTEPH dankzij een nieuw ontwikkeld 
diermodel, alhoewel er nog veel vervolg onderzoek uitgevoerd moet worden 
voordat uiteindelijk de ideale genezende therapie bij de patiënt zal belanden. 
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